(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 July 2004 (01.07.2004)

PCT

(10) International Publication Number
WO 2004/055003 A1

(51) International Patent Classification[7]: C07D 401/04, 471/04

(21) International Application Number:
PCT/US2003/039606

(22) International Filing Date:
12 December 2003 (12.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/433,139 13 December 2002 (13.12.2002) US

(71) Applicant *(for all designated States except US)*: **NEUROGEN CORPORATION** [US/US]; 35 Northeast Industrial Road, Branford, CT 06405 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BAKTHAVATCHALAM, Rajagopal** [US/US]; 67 Hickory Lane, Madison, CT 06443 (US). **BLUM, Charles, A.** [US/US]; 785 W. Pond Meadow Road, Westbrook, CT 06498 (US). **BRIELMANN, Harry** [US/US]; 14 Elm Street, Guilford, CT 06437 (US). **CALDWELL, Timothy, M.** [US/US]; 35 Indian Neck Avenue, Branford, CT 06405 (US). **DE LOMBAERT, Stephane** [BE/US]; 37 Concord Drive, Madison, CT 06443 (US). **HODGETTS, Kevin, J.** [GB/US]; 224 Reservoir Road, Killingworth, CT 06419 (US). **ZHENG, Xiaozhang** [CN/US]; 10 Roby Court, Branford, CT 06405 (US).

(74) Agents: **ALEXANDER, John, B.** et al.; Edwards & Angell, LLP, P.O. Box 9169, Boston, MA 02209 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS



(I)

(57) Abstract: Certain 2-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity *in vivo* or *in vitro*, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

WO 2004/055003 A1

2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATOR

FIELD OF THE INVENTION

This invention relates generally to 2-substituted quinazolin-4-ylamine analogues that are modulators of capsaicin receptors, and to the use of such compounds for treating conditions related to capsaicin receptor activation. The invention further relates to the use such compounds as probes for the detection and localization of capsaicin receptors.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application 60/433,139, filed December 13, 2002.

BACKGROUND OF THE INVENTION

Pain perception, or nociception, is mediated by the peripheral terminals of a group of specialized sensory neurons, termed "nociceptors." A wide variety of physical and chemical stimuli induce activation of such neurons in mammals, leading to recognition of a potentially harmful stimulus. Inappropriate or excessive activation of nociceptors, however, can result in debilitating acute or chronic pain.

Neuropathic pain involves pain signal transmission in the absence of stimulus, and typically results from damage to the nervous system. In most instances, such pain is thought to occur because of sensitization in the peripheral and central nervous systems following initial damage to the peripheral system (*e.g.*, via direct injury or systemic disease). Neuropathic pain is typically burning, shooting and unrelenting in its intensity and can sometimes be more debilitating that the initial injury or disease process that induced it.

Existing treatments for neuropathic pain are largely ineffective. Opiates, such as morphine, are potent analgesics, but their usefulness is limited because of adverse side effects, such as physical addictiveness and withdrawal properties, as well as respiratory depression, mood changes, and decreased intestinal motility with concomitant constipation, nausea, vomiting, and alterations in the endocrine and autonomic nervous systems. In addition, neuropathic pain is frequently non-responsive or only partially responsive to conventional opioid analgesic regimens. Treatments employing the N-methyl-D-aspartate antagonist ketamine or the alpha(2)-adrenergic agonist clonidine can reduce acute or chronic

pain, and permit a reduction in opioid consumption, but these agents are often poorly tolerated due to side effects.

Topical treatment with capsaicin has been used to treat chronic and acute pain, including neuropathic pain. Capsaicin is a pungent substance derived from the plants of the Solanaceae family (which includes hot chili peppers) and appears to act selectively on the small diameter afferent nerve fibers (A-delta and C fibers) that are believed to mediate pain. The response to capsaicin is characterized by persistent activation of nociceptors in peripheral tissues, followed by eventual desensitization of peripheral nociceptors to one or more stimuli. From studies in animals, capsaicin appears to trigger C fiber membrane depolarization by opening cation selective channels for calcium and sodium.

Similar responses are also evoked by structural analogues of capsaicin that share a common vanilloid moiety. One such analogue is resiniferatoxin (RTX), a natural product of *Euphorbia* plants. The term vanilloid receptor (VR) was coined to describe the neuronal membrane recognition site for capsaicin and such related irritant compounds. The capsaicin response is competitively inhibited (and thereby antagonized) by another capsaicin analog, capsazepine, and is also inhibited by the non-selective cation channel blocker ruthenium red. These antagonists bind to VR with no more than moderate affinity (typically with K_i values of no lower than 140 μM).

Rat and human vanilloid receptors have been cloned from dorsal root ganglion cells. The first type of vanilloid receptor to be identified is known as vanilloid receptor type 1 (VR1), and the terms "VR1" and "capsaicin receptor" are used interchangeably herein to refer to rat and/or human receptors of this type, as well as mammalian homologs. The role of VR1 in pain sensation has been confirmed using mice lacking this receptor, which exhibit no vanilloid-evoked pain behavior, and impaired responses to heat and inflammation. VR1 is a nonselective cation channel with a threshold for opening that is lowered in response to elevated temperatures, low pH, and capsaicin receptor agonists. For example, the channel usually opens at temperatures higher than about 45°C. Opening of the capsaicin receptor channel is generally followed by the release of inflammatory peptides from neurons expressing the receptor and other nearby neurons, increasing the pain response. After initial activation by capsaicin, the capsaicin receptor undergoes a rapid desensitization via phosphorylation by cAMP-dependent protein kinase.

Because of their ability to desensitize nociceptors in peripheral tissues, VR1 agonist vanilloid compounds have been used as topical anesthetics. However, agonist application may itself cause burning pain, which limits this therapeutic use.

Recently, it has been reported that VR1 antagonists, including nonvanilloid compounds, are also useful for the treatment of pain (see, PCT application Number WO 02/08221, which published January 31, 2002).

Thus, compounds that interact with VR1, but do not elicit the initial painful sensation of VR1 agonist vanilloid compounds, are desirable for the treatment of chronic and acute pain, including neuropathic pain. Antagonists of this receptor are particularly desirable for the treatment of pain, as well as conditions such as tear gas exposure, itch and urinary incontinence. The present invention fulfills this need, and provides further related advantages.

SUMMARY OF THE INVENTION

The present invention provides VR1 modulators that alter, and preferably inhibit, capsaicin receptor activation. Within certain aspects, VR1 modulators provided herein are 2-substituted quinazolin-4-ylamine analogues of Formula I:



Formula I

or pharmaceutically acceptable forms thereof. Within Formula I:

X, V, W, Y and Z are each independently N or CR_1, with the proviso that at least one of V and X is N;

R_1 is independently selected at each occurrence from hydrogen, halogen, hydroxy, cyano, amino, optionally substituted alkyl or more preferably C_1-C_6alkyl, optionally substituted haloalkyl or more preferably haloC_1-C_6alkyl, optionally substituted alkoxy or more preferably C_1-C_6alkoxy, optionally substituted haloalkoxy or more preferably haloC_1-C_6alkoxy, optionally substituted alkoxycarbonyl or more preferably C_1-C_4alkoxycarbonyl and opsbu mono- and dialkylamino or more preferably mono- and di-(C_1-C_6alkyl)amino;

R is -O-R_7 or $-N\begin{smallmatrix}R_4\\R_3\end{smallmatrix}$;

R_7 is:

(i) hydrogen;

(ii) optionally substituted alkyl or more preferably C_1-C_8alkyl, optionally substituted alkenyl or more preferably C_2-C_8alkenyl, optionally substituted alkynyl or more preferably C_2-C_8alkynyl, optionally substituted alkanoyl or more preferably C_2-

C_8alkanoyl, optionally substituted alkanone or more preferably C_3-C_8alkanone, optionally substituted alkyl ether or more preferably C_2-C_8alkyl ether, optionally substituted aryl or arakyl or more preferably C_6-C_{10}arylC_0-C_8alkyl or optionally substituted heterocycle or heterocycle-alkyl or more preferably (5- to 10-membered heterocycle)C_0-C_8alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from R_b; or

(iii) taken together with an R_5 or R_6 to form a 4- to 10-membered heterocycle that is substituted with from 0 to 4 substituents independently chosen from R_b;

R_3 and R_4 are:

(i) each independently selected from:

(a) hydrogen;

(b) optionally substituted alkyl or more preferably C_1-C_8alkyl, optionally substituted alkenyl or more preferably C_2-C_8alkenyl, optionally substituted alkynyl or more preferably C_2-C_8alkynyl, optionally substituted alkanone or more preferably C_3-C_8alkanone, optionally substituted alkanoyl or more preferably C_2-C_8alkanoyl, optionally substituted alkyl ether or more preferably C_2-C_8alkyl ether, optionally substituted aryl or aralkyl or more preferably C_6-C_{10}arylC_0-C_8alkyl, optionally substituted heterocycle or heterocycle-alkyl or more preferably (5- to 10-membered heterocycle)C_0-C_8alkyl and optionally substituted alkylsulfonate or more preferably -$(SO_2)C_1$-C_8alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from R_b; and

(c) groups that are taken together with an R_5 or R_6 to form a 4- to 10-membered heterocycle that is substituted with from 0 to 4 substituents independently chosen from R_b; or

(ii) taken together to form, with the N to which they are bound, a 4- to 10-membered heterocyclic group that is substituted with from 0 to 4 substituents independently chosen from R_b; and

R_5 and R_6 are, independently at each occurrence:

(i) each independently hydrogen, C_1-C_8alkyl substituted with from 0 to 2 substituents independently chosen from R_b, or taken together with R_3, R_4 or R_7 to form a 4- to 10-membered heterocyclic group that is substituted with from 0 to 4 substituents independently chosen from R_b;

(ii) taken together to form a keto group (C=O); or

(iii) taken together to form a 3- to 7-membered carbocyclic or heterocyclic ring that is substituted with from 0 to 4 substituents independently chosen from R_b;

n is 1, 2 or 3;

Ar_1 and Ar_2 are independently selected from carbocycles or heterocycles or more preferably are independently selected from 6- to 10-membered carbocycles (preferably aryl) and 5- to 10-membered heterocycles, each of which is substituted with from 0 to 3 substituents independently selected from groups of the formula LR_a;

L is independently selected at each occurrence from a bond, O, $S(O)_m$, C(=O), OC(=O), C(=O)O, O-C(=O)O, $N(R_x)$, $C(=O)N(R_x)$, $N(R_x)C(=O)$, $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl;

R_a is independently selected at each occurrence from: (i) hydrogen, halogen, cyano and nitro; and (ii) alkyl or more preferably C_1-C_8alkyl, alkenyl or more preferably C_2-C_8alkenyl, alkynyl or more preferably C_2-C_8alkynyl, alkyl ether or more preferably C_2-C_8alkyl ether, heterocycle or heterocycle-alkyl or more preferably (4- to 10-membered heterocycle)C_0-C_8alkyl and mono- and di-alkylamino or more preferably mono- and di-(C_1-C_8alkyl)amino, each of which is substituted with from 0 to 4 substituents independently selected from hydroxy, halogen, amino, cyano, nitro, oxo, –COOH, C_1-C_4alkyl, C_1-C_4alkoxy, haloC_1-C_4alkyl, haloC_1-C_4alkoxy, hydroxyC_1-C_4alkyl, and mono- and di-(C_1-C_6alkyl)amino; and

R_b is independently chosen at each occurrence from:

(i) hydroxy, halogen, amino, aminocarbonyl, cyano, nitro, oxo and –COOH; and

(ii) alkyl or more preferably C_1-C_8alkyl, haloalkyl or more preferably C_1-C_8haloalkyl, alkoxy or more preferably C_1-C_8alkoxy, haloalkoxy or more preferably C_1-C_8haloalkoxy, alkanoyl or more preferably C_1-C_8alkanoyl, alkoxycarbonyl or more preferably C_2-C_8alkoxycarbonyl, alkanoyloxy or more preferably C_2-C_8alkanoyloxy, alkylthio or more preferably C_1-C_8alkylthio, alkyl ether or more preferably C_2-C_8alkyl ether, phenyl or phenyl-alkyl or more preferably phenylC_0-C_8alkyl, phenyl or phenyl-alkoxy or more preferably phenylC_0-C_8alkoxy, mono- or di-alkyl amino or mono- and di-alkylamino alkyl or more preferably mono- and di-(C_1-C_6alkyl)aminoC_0-C_6alkyl, alkylsulfonate or more preferably -(SO_2)C_1-C_8alkyl and heterocycle or heterocycle-alkyl or more preferably (4- to 7-membered heterocycle)(C_0-C_8alkyl); each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy,

halogen, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy, hydroxyC_1-C_4alkyl, haloC_1-C_4alkyl, and mono- and di-(C_1-C_4alkyl)amino.

Within further aspects, compounds provided herein are 2-hydroxyalkyl-quinazolin-4-ylamine analogues of Formula II:



Formula II

or pharmaceutically acceptable forms thereof, wherein X, W, Y, Z, R_5, R_6, R_7, n, Ar_1 and Ar_2 are as described for Formula I.

Within still further aspects, compounds provided herein are 2-aminoalkyl-quinazolin-4-ylamine analogues of Formula III:



Formula III

or pharmaceutically acceptable forms thereof, wherein X, W, Y, Z, R_3, R_4, R_5, R_6, n, Ar_1 and Ar_2 are as described for Formula I.

Within certain aspects, VR1 modulators as described herein exhibit a K_i of no greater than 1 micromolar, 100 nanomolar, 50 nanomolar, 10 nanomolar or 1 nanomolar in a capsaicin receptor binding assay and/or have an EC_{50} or IC_{50} value of no greater than 1 micromolar, 100 nanomolar, 50 nanomolar, 10 nanomolar or 1 nanomolar in an assay for determination of capsaicin receptor antagonist activity.

In certain embodiments, VR1 modulators as described herein are VR1 antagonists and exhibit no detectable agonist activity in an *in vitro* assay of capsaicin receptor activation.

Within certain aspects, VR1 modulators and pharmaceutically acceptable forms thereof as described herein are labeled with a detectable marker (*e.g.,* radiolabeled or fluorescein conjugated).

The present invention further provides, within other aspects, pharmaceutical compositions comprising at least one VR1 modulator as described herein (*i.e.,* a compound as provided herein or a pharmaceutically acceptable form thereof) in combination with a physiologically acceptable carrier or excipient.

Within further aspects, methods are provided for reducing calcium conductance of a cellular capsaicin receptor, comprising contacting a cell (*e.g.*, neuronal) expressing a capsaicin receptor with a capsaicin receptor modulatory amount of at least one VR1 modulator as described herein. Such contact may occur *in vivo* or *in vitro*.

Methods are further provided for inhibiting binding of vanilloid ligand to a capsaicin receptor. Within certain such aspects, the inhibition takes place *in vitro*. Such methods comprise contacting a capsaicin receptor with at least one VR1 modulator as described herein, under conditions and in an amount sufficient to detectably inhibit vanilloid ligand binding to the capsaicin receptor. Within other such aspects, the capsaicin receptor is in a patient. Such methods comprise contacting cells expressing a capsaicin receptor in a patient with at least one VR1 modulator as described herein in an amount sufficient to detectably inhibit vanilloid ligand binding to cells expressing a cloned capsaicin receptor *in vitro*, and thereby inhibiting binding of vanilloid ligand to the capsaicin receptor in the patient.

The present invention further provides methods for treating a condition responsive to capsaicin receptor modulation in a patient, comprising administering to the patient a capsaicin receptor modulatory amount of at least one VR1 modulator as described herein.

Within other aspects, methods are provided for treating pain in a patient, comprising administering to a patient suffering from pain a capsaicin receptor modulatory amount of at least one VR1 modulator as described herein.

Methods are further provided for treating itch, urinary incontinence, cough and/or hiccup in a patient, comprising administering to a patient suffering from one or more of the foregoing conditions a capsaicin receptor modulatory amount of at least one VR1 modulator as described herein.

The present invention further provides methods for promoting weight loss in an obese patient, comprising administering to an obese patient a capsaicin receptor modulatory amount of at least one VR1 modulator as described herein.

Within further aspects, the present invention provides methods for determining the presence or absence of capsaicin receptor in a sample, comprising: (a) contacting a sample with a VR1 modulator as described herein under conditions that permit binding of the VR1 modulator to capsaicin receptor; and (b) detecting a level of the VR1 modulator bound to capsaicin receptor.

The present invention also provides packaged pharmaceutical preparations, comprising: (a) a pharmaceutical composition as described herein in a container; and (b)

instructions for using the composition to treat one or more conditions responsive to capsaicin receptor modulation, such as pain, itch, urinary incontinence, cough, hiccup, and/or obesity.

In yet another aspect, the invention provides methods of preparing the compounds disclosed herein, including the intermediates.

These and other aspects of the present invention will become apparent upon reference to the following detailed description.

DETAILED DESCRIPTION

As noted above, the present invention provides 2-substituted quinazolin-4-ylamine analogues which are capsaicin receptor modulators. Such modulators may be used *in vitro* or *in vivo*, to modulate capsaicin receptor activity in a variety of contexts.

TERMINOLOGY

Compounds are generally described herein using standard nomenclature. For compounds having asymmetric centers, it should be understood that (unless otherwise specified) all of the optical isomers and mixtures thereof are encompassed. In addition, compounds with carbon-carbon double bonds may occur in Z- and E- forms, with all isomeric forms of the compounds being included in the present invention unless otherwise specified. Where a compound exists in various tautomeric forms, a recited compound is not limited to any one specific tautomer, but rather is intended to encompass all tautomeric forms. Certain compounds are described herein using a general formula that includes variables (*e.g.*, R_2, Ar_1, Y, Z). Unless otherwise specified, each variable within such a formula is defined independently of any other variable, and any variable that occurs more than one time in a formula is defined independently at each occurrence.

The term "2-substituted quinazolin-4-ylamine analogue" is used herein to refer to all compounds that satisfy one or more of Formulas I, II and III, including any enantiomers, racemates and stereoisomers, as well as all pharmaceutically acceptable forms of such compounds. The terms "2-hydroxyalkyl-quinazolin-4-ylamine analogue" and "2-aminoalkyl-quinazolin-4-ylamine analogue," as used herein, encompass all compounds of Formula II or Formula III, respectively, including any enantiomers, racemates and stereoisomers, as well as all pharmaceutically acceptable forms of such compounds. 2-Substituted quinazolin-4-ylamine analogues include compounds in which the bicyclic core (which comprises V, X, W, Y and Z) is modified in the number and/or placement of ring nitrogen atoms, as well as analogues in which varied substituents, as described in more detail below, are attached to

such a core structure. In other words, compounds that are substituted quinoline-4-ylamines, quinoline-2-ylamines, quinazoline-4-ylamines (as well as analogues of the foregoing in which one or more of W, Y and Z are nitrogen, such as pyrido[2,3-*d*]pyrimidine-4-ylamines, pyrido[3,2-*d*]pyrimidin-4-ylamines, [1,8]naphthyridin-4-ylamines and [1,6]naphthyridin-5-ylamines) are within the scope of 2-substituted quinazolin-4-ylamine analogues.

"Pharmaceutically acceptable forms" of the compounds recited herein are pharmaceutically acceptable salts, hydrates, solvates, crystal forms, polymorphs, chelates, non-covalent complexes, esters, clathrates and prodrugs of such compounds. As used herein, a pharmaceutically acceptable salt is an acid or base salt that is generally considered in the art to be suitable for use in contact with the tissues of human beings or animals without excessive toxicity, irritation, allergic response, or other problem or complication. Such salts include mineral and organic acid salts of basic residues such as amines, as well as alkali or organic salts of acidic residues such as carboxylic acids. Specific pharmaceutical salts include, but are not limited to, salts of acids such as hydrochloric, phosphoric, hydrobromic, malic, glycolic, fumaric, sulfuric, sulfamic, sulfanilic, formic, toluenesulfonic, methanesulfonic, benzene sulfonic, ethane disulfonic, 2-hydroxyethylsulfonic, nitric, benzoic, 2-acetoxybenzoic, citric, tartaric, lactic, stearic, salicylic, glutamic, ascorbic, pamoic, succinic, fumaric, maleic, propionic, hydroxymaleic, hydroiodic, phenylacetic, alkanoic such as acetic, HOOC-$(CH_2)_n$-COOH where n is 0-4, and the like. Similarly, pharmaceutically acceptable cations include, but are not limited to sodium, potassium, calcium, aluminum, lithium and ammonium. Those of ordinary skill in the art will recognize further pharmaceutically acceptable salts for the compounds provided herein, including those listed by *Remington's Pharmaceutical Sciences,* 17th ed., Mack Publishing Company, Easton, PA, p. 1418 (1985). In general, a pharmaceutically acceptable acid or base salt can be synthesized from a parent compound that contains a basic or acidic moiety by any conventional chemical method. Briefly, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, the use of nonaqueous media, such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile, is preferred.

A "prodrug" is a compound that may not fully satisfy the structural requirements of the compounds provided herein, but is modified *in vivo*, following administration to a patient, to produce a compound of Formula I, II or III. For example, a prodrug may be an acylated derivative of a compound as provided herein. Prodrugs include compounds wherein hydroxy,

amine or sulfhydryl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups within the compounds provided herein. Prodrugs of the compounds provided herein may be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved to the parent compounds.

As used herein, the term "alkyl" refers to a straight chain, branched chain or cyclic saturated aliphatic hydrocarbon. An alkyl group may be bonded to an atom within a molecule of interest via any chemically suitable portion. Alkyl groups include groups having from 1 to 8 carbon atoms (C_1-C_8alkyl), from 1 to 6 carbon atoms (C_1-C_6alkyl) and from 1 to 4 carbon atoms (C_1-C_4alkyl), such as methyl, ethyl, propyl, isopropyl, n-butyl, *sec*-butyl, *tert*-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, 3-methylpentyl, cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cycloheptyl and norbornyl. "C_0-C_4alkyl" refers to a bond or an alkyl group having 1, 2, 3 or 4 carbon atoms; "C_0-C_6alkyl" refers to a bond or a C_1-C_6alkyl group; "C_0-C_8alkyl" refers to a bond or a C_1-C_8alkyl group. In certain embodiments, preferred alkyl groups are straight or branched chain. In some instances herein, a substituent of an alkyl group is specifically indicated. For example, "cyanoC_1-C_4alkyl" refers to a C_1-C_4alkyl group that has a CN substituent. One representative branched cyanoalkyl group is $-C(CH_3)_2CN$.

Similarly, "alkenyl" refers to straight or branched chain alkene groups or cycloalkene groups, in which at least one unsaturated carbon-carbon double bond is present. Alkenyl groups include C_2-C_8alkenyl, C_2-C_6alkenyl and C_2-C_4alkenyl groups, which have from 2 to 8, 2 to 6 or 2 to 4 carbon atoms, respectively, such as ethenyl, allyl or isopropenyl. "Alkynyl" refers to straight or branched chain alkyne groups, which have one or more unsaturated carbon-carbon bonds, at least one of which is a triple bond. Alkynyl groups include C_2-C_8alkynyl, C_2-C_6alkynyl and C_2-C_4alkynyl groups, which have from 2 to 8, 2 to 6 or 2 to 4 carbon atoms, respectively. In certain embodiments, preferred alkenyl and alkynyl groups are straight or branched chain.

By "alkoxy," as used herein, is meant an alkyl, alkenyl or alkynyl group as described above attached via an oxygen bridge. Alkoxy groups include C_1-C_8alkoxy, C_1-C_6alkoxy and C_1-C_4alkoxy groups, which have from 1 to 8, 1 to 6 or 1 to 4 carbon atoms, respectively. Alkoxy groups include, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, *sec*-butoxy, *tert*-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, hexoxy, 2-

hexoxy, 3-hexoxy, and 3-methylpentoxy. Similarly, "alkylthio" refers to an alkyl, alkenyl or alkynyl group as described above attached via a sulfur bridge. Preferred alkoxy and alkylthio groups are those in which an alkyl group is attached via the heteroatom bridge.

The term "alkanoyl" refers to an acyl group in a linear, branched or cyclic arrangement (*e.g.*, -(C=O)-alkyl). Alkanoyl groups include C_2-C_8alkanoyl, C_2-C_6alkanoyl and C_2-C_4alkanoyl groups, which have from 2 to 8, 2 to 6 or 2 to 4 carbon atoms, respectively. "C_1alkanoyl" refers to –(C=O)-H, which (along with C_2-C_8alkanoyl) is encompassed by the term "C_1-C_8alkanoyl."

An "alkanone" is a ketone group in which carbon atoms are in a linear, branched or cyclic alkyl arrangement. "C_3-C_8alkanone," "C_3-C_6alkanone" and "C_3-C_4alkanone" refer to an alkanone having from 3 to 8, 6 or 4 carbon atoms, respectively. By way of example, a C_3 alkanone group has the structure –CH_2-(C=O)-CH_3.

Similarly, "alkyl ether" refers to a linear or branched ether substituent linked via a carbon-carbon bond. Alkyl ether groups include C_2-C_8alkyl ether, C_2-C_6alkyl ether and C_2-C_4alkyl ether groups, which have 2 to 8, 6 or 4 carbon atoms, respectively. By way of example, a C_2 alkyl ether group has the structure –CH_2-O-CH_3. A representative branced alkyl ether substituent is –$C(CH_3)_2CH_2$-O-CH_3.

The term "alkoxycarbonyl" refers to an alkoxy group linked via a carbonyl (*i.e.*, a group having the general structure –C(=O)–O–alkyl). Alkoxycarbonyl groups include C_2-C_8, C_2-C_6 and C_2-C_4alkoxycarbonyl groups, which have from 2 to 8, 6 or 4 carbon atoms, respectively. "C_1alkoxycarbonyl" refers to -C(=O)-OH, which is encompassed by the term "C_1-C_8alkoxycarbonyl."

"Alkanoyloxy," as used herein, refers to an alkanoyl group linked via an oxygen bridge (*i.e.*, a group having the general structure –O–C(=O)–alkyl). Alkanoyloxy groups include C_2-C_8, C_2-C_6 and C_2-C_4alkanoyloxy groups, which have from 2 to 8, 6 or 4 carbon atoms, respectively.

"Alkylamino" refers to a secondary or tertiary amine having the general structure –NH–alkyl or –N(alkyl)(alkyl), wherein each alkyl may be the same or different. Such groups include, for example, mono- and di-(C_1-C_8alkyl)amino groups, in which each alkyl may be the same or different and may contain from 1 to 8 carbon atoms, as well as mono- and di-(C_1-C_6alkyl)amino groups and mono- and di-(C_1-C_4alkyl)amino groups.

"Alkylaminoalkyl" refers to an alkylamino group linked via an alkyl group (*i.e.*, a group having the general structure -alkyl–NH–alkyl or -alkyl–N(alkyl)(alkyl)) in which each

alkyl is selected independently. Such groups include, for example, mono- and di-(C_1-C_8alkyl)aminoC_1-C_8alkyl, mono- and di-(C_1-C_6alkyl)aminoC_1-C_6alkyl and mono- and di-(C_1-C_4alkyl)aminoC_1-C_4alkyl, in which each alkyl may be the same or different. "Mono- or di-(C_1-C_6alkyl)aminoC_0-C_6alkyl" refers to a mono- or di-(C_1-C_6alkyl)amino group linked via a direct bond or a C_1-C_6alkyl group. The following are representative alkylaminoalkyl groups:





The term "aminocarbonyl" refers to an amide group (*i.e.*, -(C=O)NH_2). "Mono- or di-(C_1-C_8alkyl)aminocarbonyl" is an aminocarbonyl group in which one or both of the hydrogen atoms is replaced with C_1-C_8alkyl. If both hydrogen atoms are so replaced, the C_1-C_8alkyl groups may be the same or different.

The term "halogen" refers to fluorine, chlorine, bromine and iodine.

A "haloalkyl" is a branched, straight-chain or cyclic alkyl group, substituted with 1 or more halogen atoms (*e.g.*, "haloC_1-C_8alkyl" groups have from 1 to 8 carbon atoms; "haloC_1-C_6alkyl" groups have from 1 to 6 carbon atoms). Examples of haloalkyl groups include, but are not limited to, mono-, di- or tri-fluoromethyl; mono-, di- or tri-chloromethyl; mono-, di-, tri-, tetra- or penta-fluoroethyl; mono-, di-, tri-, tetra- or penta-chloroethyl; and 1,2,2,2-tetrafluoro-1-trifluoromethyl-ethyl. Typical haloalkyl groups are trifluoromethyl and difluoromethyl. The term "haloalkoxy" refers to a haloalkyl group as defined above attached via an oxygen bridge. "HaloC_1-C_8alkoxy" groups have 1 to 8 carbon atoms.

A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -$CONH_2$ is attached through the carbon atom.

A "heteroatom," as used herein, is oxygen, sulfur or nitrogen.

A "carbocycle" or "carbocyclic group" comprises at least one ring formed entirely by carbon-carbon bonds (referred to herein as a carbocyclic ring), and does not contain a heterocyclic ring. Unless otherwise specified, each carbocyclic ring within a carbocycle may be saturated, partially saturated or aromatic. A carbocycle generally has from 1 to 3 fused, pendant or spiro rings; carbocycles within certain embodiments have one ring or two fused rings. Typically, each ring contains from 3 to 8 ring members (*i.e.*, C_3-C_8); C_5-C_7 rings are recited in certain embodiments. Carbocycles comprising fused, pendant or spiro rings typically contain from 9 to 14 ring members. Certain representative carbocycles are cycloalkyl (*i.e.*, groups that comprise saturated and/or partially saturated rings, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, adamantyl,

decahydro-naphthalenyl, octahydro-indenyl, and partially saturated variants of any of the foregoing, such as cyclohexenyl). Other carbocycles are aryl (*i.e.*, contain at least one aromatic carbocyclic ring). Such carbocycles include, for example, phenyl, naphthyl, fluorenyl, indanyl and 1,2,3,4-tetrahydro-naphthyl.

Certain carbocycles recited herein are C_6-C_{10}arylC_0-C_8alkyl groups (*i.e.*, groups in which a carbocyclic group comprising at least one aromatic ring is linked via a direct bond or a C_1-C_8alkyl group). Such groups include, for example, phenyl and indanyl, as well as groups in which either of the foregoing is linked via C_1-C_8alkyl, preferably via C_1-C_4alkyl. Phenyl groups linked via a direct bond or alkyl group may be designated phenylC_0-C_8alkyl (*e.g.*, benzyl, 1-phenyl-ethyl, 1-phenyl-propyl and 2-phenyl-ethyl). A phenylC_0-C_8alkoxy group is a phenyl ring linked via an oxygen bridge or an alkoxy group having from 1 to 8 carbon atoms (*e.g.*, phenoxy or benzoxy).

A "heterocycle" or "heterocyclic group" has from 1 to 3 fused, pendant or spiro rings, at least one of which is a heterocyclic ring (*i.e.*, one or more ring atoms is a heteroatom, with the remaining ring atoms being carbon). Typically, a heterocyclic ring comprises 1, 2, 3 or 4 heteroatoms; within certain embodiments each heterocyclic ring has 1 or 2 heteroatoms per ring. Each heterocyclic ring generally contains from 3 to 8 ring members (rings having from 4 or 5 to 7 ring members are recited in certain embodiments) and heterocycles comprising fused, pendant or spiro rings typically contain from 9 to 14 ring members. Certain heterocycles comprise a sulfur atom as a ring member; in certain embodiments, the sulfur atom is oxidized to SO or SO_2. Heterocycles may be optionally substituted with a variety of substituents, as indicated. Unless otherwise specified, a heterocycle may be a heterocycloalkyl group (*i.e.*, each ring is saturated or partially saturated) or a heteroaryl group (*i.e.*, at least one ring within the group is aromatic). A heterocyclic group may generally be linked via any ring or substituent atom, provided that a stable compound results. N-linked heterocyclic groups are linked via a component nitrogen atom.

Heterocyclic groups include, for example, azepanyl, azocinyl, benzimidazolyl, benzimidazolinyl, benzisothiazolyl, benzisoxazolyl, benzofuranyl, benzothiofuranyl, benzoxazolyl, benzothiazolyl, benztetrazolyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, dihydrofuro[2,3-b]tetrahydrofuranyl, dihydroisoquinolinyl, dihydrotetrahydrofuranyl, 1,4-dioxa-8-aza-spiro[4.5]decyl, dithiazinyl, furanyl, furazanyl, imidazolinyl, imidazolidinyl, imidazolyl, indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isothiazolyl, isoxazolyl, isoquinolinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl,

oxazolidinyl, oxazolyl, phthalazinyl, piperazinyl, piperidinyl, piperidinyl, piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridoimidazolyl, pyridooxazolyl, pyridothiazolyl, pyridyl, pyrimidyl, pyrrolidinyl, pyrrolidonyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, quinuclidinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, thiadiazinyl, thiadiazolyl, thiazolyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thienyl, thiophenyl, thiomorpholinyl and variants thereof in which the sulfur atom is oxidized, triazinyl, and any of the foregoing that are substituted with from 1 to 4 substituents as described above.

A "heterocycleC_0-C_8alkyl" is a heterocyclic group linked via a direct bond or C_1-C_8alkyl group. A (5- to 10-membered heterocycle)C_0-C_8alkyl is a heterocyclic group having from 5 to 10 ring members linked via a direct bond or an alkyl group having from 1 to 8 carbon atoms. If the heterocycle is heteroaryl, the group is designated (5- to 10-membered heteroaryl)C_0-C_8alkyl. A (5- to 7-membered heterocycle)C_0-C_8alkyl is a 5- to 7-membered heterocyclic ring linked via a bond or a C_1-C_8alkyl group; a (4- to 7-membered heterocycle)C_0-C_8alkyl is a 4- to 7-membered heterocyclic ring linked via a bond or a C_1-C_8alkyl group.

Certain heterocyclic groups are 4- to 10-membered, 5- to 10-membered, 3- to 7-membered, 4- to 7-membered or 5- to 7-membered groups that contain 1 heterocyclic ring or 2 fused or spiro rings, optionally substituted. 4- to 10-membered heterocycloalkyl groups include, for example, piperidinyl, piperazinyl, pyrrolidinyl, azepanyl, 1,4-dioxa-8-aza-spiro[4.5]dec-8-yl, morpholino, thiomorpholino and 1,1-dioxo-thiomorpholin-4-yl. Such groups may be substituted as indicated. Representative aromatic heterocycles are azocinyl, pyridyl, pyrimidyl, imidazolyl, tetrazolyl and 3,4-dihydro-1H-isoquinolin-2-yl.

A "substituent," as used herein, refers to a molecular moiety that is covalently bonded to an atom within a molecule of interest. For example, a ring substituent may be a moiety such as a halogen, alkyl group, haloalkyl group or other group discussed herein that is covalently bonded to an atom (preferably a carbon or nitrogen atom) that is a ring member. The term "substitution" refers to replacing a hydrogen atom in a molecular structure with a substituent as described above, such that the valence on the designated atom is not exceeded, and such that a chemically stable compound *(i.e.,* a compound that can be isolated, characterized, and tested for biological activity) results from the substitution.

Groups that are "optionally substituted" are unsubstituted or are substituted by other than hydrogen at one or more available positions, typically 1, 2, 3, 4 or 5 positions, by one or more suitable groups (which may be the same or different). Such optional substituents

include, for example, hydroxy, halogen, cyano, nitro, C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, C_1-C_8alkoxy, C_2-C_8alkyl ether, C_3-C_8alkanone, C_1-C_8alkylthio, amino, mono- or di-(C_1-C_8alkyl)amino, haloC_1-C_8alkyl, haloC_1-C_8alkoxy, C_1-C_8alkanoyl, C_2-C_8alkanoyloxy, C_1-C_8alkoxycarbonyl,

-COOH, -$CONH_2$, mono- or di-(C_1-C_8alkyl)aminocarbonyl, -SO_2NH_2, and/or mono or di(C_1-C_8alkyl)sulfonamido, as well as carbocyclic and heterocyclic groups. Optional substitution is also indicated by the phrase "substituted with from 0 to X substituents," where X is the maximum number of possible substituents. Certain optionally substituted groups are substituted with from 0 to 2, 3 or 4 independently selected substituents (*i.e.*, are unsubstituted or substituted with up to the recited maximum number of substitutents).

The terms "VR1" and "capsaicin receptor" are used interchangeably herein to refer to a type 1 vanilloid receptor. Unless otherwise specified, these terms encompass both rat and human VR1 receptors (*e.g.*, GenBank Accession Numbers AF327067, AJ277028 and NM_018727; sequences of certain human VR1 cDNAs are provided in SEQ ID NOs:1-3, and the encoded amino acid sequences shown in SEQ ID NOs:4 and 5, of U.S. Patent No. 6,482,611), as well as homologs thereof found in other species.

A "VR1 modulator," also referred to herein as a "modulator," is a compound that modulates VR1 activation and/or VR1-mediated signal transduction. VR1 modulators specifically provided herein are compounds of Formula I and pharmaceutically acceptable forms of compounds of Formula I. A VR1 modulator may be a VR1 agonist or antagonist. A modulator binds with "high affinity" if the K_i at VR1 is less than 1 micromolar, preferably less than 100 nanomolar, 10 nanomolar or 1 nanomolar. A representative assay for determining K_i at VR1 is provided in Example 5, herein.

A modulator is considered an "antagonist" if it detectably inhibits vanilloid ligand binding to VR1 and/or VR1-mediated signal transduction (using, for example, the representative assay provided in Example 6); in general, such an antagonist inhibits VR1 activation with a IC_{50} value of less than 1 micromolar, preferably less than 100 nanomolar, and more preferably less than 10 nanomolar or 1 nanomolar within the assay provided in Example 6. VR1 antagonists include neutral antagonists and inverse agonists. In certain embodiments, capsaicin receptor antagonists provided herein are not vanilloids.

An "inverse agonist" of VR1 is a compound that reduces the activity of VR1 below its basal activity level in the absence of added vanilloid ligand. Inverse agonists of VR1 may also inhibit the activity of vanilloid ligand at VR1, and/or may also inhibit binding of vanilloid ligand to VR1. The ability of a compound to inhibit the binding of vanilloid ligand

to VR1 may be measured by a binding assay, such as the binding assay given in Example 5. The basal activity of VR1, as well as the reduction in VR1 activity due to the presence of VR1 antagonist, may be determined from a calcium mobilization assay, such as the assay of Example 6.

A "neutral antagonist" of VR1 is a compound that inhibits the activity of vanilloid ligand at VR1, but does not significantly change the basal activity of the receptor (*i.e.*, within a calcium mobilization assay as described in Example 6 performed in the absence of vanilloid ligand, VR1 activity is reduced by no more than 10%, more preferably by no more than 5%, and even more preferably by no more than 2%; most preferably, there is no detectable reduction in activity). Neutral antagonists of VR1 may inhibit the binding of vanilloid ligand to VR1.

As used herein a "capsaicin receptor agonist" or "VR1 agonist" is a compound that elevates the activity of the receptor above the basal activity level of the receptor (*i.e.*, enhances VR1 activation and/or VR1-mediated signal transduction). Capsaicin receptor agonist activity may be identified using the representative assay provided in Example 6. In general, such an agonist has an EC_{50} value of less than 1 micromolar, preferably less than 100 nanomolar, and more preferably less than 10 nanomolar within the assay provided in Example 6. In certain embodiments, capsaicin receptor agonists provided herein are not vanilloids.

A "vanilloid" is capsaicin or any capsaicin analogue that comprises a phenyl ring with two oxygen atoms bound to adjacent ring carbon atoms (one of which carbon atom is located *para* to the point of attachment of a third moiety that is bound to the phenyl ring). A vanilloid is a "vanilloid ligand" if it binds to VR1 with a K_i (determined as described herein) that is no greater than 10 μM. Vanilloid ligand agonists include capsaicin, olvanil, N-arachidonoyl-dopamine and resiniferatoxin (RTX). Vanilloid ligand antagonists include capsazepine and iodo-resiniferatoxin.

A "capsaicin receptor modulatory amount" is an amount that, upon administration to a patient, achieves a concentration of VR1 modulator at a capsaicin receptor within the patient that is sufficient to alter the binding of vanilloid ligand to VR1 *in vitro* (using the assay provided in Example 5) and/or VR1-mediated signal transduction (using an assay provided in Example 6). The capsaicin receptor may be present, or example, in a body fluid such as blood, plasma, serum, CSF, synovial fluid, lymph, cellular interstitial fluid, tears or urine.

A "therapeutically effective amount" is an amount that, upon administration, is sufficient to provide detectable patient relief from a condition being treated. Such relief may

be detected using any appropriate criteria, including alleviation of one or more symptoms such as pain.

A "patient" is any individual treated with a VR1 modulator as provided herein. Patients include humans, as well as other animals such as companion animals (*e.g.*, dogs and cats) and livestock. Patients may be experiencing one or more symptoms of a condition responsive to capsaicin receptor modulation (*e.g.*, pain, exposure to vanilloid ligand, itch, urinary incontinence, respiratory disorders, cough and/or hiccup), or may be free of such symptom(s) (*i.e.*, treatment may be prophylactic).

VR1 MODULATORS

As noted above, the present invention provides VR1 modulators that may be used in a variety of contexts, including in the treatment of pain (*e.g.*, neuropathic or peripheral nerve-mediated pain); exposure to capsaicin; exposure to acid, heat, light, tear gas air pollutants, pepper spray or related agents; respiratory conditions such as asthma or chronic obstructive pulmonary disease; itch; urinary incontinence; cough or hiccup; and/or obesity. VR1 modulators may also be used within *in vitro* assays (*e.g.*, assays for receptor activity), as probes for detection and localization of VR1 and as standards in ligand binding and VR1-mediated signal transduction assays.

VR1 modulators provided herein are 2-substituted quinazolin-4-ylamine analogues that detectably modulate the binding of capsaicin to VR1 at nanomolar (*i.e.*, submicromolar) concentrations, preferably at subnanomolar concentrations, more preferably at concentrations below 100 picomolar, 20 picomolar, 10 picomolar or 5 picomolar. Such modulators are preferably not vanilloids. Certain preferred modulators are VR1 antagonists and have no detectable agonist activity in the assay described in Example 6. Preferred VR1 modulators further bind with high affinity to VR1, and do not substantially inhibit activity of human EGF receptor tyrosine kinase.

As noted above, X, V, W, Y and Z are each independently N or CR_1, with at least one of X and V being N, and R_1 is as described above. In certain embodiments, no more than 2 of W, Y and Z are N, and each R_1 is hydrogen. Representative 2-substituted quinazolin-4-ylamine analogues include, but are not limited to, compounds in which W is CH and X, V, Y and Z are as indicated for any one of the embodiments listed in Table I.

Table I
Representative Quinazoline-4-ylamine Analogue Core Structures

X	V	Y	Z
CH	N	CH	CH
N	CH	CH	CH
N	N	CH	CH
CH	N	N	CH
N	CH	N	CH
N	N	N	CH
CH	N	CH	N
N	CH	CH	N
N	N	CH	N
CH	N	N	N
N	CH	N	N
N	N	N	N

In certain embodiments of Formula I and Formula II, R_7 is (i) hydrogen or (ii) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, C_2-C_8alkanoyl, C_3-C_8alkanone, C_2-C_8alkyl ether, C_6-C_{10}arylC_0-C_8alkyl, or (5- to 10-membered heterocycle)C_0-C_8alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from R_b. Within other embodiments, R_7 is (i) hydrogen or (ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkanoyl, C_2-C_6alkyl ether, mono- or di-(C_1-C_6alkyl)aminoC_1-C_6alkyl, phenylC_0-C_4alkyl, 5- or 6-membered heteroarylC_0-C_4alkyl, or 5- to 7-membered heterocycloalkylC_0-C_4alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from hydroxy, halogen, amino, C_1-C_4alkyl, haloC_1-C_4alkyl, C_1-C_4alkoxy and haloC_1-C_4alkoxy. Representative R_7 groups include C_1-C_4alkyl, C_2-C_4alkyl ether, mono- and di-(C_1-C_6alkyl)aminoC_1-C_6alkyl, 6-membered heterocycles and benzyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen and C_1-C_4alkyl.

Alternatively, R_7 may be taken together with an R_5 or R_6 group (along with the O to which R_7 is bound and any carbon atoms between the O and R_5 or R_6) to form an optionally substituted heterocycle, such as a 4- to 10-membered mono- or bi-cyclic group. The resulting heterocycle may, for example, be substituted with from 0 to 4 (*e.g.*, 0, 1 or 2) substituents independently chosen from hydroxy, halogen, C_1-C_4alkyl, haloC_1-C_4alkyl, C_1-C_4alkoxy, haloC_1-C_4alkoxy, C_1-C_4alkanoyl, C_1-C_4alkoxycarbonyl, aminocarbonyl, heterocycleC_0-C_8alkyl and heterocycleC_1-C_8alkoxycarbonyl.

Within certain embodiments, R_3 and R_4 of Formulas I and III are each independently selected from (i) hydrogen; and (ii) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, C_3-C_8alkanone, C_1-C_8alkanoyl, C_2-C_8alkyl ether, C_6-C_{10}arylC_0-C_8alkyl, (5- to 10-membered heterocycle)C_0-

C_8alkyl and -(SO_2)C_1-C_8alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from R_b. Within other embodiments, R_3 and R_4 are each independently selected from (i) hydrogen and (ii) C_1-C_8alkyl, C_2-C_8alkenyl, phenylC_0-C_4alkyl, indanylC_0-C_4alkyl, 5- to 6-membered heteroarylC_0-C_4alkyl and (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 4 substituents independently selected from hydroxy, halogen, amino, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkoxy and haloC_1-C_6alkoxy. Representative R_3 and R_4 groups include hydrogen,C_1-C_6alkyl, C_2-C_6alkenyl, (5- to 7-membered heterocycle)C_0-C_4alkyl, C_2-C_6alkyl ether, indanyl, benzyl, 1-phenyl-ethyl, 1-phenyl-propyl and 2-phenyl-ethyl, each of which is substituted with from 0 to 3 substituents independently selected from hydroxy, halogen and C_1-C_4alkyl. For example, at least one of R_3 and R_4 may be pyridylC_0-C_4alkyl, pyrimidylC_0-C_4alkyl, imidazolylC_0-C_4alkyl or tetrazolylC_0-C_4alkyl, each of which is substituted with 0, 1 or 2 substituents. Preferably, at least one of R_3 and R_4 is not hydrogen. In certain embodiments, compounds of Formula I and III are not [2-pyrrolidin-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine.

Within other embodiments, R_3 and/or R_4 of Formulas I and III may form an optionally substituted heterocycle. For example, R_3 and R_4 may be taken together to form, with the N to which they are bound, an optionally substituted heterocycle; or one of R_3 and R_4 may be taken together with an R_5 or R_6 moiety (along with the N to which R_3 and R_4 are bound and any carbon atoms located between the N and the linked R_5 or R_6) to from an optionally substituted heterocycle. In either case, the resulting heterocycle may be, for example, a 4-, 5- or 6- to 10-membered, mono- or bi-cyclic group substituted with from 0 to 4 substituents (*e.g.,* from 1 to 4 substituents or 0, 1 or 2 substituents). In certain embodiments, each substituent is independently selected from hydroxy, halogen, C_1-C_4alkyl, haloC_1-C_4alkyl, C_1-C_4alkoxy, haloC_1-C_4alkoxy, C_1-C_4alkanoyl, C_1-C_4alkoxycarbonyl, aminocarbonyl and (4- to 10-membered)heterocycleC_0-C_8alkyl. In certain embodiments, each substituent, if any, is a lower alkyl group such as methyl or ethyl.

A heterocyclic group that comprises R_3 and/or R_4 may be an optionally substituted heteroaryl or heterocycloalkyl group. Such heterocyclic groups include, for example, azepane, azocine, benzimidazoline, benzimidazole, benzotriazole, cinnoline, decahydroquinoline, dihydroisoquinoline, 1,4-dioxa-8-aza-spiro[4.5]decane, imidazole, imidazolidine, imidazoline, indazole, indoline, indole, isoquinoline, quinoxaline, morpholine, naphthyridine, octahydroquinoline, phthalazine, piperazine, piperidine, pteridine, purine, pyridazine, pyrazolidine, pyrazoline, pyrrolidine, pyrroline, quinoline, quinoxaline,

quinazoline, tetrahydroisoquinoline, tetrahydroquinoline, thiomorpholine or thiomorpholine 1,1-dioxide. One suitable heteroaryl group is 3,4-dihydro-1H-isoquinolin-2-yl.

Within certain compounds of Formulas I-III, R_5 and R_6 are independently (at each occurrence) hydrogen or optionally substituted C_1-C_6alkyl or C_1-C_4alkyl; in addition, or alternatively, any R_5 or R_6 may be taken together with any other R_5 or R_6 to form an optionally substituted 5- to 7-membered cycloalkyl or heterocycloalkyl, or (as discussed above) taken together with R_7, R_3 or R_4 to form an optionally substituted heterocycle. Preferably, no more than one R_5 or R_6 moiety is taken together with another group to form a carbocycle or heterocycle. In certain compounds, one R_5 or R_6 is hydrogen or methyl and the other(s) are hydrogen. In further compounds, each R_5 and R_6 is hydrogen. The variable n is generally 1, 2 or 3; in certain compounds n is 1. In other compounds of Formulas I-III, n is chosen from 2 and 3.

Within certain embodiments of Formulas I-III, Ar_1 and Ar_2 are independently selected from optionally substituted phenyl and optionally substituted 5- to 7-membered heterocycles. For example, Ar_1 and Ar_2 may be independently selected from phenyl and 6-membered aromatic heterocycles, each of which is substituted with 0, 1 or 2 substituents. Substituents of Ar_1 and Ar_2 are generally groups of the formula LR_a, in which L is a bond, O, $S(O)_m$ (*i.e.*, S, $-\overset{O}{\overset{\|}{S}}-$ or $-\overset{O\ O}{\overset{\|\|}{S}}-$), C(=O) (*i.e.*, $-\overset{O}{\overset{\|}{C}}-$), OC(=O) (*i.e.*, $-O-\overset{O}{\overset{\|}{C}}-$), C(=O)O (*i.e.*, $-\overset{O}{\overset{\|}{C}}-O-$), O-C(=O)O (*i.e.*, $-O-\overset{O}{\overset{\|}{C}}-O-$), $N(R_x)$ (*i.e.*, $-\overset{R_x}{\overset{|}{N}}-$), C(=O)$N(R_x)$ (*i.e.*, $-\overset{O}{\overset{\|}{C}}-\overset{R_x}{\overset{|}{N}}-$), $N(R_x)$C(=O) (*i.e.*, $-\overset{R_x}{\overset{|}{N}}-\overset{O}{\overset{\|}{C}}-$), $N(R_x)S(O)_m$ (*e.g.*, $-\overset{R_x}{\overset{|}{N}}-\overset{O\ O}{\overset{\|\|}{S}}-$), $S(O)_mN(R_x)$ (*e.g.*, $-\overset{O\ O}{\overset{\|\|}{S}}-\overset{R_x}{\overset{|}{N}}-$), or $N[S(O)_mR_x]S(O)_m$ (*e.g.*, $-N(-\overset{O}{\overset{\|}{S}}(=O)-R_x)-\overset{O}{\overset{\|}{S}}(=O)-$); and R_a is as described above. If L is a bond, R_a is linked directly to a ring atom of Ar_1 or Ar_2; otherwise, L is located between a ring atom and R_a. It will be apparent that L is generally a bond if R_a is halogen, cyano or nitro. In the structural drawings of L moieties shown above, the bond on the left side is attached to the ring atom and the bond on the right is attached to R_a.

In certain embodiments, Ar_1 is phenyl or pyridyl, each of which is substituted with from 0 to 3 substituents as described above; preferably such substituents, if any, are independently selected from halogen, hydroxy, cyano, amino, nitro, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkoxy and haloC_1-C_6alkoxy. For example, Ar_1 may contain one substituent selected from halogen, cyano, C_1-C_4alkyl, C_1-C_4alkoxy,

haloC_1-C_4alkyl and haloC_1-C_4alkoxy. If one or more Ar_1 substituents is present, at least one such substituent is preferably located in the *ortho* position (*e.g.*, Ar_1 may be phenyl substituted at the 2-position, or pyridin-2-yl substituted at the 3-position). Ar_1 groups include, but are not limited to, pyridin-2-yl, 3-methyl-pyridin-2-yl, 3-trifluoromethyl-pyridin-2-yl, 3-halo-pyridin-2-yl, phenyl, 2-methyl-phenyl, 3-trifluoromethyl-phenyl and 3-halo-phenyl.

Ar_2 groups include, but are not limited to, phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl and thiadiazolyl, each of which is optionally substituted as described above. Preferred Ar_2 groups are phenyl, pyridyl, isoxazolyl, thiadiazolyl and pyrazolyl, each of which is optionally substituted as described above. Within certain embodiments, Ar_2 is phenyl or pyridyl, each of which is substituted with 0, 1 or 2 substituents as described above.

Optional substituents on the foregoing Ar_2 groups are preferably independently chosen from halogen, hydroxy, cyano, amino, nitro, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkoxy, haloC_1-C_6alkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoyl, $-(SO_2)R_d$, $-N(R_x)S(O)_mR_d$, and $-N[S(O_m)R_x]S(O)_mR_d$; wherein m is 1 or 2, R_x is hydrogen or C_1-C_6alkyl, and R_d is C_1-C_6alkyl, haloC_1-C_6alkyl, amino, mono- or di-(C_1-C_6alkyl)amino or a 5- to 10-membered, N-linked heterocyclic group, each of which R_d is substituted with from 0 to 2 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, mono- and di-(C_1-C_6alkyl)amino, C_1-C_4alkyl, haloC_1-C_4alkyl, C_1-C_4alkoxy and haloC_1-C_4alkoxy. Certain substituents of Ar_2 (*e.g.*, when Ar_2 is phenyl or pyridyl) are independently chosen from halogen, hydroxy, cyano, amino, nitro, C_1-C_4alkyl, haloC_1-C_4alkyl, C_2-C_4alkyl ether, C_1-C_4alkanoyl and groups of the formula $-(SO_2)R_d$ or $-SO_2N(R_x)$-R_d, wherein R_d is C_1-C_6alkyl or haloC_1-C_6alkyl. For example, each substituent is, in certain embodiments, independently chosen from halogen, C_1-C_4alkyl, haloC_1-C_4alkyl, cyano and groups of the formula $-(SO_2)R_d$, wherein R_d is C_1-C_4alkyl or haloC_1-C_4alkyl. Certain Ar_2 groups have 1 or 2 substituents independently chosen from halogen, cyano, C_1-C_4alkyl and haloC_1-C_4alkyl.

In certain embodiments, one Ar_2 substituent is located in the *para* position of a 6-membered Ar_2. Optional Ar_2 substituents are as described above and include, for example, groups in which R_a is independently selected at each occurrence from: (i) hydrogen, halogen, cyano and nitro; and (ii) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl and 4- to 10-membered heterocycles, each of which is substituted with from 0 to 4 substituents independently selected from hydroxy, halogen, C_1-C_6alkyl and haloC_1-C_6alkyl. Preferred R_a moieties include halogen, hydroxy, cyano, amino, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkyl,

haloC_1-C_6alkyl, C_1-C_6alkoxy, haloC_1-C_6alkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoyl, -$(SO_2)R_a$, -$NR_xS(O)_m$, and $-N(S(O)_m)_2$; wherein m is 1 or 2, R_x is hydrogen or C_1-C_6alkyl, and R_a is C_1-C_6alkyl, haloC_1-C_6alkyl, or a 5- to 10-membered, N-linked heterocyclic group, each of which R_a is substituted with from 0 to 4 substituents as described for Formula I. Preferred Ar_2 substituents include C_1-C_4alkyl, haloC_1-C_4alkyl and groups of the formula $-(SO_2)R_a$, wherein R_a is C_1-C_4alkyl or haloC_1-C_4alkyl.

Certain preferred Ar_2 groups are phenyl, pyridin-2-yl and pyridin-3-yl, each of which is substituted at the *para*-position with halogen, cyano, methyl, ethyl, propyl, isopropyl, *t*-butyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2,2,2-trifluoro-1-methyl-ethyl, methanesulfonyl, ethanesulfonyl, propanesulfonyl, propane-2-sulfonyl, trifluoromethanesulfonyl or 2,2,2-trifluoroethanesulfonyl. The term "*para*-position" is used herein to refer to the position on a 6-membered Ar_2 group that is *para* to the point of attachment to the core of the molecule. In other words, if Ar_2 is phenyl, the 4-position is the *para*-position; if Ar_2 is pyridin-2-yl, the 5-position is the *para*-position; and if Ar_2 is pyridin-3-yl, the 6-position is the *para*-position. Additional substitutions, not at the *para* position, may also be present on certain preferred Ar_2 groups – preferably no more than 2 additional substitutions, and more preferably 0 or 1 additional substitution.

Certain compounds provided herein satisfy one or more of subformulas Ia-Ic, IIa-IId and IIIa-IIId, in which A, B and C are independently N or CH, and other variables are as described above for Formulas I-III or preferred embodiments thereof. X, in certain embodiments, is N or CH. $(LR_a)_{1-3}$ indicates 1, 2 or 3 ring substituents independently chosen from LR_a as described above; $(LR_a)_{0-2}$ indicates 0, 1 or 2 ring substituents (in addition to the substituent shown at the *para* position) independently chosen from LR_a as described above.



Ia



Ib



Ic



IIa



IIb



IIc



IId



IIe



IIIa



IIIb



IIIc



IIId



IIIe

In certain compounds of the above subformulas, Y and Z are independently CH or N. In further compounds of Formulas Ia, IIb and IIIb, Ar_1 is pyridyl, unsubstituted or substituted with halogen, cyano, C_1-C_4alkyl or haloC_1-C_4alkyl; Ar_2 is phenyl or pyridyl, unsubstituted or substituted with C_1-C_4alkyl, cyanoC_1-C_4alkyl, haloC_1-C_4alkyl, C_2-C_6alkyl ether or a group of the formula -$(SO_2)R_d$, wherein R_d is C_1-C_4alkyl or haloC_1-C_4alkyl; and R_5 and R_6 are independently selected from hydrogen and C_1-C_4alkyl. In certain compounds of Formulas IIa-IIe, R_7 is (a) hydrogen; or (b) C_1-C_6alkyl, C_2-C_6alkenyl or phenylC_0-C_4alkyl, each of which is substituted with 0, 1 or 2 substituents independently selected from hydroxy, halogen,

C_1-C_4alkyl and haloC_1-C_4alkyl. In certain compounds of Formulas IIIa-IIIe, R_3 and R_4 are (a) independently selected from: (i) hydrogen; and (ii) C_1-C_6alkyl, C_2-C_6alkenyl, (5- to 7-membered heterocycle)C_0-C_4alkyl, C_2-C_6alkyl ether, indanyl, benzyl, 1-phenyl-ethyl, 1-phenyl-propyl and 2-phenyl-ethyl, each of which is substituted with from 0 to 3 substituents independently selected from hydroxy, cyano, halogen, C_1-C_4alkyl and haloC_1-C_4alkyl; or (b) taken together to form a 5- to 7-membered heterocycloalkyl that is substituted with from 0 to 3 substituents independently selected from hydroxy, cyano, halogen, C_1-C_4alkyl and haloC_1-C_4alkyl. In Formulas IIc-IIe and IIIc-IIIe, R_6 is preferably hydrogen or methyl.

In certain embodiments of the invention, preferred compounds of Formula III and subformulas thereof (e.g., IIIa-IIIe) include those compounds in which at least one of R_5 and R_6 is not hydrogen when n is 1.

Representative compounds of Formulas I-III, and subformulas thereof, include, but are not limited to, those specifically described in Examples 1-3. It will be apparent that the specific compounds recited therein are representative only, and are not intended to limit the scope of the present invention. Further, as noted above, all compounds of the present invention may be present as a pharmaceutically acceptable form, such as a hydrate or acid addition salt.

2-Substituted quinazolin-4-ylamine analogues provided herein detectably alter (modulate) VR1 activity, as determined using an *in vitro* VR1 ligand binding assay and/or a functional assay such as a calcium mobilization assay, dorsal root ganglion assay or *in vivo* pain relief assay. References herein to a "VR1 ligand binding assay" are intended to refer to a standard *in vitro* receptor binding assay such as that provided in Example 5, and a "calcium mobilization assay" (also referred to herein as a "signal transduction assay") may be performed as described in Example 6. Briefly, to assess binding to VR1, a competition assay may be performed in which a VR1 preparation is incubated with labeled (*e.g.*, ^{125}I or ^{3}H) compound that binds to VR1 (*e.g.*, a capsaicin receptor agonist such as RTX) and unlabeled test compound. Within the assays provided herein, the VR1 used is preferably mammalian VR1, more preferably human or rat VR1. The receptor may be recombinantly expressed or naturally expressed. The VR1 preparation may be, for example, a membrane preparation from HEK293 or CHO cells that recombinantly express human VR1. Incubation with a compound that detectably modulates vanilloid ligand binding to VR1 results in a decrease or increase in the amount of label bound to the VR1 preparation, relative to the amount of label bound in the absence of the compound. This decrease or increase may be used to determine

the K_i at VR1 as described herein. In general, compounds that decrease the amount of label bound to the VR1 preparation within such an assay are preferred.

As noted above, compounds that are VR1 antagonists are preferred within certain embodiments. IC_{50} values for such compounds may be determined using a standard *in vitro* VR1-mediated calcium mobilization assay, as provided in Example 6. Briefly, cells expressing capsaicin receptor are contacted with a compound of interest and with an indicator of intracellular calcium concentration (*e.g.*, a membrane permeable calcium sensitivity dye such as Fluo-3 or Fura-2 (both of which are available, for example, from Molecular Probes, Eugene, OR), each of which produce a fluorescent signal when bound to Ca^{++}). Such contact is preferably carried out by one or more incubations of the cells in buffer or culture medium comprising either or both of the compound and the indicator in solution. Contact is maintained for an amount of time sufficient to allow the dye to enter the cells (*e.g.*, 1-2 hours). Cells are washed or filtered to remove excess dye and are then contacted with a vanilloid receptor agonist (*e.g.*, capsaicin, RTX or olvanil), typically at a concentration equal to the EC_{50} concentration, and a fluorescence response is measured. When agonist-contacted cells are contacted with a compound that is a VR1 antagonist the fluorescence response is generally reduced by at least 20%, preferably at least 50% and more preferably at least 80%, as compared to cells that are contacted with the agonist in the absence of test compound. The IC_{50} for VR1 antagonists provided herein is preferably less than 1 micromolar, less than 100 nM, less than 10 nM or less than 1 nM.

In other embodiments, compounds that are capsaicin receptor agonists are preferred. Capsaicin receptor agonist activity may generally be determined as described in Example 6. When cells are contacted with 1 micromolar of a compound that is a VR1 agonist, the fluorescence response is generally increased by an amount that is at least 30% of the increase observed when cells are contacted with 100 nM capsaicin. The EC_{50} for VR1 agonists provided herein is preferably less than 1 micromolar, less than 100 nM or less than 10 nM.

VR1 modulating activity may also, or alternatively, be assessed using a cultured dorsal root ganglion assay as provided in Example 9 and/or an *in vivo* pain relief assay as provided in Example 10. Compounds provided herein preferably have a statistically significant specific effect on VR1 activity within one or more functional assays provided herein.

Within certain embodiments, VR1 modulators provided herein do not substantially modulate ligand binding to other cell surface receptors, such as EGF receptor tyrosine kinase or the nicotinic acetylcholine receptor. In other words, such modulators do not substantially

inhibit activity of a cell surface receptor such as the human epidermal growth factor (EGF) receptor tyrosine kinase or the nicotinic acetylcholine receptor (*e.g.*, the IC_{50} or IC_{40} at such a receptor is preferably greater than 1 micromolar, and most preferably greater than 10 micromolar). Preferably, a modulator does not detectably inhibit EGF receptor activity or nicotinic acetylcholine receptor activity at a concentration of 0.5 micromolar, 1 micromolar or more preferably 10 micromolar. Assays for determining cell surface receptor activity are commercially available, and include the tyrosine kinase assay kits available from Panvera (Madison, WI).

Preferred VR1 modulators provided herein are non-sedating. In other words, a dose of VR1 modulator that is twice the minimum dose sufficient to provide analgesia in an animal model for determining pain relief (such as a model provided in Example 10, herein) causes only transient (*i.e.*, lasting for no more than ½ the time that pain relief lasts) or preferably no statistically significant sedation in an animal model assay of sedation (using the method described by Fitzgerald et al. (1988) *Toxicology* 49(2-3):433-9). Preferably, a dose that is five times the minimum dose sufficient to provide analgesia does not produce statistically significant sedation. More preferably, a VR1 modulator provided herein does not produce sedation at intravenous doses of less than 25 mg/kg (preferably less than 10 mg/kg) or at oral doses of less than 140 mg/kg (preferably less than 50 mg/kg, more preferably less than 30 mg/kg).

If desired, VR1 modulators provided herein may be evaluated for certain pharmacological properties including, but not limited to, oral bioavailability (preferred compounds are orally bioavailable to an extent allowing for therapeutically effective concentrations of the compound to be achieved at oral doses of less than 140 mg/kg, preferably less than 50 mg/kg, more preferably less than 30 mg/kg, even more preferably less than 10 mg/kg, still more preferably less than 1 mg/kg and most preferably less than 0.1 mg/kg), toxicity (a preferred VR1 modulator is nontoxic when a capsaicin receptor modulatory amount is administered to a subject), side effects (a preferred VR1 modulator produces side effects comparable to placebo when a therapeutically effective amount of the compound is administered to a subject), serum protein binding and *in vitro* and *in vivo* half-life (a preferred VR1 modulator exhibits an *in vitro* half-life that is equal to an *in vivo* half-life allowing for Q.I.D. dosing, preferably T.I.D. dosing, more preferably B.I.D. dosing, and most preferably once-a-day dosing). In addition, differential penetration of the blood brain barrier may be desirable for VR1 modulators used to treat pain by modulating CNS VR1 activity such that total daily oral doses as described above provide such modulation to a

therapeutically effective extent, while low brain levels of VR1 modulators used to treat peripheral nerve mediated pain may be preferred (*i.e.,* such doses do not provide brain (*e.g.,* CSF) levels of the compound sufficient to significantly modulate VR1 activity). Routine assays that are well known in the art may be used to assess these properties, and identify superior compounds for a particular use. For example, assays used to predict bioavailability include transport across human intestinal cell monolayers, including Caco-2 cell monolayers. Penetration of the blood brain barrier of a compound in humans may be predicted from the brain levels of the compound in laboratory animals given the compound (*e.g.,* intravenously). Serum protein binding may be predicted from albumin binding assays. Compound half-life is inversely proportional to the frequency of dosage of a compound. *In vitro* half-lives of compounds may be predicted from assays of microsomal half-life as described within Example 7, herein.

As noted above, preferred VR1 modulators provided herein are nontoxic. In general, the term "nontoxic" as used herein shall be understood in a relative sense and is intended to refer to any substance that has been approved by the United States Food and Drug Administration ("FDA") for administration to mammals (preferably humans) or, in keeping with established criteria, is susceptible to approval by the FDA for administration to mammals (preferably humans). In addition, a highly preferred nontoxic compound generally satisfies one or more of the following criteria: (1) does not substantially inhibit cellular ATP production; (2) does not significantly prolong heart QT intervals; (3) does not cause substantial liver enlargement, and (4) does not cause substantial release of liver enzymes.

As used herein, a VR1 modulator that "does not substantially inhibit cellular ATP production" is a compound that satisfies the criteria set forth in Example 8, herein. In other words, cells treated as described in Example 8 with 100 μM of such a compound exhibit ATP levels that are at least 50% of the ATP levels detected in untreated cells. In more highly preferred embodiments, such cells exhibit ATP levels that are at least 80% of the ATP levels detected in untreated cells.

A VR1 modulator that "does not significantly prolong heart QT intervals" is a compound that does not result in a statistically significant prolongation of heart QT intervals (as determined by electrocardiography) in guinea pigs, minipigs or dogs upon administration of twice the minimum dose yielding a therapeutically effective *in vivo* concentration. In certain preferred embodiments, a dose of 0.01, 0.05. 0.1, 0.5, 1, 5, 10, 40 or 50 mg/kg administered parenterally or orally does not result in a statistically significant prolongation of heart QT intervals. By "statistically significant" is meant results varying from control at the

$p<0.1$ level or more preferably at the $p<0.05$ level of significance as measured using a standard parametric assay of statistical significance such as a student's T test.

A VR1 modulator "does not cause substantial liver enlargement" if daily treatment of laboratory rodents (*e.g.*, mice or rats) for 5-10 days with twice the minimum dose that yields a therapeutically effective *in vivo* concentration results in an increase in liver to body weight ratio that is no more than 100% over matched controls. In more highly preferred embodiments, such doses do not cause liver enlargement of more than 75% or 50% over matched controls. If non-rodent mammals (*e.g.*, dogs) are used, such doses should not result in an increase of liver to body weight ratio of more than 50%, preferably not more than 25%, and more preferably not more than 10% over matched untreated controls. Preferred doses within such assays include 0.01, 0.05. 0.1, 0.5, 1, 5, 10, 40 or 50 mg/kg administered parenterally or orally.

Similarly, a VR1 modulator "does not promote substantial release of liver enzymes" if administration of twice the minimum dose yielding a therapeutically effective *in vivo* concentration does not elevate serum levels of ALT, LDH or AST in laboratory rodents by more than 100% over matched mock-treated controls. In more highly preferred embodiments, such doses do not elevate such serum levels by more than 75% or 50% over matched controls. Alternatively, a VR1 modulator "does not promote substantial release of liver enzymes" if, in an *in vitro* hepatocyte assay, concentrations (in culture media or other such solutions that are contacted and incubated with hepatocytes *in vitro*) equivalent to two-fold the minimum *in vivo* therapeutic concentration of the compound do not cause detectable release of any of such liver enzymes into culture medium above baseline levels seen in media from matched mock-treated control cells. In more highly preferred embodiments, there is no detectable release of any of such liver enzymes into culture medium above baseline levels when such compound concentrations are five-fold, and preferably ten-fold the minimum *in vivo* therapeutic concentration of the compound.

In other embodiments, certain preferred VR1 modulators do not inhibit or induce microsomal cytochrome P450 enzyme activities, such as CYP1A2 activity, CYP2A6 activity, CYP2C9 activity, CYP2C19 activity, CYP2D6 activity, CYP2E1 activity or CYP3A4 activity at a concentration equal to the minimum therapeutically effective *in vivo* concentration.

Certain preferred VR1 modulators are not clastogenic (*e.g.*, as determined using a mouse erythrocyte precursor cell micronucleus assay, an Ames micronucleus assay, a spiral micronucleus assay or the like) at a concentration equal to the minimum therapeutically

effective *in vivo* concentration. In other embodiments, certain preferred VR1 modulators do not induce sister chromatid exchange (*e.g.,* in Chinese hamster ovary cells) at such concentrations.

For detection purposes, as discussed in more detail below, VR1 modulators provided herein may be isotopically-labeled or radiolabeled. For example, compounds recited in Formulas I-III may have one or more atoms replaced by an atom of the same element having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be present in the compounds provided herein include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as ^{2}H, ^{3}H, ^{11}C, ^{13}C, ^{14}C, ^{15}N, ^{18}O, ^{17}O, ^{31}P, ^{32}P, ^{35}S, ^{18}F and ^{36}Cl. In addition, substitution with heavy isotopes such as deuterium (*i.e.,* ^{2}H) can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances.

PREPARATION OF VR1 MODULATORS

2-Substituted quinazolin-4-ylamine analogues may generally be prepared using standard synthetic methods. Starting materials are commercially available from suppliers such as Sigma-Aldrich Corp. (St. Louis, MO), or may be synthesized from commercially available precursors using established protocols. By way of example, a synthetic route similar to that shown in any of Schemes 1-13 may be used, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereon as appreciated by those skilled in the art. Variables in the following schemes refer to any group consistent with at least one of Formulas I-III herein. Where a structure contains more than one variable "R," each R is selected independently of any other R group(s).

In the Schemes that follow, the term "activate" refers to a synthetic transformation in which a carbonyl of an amide moiety is converted to a suitable leaving group (L). Such a transformation can be used to prepare compounds of general structure 1I (Scheme 1), 2G (Scheme 2), 3G and 3L (Scheme 3), 4C (Scheme 4), 5F (Scheme 5), 7H (Scheme 7), 10H (Scheme 10), 12I (Scheme 12) and 13I (Scheme 13). Reagents suitable for carrying out this transformation are well known to those skilled in the art of organic synthesis and include, but are not limited to, $SOCl_2$, $POCl_3$ and triflic anhydride.

The term "catalyst" refers to a suitable transition metal catalyst such as, but not limited to, tetrakis(triphenylphosphine)palladium(0) or palladium(II) acetate. In addition, the catalytic systems may include ligands such as, but not limited to, 2-

(Dicyclohexylphosphino)biphenyl and tri-*tert*-butylphosphine, and may also include a base such as K_3PO_4, Na_2CO_3 or sodium or potassium *tert*-butoxide. Transition metal-catalyzed reactions can be carried out at ambient or elevated temperatures using various inert solvents including, but not limited to, toluene, dioxane, DMF, N-methylpyrrolidinone, ethyleneglycol, dimethyl ether, diglyme and acetonitrile. When used in conjunction with suitable metallo-aryl reagents, transition metal-catalyzed (hetero)aryl-aryl coupling reactions can be used to prepare the compounds encompassed in general structures 1C (Scheme 1), 2A (Scheme 2), 3D (Scheme 3), 5C (Scheme 5), 6C (Scheme 6), 11D (Scheme 11), 12C (Scheme 12) and 13C (Scheme 13). Commonly employed reagent/catalyst pairs include aryl boronic acid/palladium(0) (Suzuki reaction; Miyaura and Suzuki (1995) *Chemical Reviews 95*:2457) and aryl trialkylstannane/palladium(0) (Stille reaction; T. N. Mitchell, (1992) *Synthesis 9*:803-815), arylzinc/palladium(0) and aryl Grignard/nickel(II).

The term "demethylation" refers to the cleavage of the Me-O bond in a methyl ether functionality as exemplified by the conversion of 3-D to 3-E (Scheme 3). This transformation can be carried out in a variety of ways familiar to those skilled in the art of organic synthesis including, but not limited to, treatment with HBr, treatment with Lewis acid/nucleophile combinations, Trimethylsilyl iodide, etc.

"Diazotize," in Scheme 11 refers to the process whereby a primary aromatic amine is converted to a diazonium salt. This transformation is carried out by treating the aromatic amine with nitrous acid which can be generated in a number of ways well known to those skilled in the art of organic synthesis. The diazonium group thus generated can then be replaced by a cyano group upon treatment with CuCN (Sandmeyer reaction) as shown in Scheme 11.

In Scheme 12, the term "deprotection" refers to the process of cleaving the C-O bond of a benzylic ether to give a "deprotected" alcohol using various methods familiar to those who are skilled in the art of organic synthesis. This is exemplified in Scheme 12 in which compounds of general structure 12I can be converted to deprotected alcohols of general structure 12J. Methods to effect this transformation include, but are not limited to, hydrogenolysis using hydrogen gas and an appropriate catalyst system such as palladium on carbon or Raney nickel. For an overview of protection and deprotection methods as used by those skilled in the art of organic synthesis, see: Greene, T. and Wuts, P. *Protective Groups in Organic Synthesis*, 3rd ed., John Wiley and Sons, 1999.

The term "hydrolyze" refers to the conversion of a nitrile functionality to an amide functionality by reaction with water. The reaction with water can be catalyzed by a variety of

acids or bases well known to those skilled in the art of organic synthesis. This process is exemplified by the conversion of 8-B to 8-C (Scheme 8) and 10-E to 10-F (Scheme 10).

The term "oxidize" refers to a synthetic transformation wherein a methyl group is converted to a carboxylic acid functionality. Such a transformation can be used to prepare compounds such as 1E, 6D, 12E and 13E (Schemes 1, 6, 12 and 13 respectively). Various reagents familiar to those skilled in the art of organic synthesis may be used to carry out this transformation including, but not limited to, $KMnO_4$ in basic media (*e.g.*, NaOH solution or aqueous pyridine) and $K_2Cr_2O_7$ in acidic media (*e.g.*, H_2SO_4).

The term "reduce" in the following Schemes refers to the process of reducing a nitro functionality to an amino functionality. This transformation can be carried out in a number of ways well known to those skilled in the art of organic synthesis including, but not limited to, catalytic hydrogenation, reduction with $SnCl_2$ and reduction with titanium trichloride. For an overview of reduction methods see: Hudlicky, M. *Reductions in Organic Chemistry*, ACS Monograph 188, 1996.

Scheme 1



Scheme 2



5

REST OF THIS PAGE LEFT INTENTIONALLY LEFT BLANK

Scheme 3



Scheme 4



5

Scheme 5



5-B 5-C 5-D 5-E 5-F 5-A

Scheme 6



Eur.J.Med.Chem. - Chim. Ther., **1977**, 12(6), 541-7

6-B 6-C 6-D 6-E 6-A

Scheme 7



Scheme 8



Scheme 9



Scheme 10



Scheme 11



Scheme 12


B(OH)2
Catalyst
A = CH,N
12-B
12-C
HNO3
NO2
Oxidize
12-D
COOH
1) SOCl2
2) NH3
CONH2
Reduce
NH2
12-E
12-F
12-G
1) Cl
Ph
2) Base
n = 1 or 2
NH
n = 1 or 2
12-H
1) Activate
2) R-Ar-NH2
HN
Deprotection
SOCl2
OH
12-I
12-J
Cl
R'-NH-R"
R'
R"
12-K
12-A

Scheme 13



In certain embodiments, a VR1 modulator may contain one or more asymmetric carbon atoms, so that the compound can exist in different stereoisomeric forms. Such forms can be, for example, racemates or optically active forms. As noted above, all stereoisomers are encompassed by the present invention. Nonetheless, it may be desirable to obtain single enantiomers (*i.e.*, optically active forms). Standard methods for preparing single enantiomers include asymmetric synthesis and resolution of the racemates. Resolution of the racemates can be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography using, for example a chiral HPLC column.

Compounds may be radiolabeled by carrying out their synthesis using precursors comprising at least one atom that is a radioisotope. Each radioisotope is preferably carbon (*e.g.*, ^{14}C), hydrogen (*e.g.*, ^{3}H), sulfur (*e.g.*, ^{35}S), or iodine (*e.g.*, ^{125}I). Tritium labeled compounds may also be prepared catalytically via platinum-catalyzed exchange in tritiated acetic acid, acid-catalyzed exchange in tritiated trifluoroacetic acid, or heterogeneous-catalyzed exchange with tritium gas using the compound as substrate. In addition, certain precursors may be subjected to tritium-halogen exchange with tritium gas, tritium gas

reduction of unsaturated bonds, or reduction using sodium borotritide, as appropriate. Preparation of radiolabeled compounds may be conveniently performed by a radioisotope supplier specializing in custom synthesis of radiolabeled probe compounds.

PHARMACEUTICAL COMPOSITIONS

The present invention also provides pharmaceutical compositions comprising one or more VR1 modulators, together with at least one physiologically acceptable carrier or excipient. Pharmaceutical compositions may comprise, for example, one or more of water, buffers (*e.g.,* neutral buffered saline or phosphate buffered saline), ethanol, mineral oil, vegetable oil, dimethylsulfoxide, carbohydrates (*e.g.,* glucose, mannose, sucrose or dextrans), mannitol, proteins, adjuvants, polypeptides or amino acids such as glycine, antioxidants, chelating agents such as EDTA or glutathione and/or preservatives. In addition, other active ingredients may (but need not) be included in the pharmaceutical compositions provided herein.

Pharmaceutical compositions may be formulated for any appropriate manner of administration, including, for example, topical, oral, nasal, rectal or parenteral administration. The term parenteral as used herein includes subcutaneous, intradermal, intravascular (*e.g.,* intravenous), intramuscular, spinal, intracranial, intrathecal and intraperitoneal injection, as well as any similar injection or infusion technique. In certain embodiments, compositions suitable for oral use are preferred. Such compositions include, for example, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs. Within yet other embodiments, compositions of the present invention may be formulated as a lyophilizate. Formulation for topical administration may be preferred for certain conditions (*e.g.,* in the treatment of skin conditions such as burns or itch). Formulation for direct administration into the bladder (intravesicular administration) may be preferred for treatment of urinary incontinence.

Compositions intended for oral use may further comprise one or more components such as sweetening agents, flavoring agents, coloring agents and/or preserving agents in order to provide appealing and palatable preparations. Tablets contain the active ingredient in admixture with physiologically acceptable excipients that are suitable for the manufacture of tablets. Such excipients include, for example, inert diluents (*e.g.,* calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate), granulating and disintegrating agents (*e.g.,* corn starch or alginic acid), binding agents (*e.g.,* starch, gelatin or acacia) and lubricating agents (*e.g.,* magnesium stearate, stearic acid or talc). The tablets may be

uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monosterate or glyceryl distearate may be employed.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent (*e.g.,* calcium carbonate, calcium phosphate or kaolin), or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium (*e.g.,* peanut oil, liquid paraffin or olive oil).

Aqueous suspensions contain the active material(s) in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include suspending agents (*e.g.,* sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia); and dispersing or wetting agents *(e.g.,* naturally-occurring phosphatides such as lecithin, condensation products of an alkylene oxide with fatty acids such as polyoxyethylene stearate, condensation products of ethylene oxide with long chain aliphatic alcohols such as heptadecaethyleneoxycetanol, condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides such as polyethylene sorbitan monooleate). Aqueous suspensions may also comprise one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

Oily suspensions may be formulated by suspending the active ingredient(s) in a vegetable oil (*e.g.,* arachis oil, olive oil, sesame oil or coconut oil) or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and/or flavoring agents may be added to provide palatable oral preparations. Such suspensions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, such as sweetening, flavoring and coloring agents, may also be present.

Pharmaceutical compositions may also be formulated as oil-in-water emulsions. The oily phase may be a vegetable oil (*e.g.,* olive oil or arachis oil), a mineral oil (*e.g.,* liquid paraffin) or a mixture thereof. Suitable emulsifying agents include naturally-occurring gums (*e.g.,* gum acacia or gum tragacanth), naturally-occurring phosphatides (*e.g.,* soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol), anhydrides (*e.g.,* sorbitan monoleate) and condensation products of partial esters derived from fatty acids and hexitol with ethylene oxide (*e.g.,* polyoxyethylene sorbitan monoleate). An emulsion may also comprise one or more sweetening and/or flavoring agents.

Syrups and elixirs may be formulated with sweetening agents, such as glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also comprise one or more demulcents, preservatives, flavoring agents and/or coloring agents.

Formulations for topical administration typically comprise a topical vehicle combined with active agent(s), with or without additional optional components. Suitable topical vehicles and additional components are well known in the art, and it will be apparent that the choice of a vehicle will depend on the particular physical form and mode of delivery. Topical vehicles include water; organic solvents such as alcohols (*e.g.,* ethanol or isopropyl alcohol) or glycerin; glycols (*e.g.,* butylene, isoprene or propylene glycol); aliphatic alcohols (*e.g.,* lanolin); mixtures of water and organic solvents and mixtures of organic solvents such as alcohol and glycerin; lipid-based materials such as fatty acids, acylglycerols (including oils, such as mineral oil, and fats of natural or synthetic origin), phosphoglycerides, sphingolipids and waxes; protein-based materials such as collagen and gelatin; silicone-based materials (both non-volatile and volatile); and hydrocarbon-based materials such as microsponges and polymer matrices. A composition may further include one or more components adapted to improve the stability or effectiveness of the applied formulation, such as stabilizing agents, suspending agents, emulsifying agents, viscosity adjusters, gelling agents, preservatives, antioxidants, skin penetration enhancers, moisturizers and sustained release materials. Examples of such components are described in Martindale--The Extra Pharmacopoeia (Pharmaceutical Press, London 1993) and Martin (ed.), Remington's Pharmaceutical Sciences. Formulations may comprise microcapsules, such as hydroxymethylcellulose or gelatin-microcapsules, liposomes, albumin microspheres, microemulsions, nanoparticles or nanocapsules.

A topical formulation may be prepared in a variety of physical forms including, for example, solids, pastes, creams, foams, lotions, gels, powders, aqueous liquids and emulsions. The physical appearance and viscosity of such pharmaceutically acceptable forms

can be governed by the presence and amount of emulsifier(s) and viscosity adjuster(s) present in the formulation. Solids are generally firm and non-pourable and commonly are formulated as bars or sticks, or in particulate form; solids can be opaque or transparent, and optionally can contain solvents, emulsifiers, moisturizers, emollients, fragrances, dyes/colorants, preservatives and other active ingredients that increase or enhance the efficacy of the final product. Creams and lotions are often similar to one another, differing mainly in their viscosity; both lotions and creams may be opaque, translucent or clear and often contain emulsifiers, solvents, and viscosity adjusting agents, as well as moisturizers, emollients, fragrances, dyes/colorants, preservatives and other active ingredients that increase or enhance the efficacy of the final product. Gels can be prepared with a range of viscosities, from thick or high viscosity to thin or low viscosity. These formulations, like those of lotions and creams, may also contain solvents, emulsifiers, moisturizers, emollients, fragrances, dyes/colorants, preservatives and other active ingredients that increase or enhance the efficacy of the final product. Liquids are thinner than creams, lotions, or gels and often do not contain emulsifiers. Liquid topical products often contain solvents, emulsifiers, moisturizers, emollients, fragrances, dyes/colorants, preservatives and other active ingredients that increase or enhance the efficacy of the final product.

Suitable emulsifiers for use in topical formulations include, but are not limited to, ionic emulsifiers, cetearyl alcohol, non-ionic emulsifiers like polyoxyethylene oleyl ether, PEG-40 stearate, ceteareth-12, ceteareth-20, ceteareth-30, ceteareth alcohol, PEG-100 stearate and glyceryl stearate. Suitable viscosity adjusting agents include, but are not limited to, protective colloids or non-ionic gums such as hydroxyethylcellulose, xanthan gum, magnesium aluminum silicate, silica, microcrystalline wax, beeswax, paraffin, and cetyl palmitate. A gel composition may be formed by the addition of a gelling agent such as chitosan, methyl cellulose, ethyl cellulose, polyvinyl alcohol, polyquaterniums, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carbomer or ammoniated glycyrrhizinate. Suitable surfactants include, but are not limited to, nonionic, amphoteric, ionic and anionic surfactants. For example, one or more of dimethicone copolyol, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, lauramide DEA, cocamide DEA, and cocamide MEA, oleyl betaine, cocamidopropyl phosphatidyl PG-dimonium chloride, and ammonium laureth sulfate may be used within topical formulations. Suitable preservatives include, but are not limited to, antimicrobials such as methylparaben, propylparaben, sorbic acid, benzoic acid, and formaldehyde, as well as physical stabilizers and antioxidants such as vitamin E, sodium ascorbate/ascorbic acid and propyl gallate.

Suitable moisturizers include, but are not limited to, lactic acid and other hydroxy acids and their salts, glycerin, propylene glycol, and butylene glycol. Suitable emollients include lanolin alcohol, lanolin, lanolin derivatives, cholesterol, petrolatum, isostearyl neopentanoate and mineral oils. Suitable fragrances and colors include, but are not limited to, FD&C Red No. 40 and FD&C Yellow No. 5. Other suitable additional ingredients that may be included a topical formulation include, but are not limited to, abrasives, absorbents, anti-caking agents, anti-foaming agents, anti-static agents, astringents (*e.g.,* witch hazel, alcohol and herbal extracts such as chamomile extract), binders/excipients, buffering agents, chelating agents, film forming agents, conditioning agents, propellants, opacifying agents, pH adjusters and protectants.

An example of a suitable topical vehicle for formulation of a gel is: hydroxypropylcellulose (2.1%); 70/30 isopropyl alcohol/water (90.9%); propylene glycol (5.1%); and Polysorbate 80 (1.9%). An example of a suitable topical vehicle for formulation as a foam is: cetyl alcohol (1.1%); stearyl alcohol (0.5%; Quaternium 52 (1.0%); propylene glycol (2.0%); Ethanol 95 PGF3 (61.05%); deionized water (30.05%); P75 hydrocarbon propellant (4.30%). All percents are by weight.

Typical modes of delivery for topical compositions include application using the fingers; application using a physical applicator such as a cloth, tissue, swab, stick or brush; spraying (including mist, aerosol or foam spraying); dropper application; sprinkling; soaking; and rinsing. Controlled release vehicles can also be used.

A pharmaceutical composition may be prepared as a sterile injectible aqueous or oleaginous suspension. The modulator, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Such a composition may be formulated according to the known art using suitable dispersing, wetting agents and/or suspending agents such as those mentioned above. Among the acceptable vehicles and solvents that may be employed are water, 1,3-butanediol, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils may be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectible compositions, and adjuvants such as local anesthetics, preservatives and/or buffering agents can be dissolved in the vehicle.

Modulators may also be formulated as suppositories (*e.g.,* for rectal administration). Such compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will

therefore melt in the rectum to release the drug. Suitable excipients include, for example, cocoa butter and polyethylene glycols.

Pharmaceutical compositions may be formulated as sustained release formulations (*i.e.*, a formulation such as a capsule that effects a slow release of modulator following administration). Such formulations may generally be prepared using well known technology and administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site. Carriers for use within such formulations are biocompatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of modulator release. The amount of modulator contained within a sustained release formulation depends upon, for example, the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

In addition to or together with the above modes of administration, a modulator may be conveniently added to food or drinking water (*e.g.*, for administration to non-human animals including companion animals (such as dogs and cats) and livestock). Animal feed and drinking water compositions may be formulated so that the animal takes in an appropriate quantity of the composition along with its diet. It may also be convenient to present the composition as a premix for addition to feed or drinking water.

Modulators are generally administered in a capsaicin receptor modulatory amount, and preferably a therapeutically effective amount. Preferred systemic doses are no higher than 50 mg per kilogram of body weight per day (*e.g.*, ranging from about 0.001 mg to about 50 mg per kilogram of body weight per day), with oral doses generally being about 5-20 fold higher than intravenous doses (*e.g.*, ranging from 0.01 to 40 mg per kilogram of body weight per day).

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage unit will vary depending, for example, upon the patient being treated and the particular mode of administration. Dosage units will generally contain between from about 10 μg to about 500 mg of an active ingredient. Optimal dosages may be established using routine testing, and procedures that are well known in the art.

Pharmaceutical compositions may be packaged for treating conditions responsive to VR1 modulation (*e.g.*, treatment of exposure to vanilloid ligand, pain, itch, obesity or urinary incontinence). Packaged pharmaceutical compositions may include a container holding a therapeutically effective amount of at least one VR1 modulator as described herein and instructions (*e.g.*, labeling) indicating that the contained composition is to be used for treating a condition responsive to VR1 modulation in the patient.

METHODS OF USE

VR1 modulators provided herein may be used to alter activity and/or activation of capsaicin receptors in a variety of contexts, both *in vitro* and *in vivo*. Within certain aspects, VR1 antagonists may be used to inhibit the binding of vanilloid ligand agonist (such as capsaicin and/or RTX) to capsaicin receptor *in vitro* or *in vivo*. In general, such methods comprise the step of contacting a capsaicin receptor with a capsaicin receptor modulatory amount of one or more 2-substituted quinazolin-4-ylamine analogues, or pharmaceutically acceptable forms thereof, in the presence of vanilloid ligand in aqueous solution and under conditions otherwise suitable for binding of the ligand to capsaicin receptor. The capsaicin receptor may be present in solution or suspension (*e.g.,* in an isolated membrane or cell preparation), or in a cultured or isolated cell. Within certain embodiments, the capsaicin receptor is expressed by a neuronal cell present in a patient, and the aqueous solution is a body fluid. Preferably, one or more VR1 modulators are administered to an animal in an amount such that the analogue is present in at least one body fluid of the animal at a therapeutically effective concentration that is 1 micromolar or less; preferably 500 nanomolar or less; more preferably 100 nanomolar or less, 50 nanomolar or less, 20 nanomolar or less, or 10 nanomolar or less. For example, such compounds may be administered at a dose that is less than 20 mg/kg body weight, preferably less than 5 mg/kg and, in some instances, less than 1 mg/kg.

Also provided herein are methods for modulating, preferably inhibiting, the signal-transducing activity of a capsaicin receptor. Such modulation may be achieved by contacting a capsaicin receptor (either *in vitro* or *in vivo*) with a capsaicin receptor modulatory amount of one or more VR1 modulators provided herein under conditions suitable for binding of the modulator(s) to the receptor. The receptor may be present in solution or suspension, in a cultured or isolated cell preparation or within a patient. Modulation of signal tranducing activity may be assessed by detecting an effect on calcium ion conductance (also referred to as calcium mobilization or flux). Modulation of signal transducing activity may alternatively be assessed by detecting an alteration of a symptom (*e.g.,* pain, burning sensation, broncho-constriction, inflammation, cough, hiccup, itch, and urinary incontinence) of a patient being treated with one or more VR1 modulators provided herein.

VR1 modulator(s) provided herein are preferably administered to a patient (*e.g.,* a human) orally or topically, and are present within at least one body fluid of the animal while modulating VR1 signal-transducing activity. Preferred VR1 modulators for use in such methods modulate VR1 signal-transducing activity *in vitro* at a concentration of 1 nanomolar

or less, preferably 100 picomolar or less, more preferably 20 picomolar or less, and *in vivo* at a concentration of 1 micromolar or less, 500 nanomolar or less, or 100 nanomolar or less in a body fluid such as blood.

The present invention further provides methods for treating conditions responsive to VR1 modulation. Within the context of the present invention, the term "treatment" encompasses both disease-modifying treatment and symptomatic treatment, either of which may be prophylactic (*i.e.*, before the onset of symptoms, in order to prevent, delay or reduce the severity of symptoms) or therapeutic (*i.e.*, after the onset of symptoms, in order to reduce the severity and/or duration of symptoms). A condition is "responsive to VR1 modulation" if it is characterized by inappropriate activity of a capsaicin receptor, regardless of the amount of vanilloid ligand present locally, and/or if modulation of capsaicin receptor activity results in alleviation of the condition or a symptom thereof. Such conditions include, for example, symptoms resulting from exposure to VR1-activating stimuli, pain, respiratory disorders such as asthma and chronic obstructive pulmonary disease, itch, urinary incontinence, cough, hiccup, and obesity, as described in more detail below. Such conditions may be diagnosed and monitored using criteria that have been established in the art. Patients may include humans, domesticated companion animals and livestock, with dosages as described above.

Treatment regimens may vary depending on the compound used and the particular condition to be treated. However, for treatment of most disorders, a frequency of administration of 4 times daily or less is preferred. In general, a dosage regimen of 2 times daily is more preferred, with once a day dosing particularly preferred. For the treatment of acute pain, a single dose that rapidly reaches effective concentrations is desirable. It will be understood, however, that the specific dose level and treatment regimen for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy. In general, the use of the minimum dose sufficient to provide effective therapy is preferred. Patients may generally be monitored for therapeutic effectiveness using medical or veterinary criteria suitable for the condition being treated or prevented.

Patients experiencing symptoms resulting from exposure to capsaicin receptor-activating stimuli include individuals with burns caused by heat, light, tear gas or acid and those whose mucous membranes are exposed (*e.g.*, via ingestion, inhalation or eye contact) to capsaicin (*e.g.*, from hot peppers or in pepper spray) or a related irritant such as acid, tear gas

or air pollutants. The resulting symptoms (which may be treated using VR1 modulators, especially antagonists, provided herein) may include, for example, pain, broncho-constriction and inflammation.

Pain that may be treated using the VR1 modulators provided herein may be chronic or acute and includes, but is not limited to, peripheral nerve-mediated pain (especially neuropathic pain). Compounds provided herein may be used in the treatment of, for example, postmastectomy pain syndrome, stump pain, phantom limb pain, oral neuropathic pain, toothache (dental pain), denture pain, postherpetic neuralgia, diabetic neuropathy, reflex sympathetic dystrophy, trigeminal neuralgia, osteoarthritis, rheumatoid arthritis, fibromyalgia, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome and/or bilateral peripheral neuropathy. Additional neuropathic pain conditions include causalgia (reflex sympathetic dystrophy - RSD, secondary to injury of a peripheral nerve), neuritis (including, for example, sciatic neuritis, peripheral neuritis, polyneuritis, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis and Gombault's neuritis), neuronitis, neuralgias (*e.g.,* those mentioned above, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngial neuralgia, migranous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, mandibular joint neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia and vidian neuralgia), surgery-related pain, musculoskeletal pain, AIDS-related neuropathy, MS-related neuropathy, and spinal cord injury-related pain. Headache, including headaches involving peripheral nerve activity, such as sinus, cluster (*i.e.,* migranous neuralgia) and some tension headaches and migraine, may also be treated as described herein. For example, migraine headaches may be prevented by administration of a compound provided herein as soon as a pre-migrainous aura is experienced by the patient. Further pain conditions that can be treated as described herein include "burning mouth syndrome," labor pains, Charcot's pains, intestinal gas pains, menstrual pain, acute and chronic back pain (*e.g.,* lower back pain), hemorrhoidal pain, dyspeptic pains, angina, nerve root pain, homotopic pain and heterotopic pain – including cancer associated pain (*e.g.,* in patients with bone cancer), pain (and inflammation) associated with venom exposure (*e.g.,* due to snake bite, spider bite, or insect sting) and trauma associated pain (*e.g.,* post-surgical pain, pain from cuts, bruises and broken bones, and burn pain). Additional pain conditions that may be treated as described herein include pain associated with inflammatory bowel disease, irritable bowel syndrome and/or inflammatory bowel disease.

Within certain aspects, VR1 modulators provided herein may be used for the treatment of mechanical pain. As used herein, the term "mechanical pain" refers to pain other than headache pain that is not neuropathic or a result of exposure to heat, cold or external chemical stimuli. Mechanical pain includes physical trauma (other than thermal or chemical burns or other irritating and/or painful exposures to noxious chemicals) such as post-surgical pain and pain from cuts, bruises and broken bones; toothache, denture pain; nerve root pain; osteoartiritis; rheumatoid arthritis; fibromyalgia; meralgia paresthetica; back pain; cancer-associated pain; angina; carpel tunnel syndrome; and pain resulting from bone fracture, labor, hemorrhoids, intestinal gas, dyspepsia, and menstruation.

Itching conditions that may be treated include psoriatic pruritis, itch due to hemodialysis, aguagenic pruritus, and itching associated with vulvar vestibulitis, contact dermatitis, insect bites and skin allergies. Urinary incontinence, as used herein, includes overactive bladder conditions, detrusor hyperflexia of spinal origin and bladder hypersensitivity, all of which may be treated as described herein. In certain such treatment methods, VR1 modulator is administered via a catheter or similar device, resulting in direct injection of VR1 modulator into the bladder. Compounds provided herein may also be used as anti-tussive agents (to prevent, relieve or suppress coughing) and for the treatment of hiccup, and to promote weight loss in an obese patient.

Within other aspects, VR1 modulators provided herein may be used within combination therapy for the treatment of conditions involving inflammatory components. Such conditions include, for example, autoimmune disorders and pathologic autoimmune responses known to have an inflammatory component including, but not limited to, arthritis (especially rheumatoid arthritis), psoriasis, Crohn's disease, lupus erythematosus, irritable bowel syndrome, tissue graft rejection, and hyperacute rejection of transplanted organs. Other such conditions include trauma (*e.g.*, injury to the head or spinal cord), cardio- and cerebo-vascular disease and certain infectious diseases.

Within such combination therapy, a VR1 modulator is administered to a patient along with an anti-inflammatory agent. The VR1 modulator and anti-inflammatory agent may be present in the same pharmaceutical composition, or may be administered separately in either order. Anti-inflammatory agents include, for example, non-steroidal anti-inflammatory drugs (NSAIDs), non-specific and cyclooxygenase-2 (COX-2) specific cyclooxgenase enzyme inhibitors, gold compounds, corticosteroids, methotrexate, tumor necrosis factor (TNF) receptor antagonists, anti-TNF alpha antibodies, anti-C5 antibodies, and interleukin-1 (IL-1) receptor antagonists. Examples of NSAIDs include, but are not limited to ibuprofen (*e.g.*,

ADVIL™, MOTRIN™), flurbiprofen (ANSAID™), naproxen or naproxen sodium (*e.g.*, NAPROSYN, ANAPROX, ALEVE™), diclofenac (*e.g.*, CATAFLAM™, VOLTAREN™), combinations of diclofenac sodium and misoprostol (*e.g.*, ARTHROTEC™), sulindac (CLINORIL™), oxaprozin (DAYPRO™), diflunisal (DOLOBID™), piroxicam (FELDENE™), indomethacin (INDOCIN™), etodolac (LODINE™), fenoprofen calcium (NALFON™), ketoprofen (*e.g.*, ORUDIS™, ORUVAIL™), sodium nabumetone (RELAFEN™), sulfasalazine (AZULFIDINE™), tolmetin sodium (TOLECTIN™), and hydroxychloroquine (PLAQUENIL™). A particular class of NSAIDs consists of compounds that inhibit cyclooxygenase (COX) enzymes, such as celecoxib (CELEBREX™) and rofecoxib (VIOXX™). NSAIDs further include salicylates such as acetylsalicylic acid or aspirin, sodium salicylate, choline and magnesium salicylates (TRILISATE™), and salsalate (DISALCID™), as well as corticosteroids such as cortisone (CORTONE™ acetate), dexamethasone (e.g., DECADRON™), methylprednisolone (MEDROL™) prednisolone (PRELONE™), prednisolone sodium phosphate (PEDIAPRED™), and prednisone (*e.g.*, PREDNICEN-M™, DELTASONE™, STERAPRED™).

Suitable dosages for VR1 modulator within such combination therapy are generally as described above. Dosages and methods of administration of anti-inflammatory agents can be found, for example, in the manufacturer's instructions in the *Physician's Desk Reference*. In certain embodiments, the combination administration of a VR1 modulator with an anti-inflammatory agent results in a reduction of the dosage of the anti-inflammatory agent required to produce a therapeutic effect. Thus, preferably, the dosage of anti-inflammatory agent in a combination or combination treatment method of the invention is less than the maximum dose advised by the manufacturer for administration of the anti-inflammatory agent without combination administration of a VR1 antagonist. More preferably this dosage is less than ¾, even more preferably less than ½, and highly preferably, less than ¼ of the maximum dose, while most preferably the dose is less than 10% of the maximum dose advised by the manufacturer for administration of the anti-inflammatory agent(s) when administered without combination administration of a VR1 antagonist. It will be apparent that the dosage amount of VR1 antagonist component of the combination needed to achieve the desired effect may similarly be affected by the dosage amount and potency of the anti-inflammatory agent component of the combination.

In certain preferred embodiments, the combination administration of a VR1 modulator with an anti-inflammatory agent is accomplished by packaging one or more VR1 modulators and one or more anti-inflammatory agents in the same package, either in separate

containers within the package or in the same contained as a mixture of one or more VR1 antagonists and one or more anti-inflammatory agents. Preferred mixtures are formulated for oral administration (*e.g.*, as pills, capsules, tablets or the like). In certain embodiments, the package comprises a label bearing indicia indicating that the one or more VR1 modulators and one or more anti-inflammatory agents are to be taken together for the treatment of an inflammatory pain condition. A highly preferred combination is one in which the anti-inflammatory agent(s) include at least one COX-2 specific cyclooxgenase enzyme inhibitor such as valdecoxib (BEXTRA®), lumiracoxib (PREXIGE™), etoricoxib (ARCOXIA®), celecoxib (CELEBREX®) and/or rofecoxib (VIOXX®).

Within further aspects, VR1 modulators provided herein may be used in combination with one or more additional pain relief medications. Certain such medications are also anti-inflammatory agents, and are listed above. Other such medications are narcotic analgesic agents, which typically act at one or more opioid receptor subtypes (*e.g.*, μ, κ and/or δ), preferably as agonists or partial agonists. Such agents include opiates, opiate derivatives and opioids, as well as pharmaceutically acceptable salts and hydrates thereof. Specific examples of narcotic analgesics include, within preferred embodiments, alfentanyl, alphaprodine, anileridine, bezitramide, buprenorphine, codeine, diacetyldihydromorphine, diacetylmorphine, dihydrocodeine, diphenoxylate, ethylmorphine, fentanyl, heroin, hydrocodone, hydromorphone, isomethadone, levomethorphan, levorphane, levorphanol, meperidine, metazocine, methadone, methorphan, metopon, morphine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymorphone, paregoric, pentazocine, pethidine, phenazocine, piminodine, propoxyphene, racemethorphan, racemorphan, thebaine and pharmaceutically acceptable salts and hydrates of the foregoing agents.

Other examples of narcotic analgesic agents include acetorphine, acetyldihydrocodeine, acetylmethadol, allylprodine, alphracetylmethadol, alphameprodine, alphamethadol, benzethidine, benzylmorphine, betacetylmethadol, betameprodine, betamethadol, betaprodine, butorphanol, clonitazene, codeine methylbromide, codeine-N-oxide, cyprenorphine, desomorphine, dextromoramide, diampromide, diethylthiambutene, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiamubutene, dioxaphetyl butyrate, dipipanone, drotebanol, ethanol, ethylmethylthiambutene, etonitazene, etorphine, etoxeridine, furethidine, hydromorphinol, hydroxypethidine, ketobemidone, levomoramide, levophenacylmorphan, methyldesorphine, methyldihydromorphine, morpheridine, morphine methylpromide, morphine methylsulfonate, morphine-N-oxide, myrophin, naloxone,

nalbuyphine, naltyhexone, nicocodeine, nicomorphine, noracymethadol, norlevorphanol, normethadone, normorphine, norpipanone, pentazocaine, phenadoxone, phenampromide, phenomorphan, phenoperidine, piritramide, pholcodine, proheptazoine, properidine, propiran, racemoramide, thebacon, trimeperidine and the pharmaceutically acceptable salts and hydrates thereof.

Further specific representative analgesic agents include, for example: TALWIN® Nx and DEMEROL® (both available from Sanofi Winthrop Pharmaceuticals; New York, NY); LEVO-DROMORAN®; BUPRENEX® (Reckitt & Coleman Pharmaceuticals, Inc.; Richmond, VA); MSIR® (Purdue Pharma L.P.; Norwalk, CT); DILAUDID® (Knoll Pharmaceutical Co.; Mount Olive, NJ); SUBLIMAZE®; SUFENTA® (Janssen Pharmaceutica Inc.; Titusville, NJ); PERCOCET®, NUBAIN® and NUMORPHAN® (all available from Endo Pharmaceuticals Inc.; Chadds Ford, PA) HYDROSTAT® IR, MS/S and MS/L (all available from Richwood Pharmaceutical Co. Inc; Florence, KY), ORAMORPH® SR and ROXICODONE® (both available from Roxanne Laboratories; Columbus OH) and STADOL® (Bristol-Myers Squibb; New York, NY).

Suitable dosages for VR1 modulator within such combination therapy are generally as described above. Dosages and methods of administration of other pain relief medications can be found, for example, in the manufacturer's instructions in the *Physician's Desk Reference.* In certain embodiments, the combination administration of a VR1 modulator with one or more additional pain medications results in a reduction of the dosage of each therapeutic agent required to produce a therapeutic effect (*e.g.,* the dosage or one or both agent may less than ¾, less than ½, less than ¼ or less than 10% of the maximum dose listed above or advised by the manufacturer). In certain preferred embodiments, the combination administration of a VR1 modulator with one or more additional pain relief medications is accomplished by packaging one or more VR1 modulators and one or more additional pain relief medications in the same package, as described above.

Modulators that are VR1 agonists may further be used, for example, in crowd control (as a substitute for tear gas) or personal protection (*e.g.,* in a spray formulation) or as pharmaceutical agents for the treatment of pain, itch or urinary incontinence via capsaicin receptor desensitization. In general, compounds for use in crowd control or personal protection are formulated and used according to conventional tear gas or pepper spray technology.

Within separate aspects, the present invention provides a variety of non-pharmaceutical *in vitro* and *in vivo* uses for the compounds provided herein. For example,

such compounds may be labeled and used as probes for the detection and localization of capsaicin receptor (in samples such as cell preparations or tissue sections, preparations or fractions thereof). Compounds may also be used as positive controls in assays for receptor activity, as standards for determining the ability of a candidate agent to bind to capsaicin receptor, or as radiotracers for positron emission tomography (PET) imaging or for single photon emission computerized tomography (SPECT). Such methods can be used to characterize capsaicin receptors in living subjects. For example, a VR1 modulator may be labeled using any of a variety of well known techniques (*e.g.,* radiolabeled with a radionuclide such as tritium, as described herein), and incubated with a sample for a suitable incubation time (*e.g.,* determined by first assaying a time course of binding). Following incubation, unbound compound is removed (*e.g.,* by washing), and bound compound detected using any method suitable for the label employed (*e.g.,* autoradiography or scintillation counting for radiolabeled compounds; spectroscopic methods may be used to detect luminescent groups and fluorescent groups). As a control, a matched sample containing labeled compound and a greater (*e.g.,* 10-fold greater) amount of unlabeled compound may be processed in the same manner. A greater amount of detectable label remaining in the test sample than in the control indicates the presence of capsaicin receptor in the sample. Detection assays, including receptor autoradiography (receptor mapping) of capsaicin receptor in cultured cells or tissue samples may be performed as described by Kuhar in sections 8.1.1 to 8.1.9 of Current Protocols in Pharmacology (1998) John Wiley & Sons, New York.

Modulators provided herein may also be used within a variety of well known cell separation methods. For example, modulators may be linked to the interior surface of a tissue culture plate or other support, for use as affinity ligands for immobilizing and thereby isolating, capsaicin receptors (*e.g.,* isolating receptor-expressing cells) *in vitro*. Within one preferred embodiment, a modulator linked to a fluorescent marker, such as fluorescein, is contacted with the cells, which are then analyzed (or isolated) by fluorescence activated cell sorting (FACS).

The following Examples are offered by way of illustration and not by way of limitation. Unless otherwise specified all reagents and solvent are of standard commercial grade and are used without further purification. Using routine modifications, the starting materials may be varied and additional steps employed to produce other compounds provided herein.

EXAMPLES

In the following Examples, mass spectroscopy data is Electrospray MS, obtained in positive ion mode with a 15V or 30V cone voltage, using a Micromass Time-of-Flight LCT, equipped with a Waters 600 pump, Waters 996 photodiode array detector, Gilson 215 autosampler, and a Gilson 841 microinjector. MassLynx (Advanced Chemistry Development, Inc; Toronto, Canada) version 4.0 software was used for data collection and analysis. Sample volume of 1 microliter was injected onto a 50x4.6mm Chromolith SpeedROD C18 column, and eluted using a 2-phase linear gradient at 6ml/min flow rate. Sample was detected using total absorbance count over the 220-340nm UV range. The elution conditions were: Mobile Phase A- 95/5/0.05 Water/Methanol/TFA; Mobile Phase B- 5/95/0.025 Water/Methanol/TFA.

Gradient:	Time(min)	%B
	0	10
	0.5	100
	1.2	100
	1.21	10

The total run time was 2 minutes inject to inject.

The following abbreviations appear herein:

BOP	benzotriazol-1-yl-oxy-tris(dimethylamino)phosphonium hexafluorophosphate
DCM	dichloromethane
DME	ethylene glycol dimethyl ether
DMF	dimethylformamide
DPPF	1,1'-bis(diphenylphosphino)ferrocene
EDCI	1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
EtOAc	ethyl acetate
$Pd_2(dba)_3$	tris[dibenzylidineacetone]di-palladium
$Pd(PPh_3)_4$	tetrakis(triphenylphosphine) palladium (0)
THF	tetrahydrofuran
TLC	thin layer chromatography

EXAMPLE 1

Preparation of Representative Compounds

This Example illustrates the preparation of representative substituted 2-hydroxyalkyl-quinazolin-4-ylamine analogues.

A. [2-ISOPROPOXYMETHYL-7-(3-TRIFLUOROMETHYL-PYRIDIN-2-YL)-QUINAZOLIN-4-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE (COMPOUND 1)

1. 2-p-tolyl-3-trifluoromethyl-pyridine



To a de-gassed mixture of 2-chloro-3-(trifluoromethyl)-pyridine (70.1 mmol), *p*-tolylboronic acid (70.6 mmol), and 2M Na_2CO_3 (175.0 mmol), in DME (200 mL) under nitrogen add $Pd(PPh_3)_4$ (2.8 mmol). Stir the mixture at 80°C overnight, concentrate, and extract with EtOAc. Dry over Na_2SO_4, concentrate under vacuum, and pass through a silica gel pad to give 2-*p*-tolyl-3-trifluoromethyl-pyridine.

2. 2-(4-methyl-3-nitro-phenyl)-3-(trifluoromethyl)-pyridine



To a solution of 2-*p*-tolyl-3-trifluoromethyl-pyridine (8.4 mmol) in H_2SO_4 (6 mL) cautiously add fuming HNO_3 (2 ml). Stir the mixture for 60 minutes at room temperature. Pour the mixture onto ice-water (30 mL), extract with EtOAc, neutralize with 1 N NaOH, dry over Na_2SO_4, and concentrate under vacuum to obtain 2-(4-methyl-3-nitro-phenyl)-3-(trifluoromethyl)-pyridine.

3. 2-nitro-4-(3-trifluoromethyl-pyridin-2-yl)-benzoic acid



To a solution of 2-(4-methyl-3-nitro-phenyl)-3-(trifluoromethyl)-pyridine (7.1 mmol) in a mixture of pyridine (10 mL) and water (5 ml), add $KMnO_4$ (25.3 mmol) portionwise. Stir the mixture for 4 hours at 110°C, and then add another 25.3 mmol of $KMnO_4$ with 10 ml of water. Stir the mixture at 110°C overnight. Cool to room temperature, and filter through celite pad. Concentrate the filtrate under vacuum, dilute with water, and wash the aqueous

solution with EtOAc. Neutralize the aqueous solution with 2 N HCl and collect the precipitate to give 2-nitro-4(3-trifluoromethyl-pyridin-2-yl)-benzoic acid.

4. 2-nitro-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide



Reflux a mixture of 2-amino-4(3-trifluoromethyl-pyridin-2-yl)-benzoic acid (25 g) with $SOCl_2$ (50 ml) for 4 hours and concentrate. Dissolve the residue in DCM, cool with ice-water bath, pass NH_3 gas through the solution for 30 minutes, and stir for 15 minutes at room temperature. Concentrate and wash with water to give 2-nitro-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide.

5. 2-amino-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide



Hydrogenate 2-nitro-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide (1.0g, 0.0032 mol) with 50 psi of H_2 and 100 mg of 10% Pd/C in ethanol. After 16 hours, filter the mixture through celite and concentrate under reduced pressure to give 2-amino-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide as a solid.

6. 2-chloromethyl-7-(3-trifluoromethyl-pyridin-2-yl)-3H-quinazolin-4-one



Heat a solution of 2-amino-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide (100 mg, 0.356 mmol) in 2-chloro-1,1,1-trimethoxyethane (bp 138°C) at 130°C for 4 hours. Concentrate the mixture under reduced pressure to give 2-chloromethyl-7-(3-trifluoromethyl-pyridin-2-yl)-3*H*-quinazolin-4-one as an oil which crystallizes on standing.

7. 4-chloro-2-chloromethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline



Reflux a mixture of 2-chloromethyl-7-(3-trifluoromethyl-pyridin-2-yl)-3*H*-quinazolin-4-one (obtained from the reaction above) and $POCl_3$ for 16 hours. Cool the mixture and concentrate under reduced pressure. Partition the residue between EtOAc and saturated $NaHCO_3$ solution. Wash the EtOAc portion with additional $NaHCO_3$ and then dry (Na_2SO_4) and concentrate under reduced pressure. Filter the brown residue through 2 inches of silica gel (1:1 EtOAc/hexanes eluent) and concentrate under reduced pressure to give 4-chloro-2-chloromethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline.

8. *[2-chloromethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoro methyl-phenyl)-amine*



Heat a mixture of 4-chloro-2-chloromethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline (42 mg, 0.117 mmol) and 4-trifluoromethyl-aniline (19 mg, 0.117 mmol) in isopropyl alcohol (1 mL) at 75°C for 4 hours. Cool the mixture and wash the precipitate with isopropyl alcohol followed by ether to give [2-chloromethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine as the mono-HCl salt.

9. *[2-Isopropoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine*



To a suspension of [2-chloromethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine hydrochloride (1.9 g, 0.0037 mol) in dry isopropanol (100 mL), add 20 equivalents of NaO-i-Pr (prepared from Na and isopropanol). Stir the pale yellow mixture at 60°C for 5 hours, cool and evaporate the solvent under reduced pressure. Partition the residue between ethyl acetate and water and wash the organic layer with water (1X). Dry the organic layer (Na_2SO_4) and concentrate to give [2-isopropoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine as a foam.

B. 2-[4-(4-TRIFLUOROMETHYL-PHENYLAMINO)-7-(3-TRIFLUOROMETHYL-PYRIDIN-2-YL)-QUINAZOLIN-2-YL]-ETHANOL (COMPOUND 2)

1. 3-Benzyloxy-propionic acid



Add sodium hydride (2.22 g, 60% dispersion in mineral oil, 55.4 mmol) in small portions to a cold (0°C) solution of benzyl alcohol (4.0 g, 37 mmol) in toluene (100 mL). Add ethyl 3-bromopropionate (8.0 g, 44 mmol) dropwise to the mixture, allow the resulting solution to warm to room temperature and stir for 1 hour. Quench the reaction with the addition of water until all bubbling ceases. Dilute the mixture with ethyl acetate (100 mL) and extract with water (100 mL) and brine (100 mL). Dry the organic extract over Na_2SO_4 and remove the solvent under reduced pressure to yield the crude ester as a clear oil. Dissolve the oil in methanol (20 mL) and 6 N NaOH (20 mL), stir for 1 hour, concentrate the mixture (~ 20 mL) and dilute with water (20 mL). Extract the aqueous mixture once with CH_2Cl_2 (40 mL). Acidify the aqueous phase with conc. HCl, extract with EtOAc (3 x 50 mL), and dry the combined EtOAc extracts over Na_2SO_4. Remove the solvent under reduced pressure to yield the title compound as a clear oil that solidifies upon standing.

2. 2-(2-Benzyloxy-ethyl)-7-(3-trifluoromethyl-pyridiny-2-yl)-3H-quinazolin-4-one



Cool a solution of 3-benzyloxy-propionic acid (1.66 g, 9.19 mmol) in hexanes (40 mL) to 0°C and add oxalyl chloride (3.50 g, 27.6 mmol) dropwise. After the addition is completed, add DMF (2 drops) and stir the resulting mixture for 1 hour. Remove the solvent under reduced pressure and dissolve the crude acid chloride in dry THF (20 mL). In a separate flask, dissolve 2-amino-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide (2.35 g, 8.37 mmol) in dry THF (40 mL) and pyridine (0.727 g, 9.19 mmol) and cool to 0°C. Add the solution containing the crude acid chloride dropwise to the second solution. Allow the mixture to warm to room temperature and stir for 1 hour. Add a solution of 10% $NaOH_{(aq)}$ (20 mL) to the mixture and stir the solution for 1 hour. Concentrate the mixture (~20 mL), dilute with water (20 mL), and acidify with conc. HCl. Extract the resulting solution with

EtOAC (3 x 50 mL). Wash the combined organic extracts with brine and dry over Na_2SO_4. Remove the solvent under reduced pressure to yield the title compound as a white solid.

3. 2-(2-Benzyloxy-ethyl)4-chloro-7-(3-trifluoromethyl-pyridiny-2-yl)-quinazoline



Dissolve 2-(2-benzyloxy-ethyl)-7-(3-trifluoromethyl-pyridiny-2-yl)-3*H*-quinazolin-4-one (3.24 g, 7.62 mmol) in $CHCl_3$ (40 mL) and 2,6-lutidine (2.45 g, 22.9 mmol). Add phosphorous oxycloride (1.77 mL, 19.0 mmol) dropwise and heat the resulting solution to reflux for 18 hours. Cool the solution and remove the solvent under reduced pressure. Partition the crude residue between EtOAc (200 mL) and saturated $NaHCO_{3(aq)}$ (200 mL). Remove the organic phase and extract the aqueous phase with EtOAc (200 mL). Combine the two organic extracts, wash with brine (200 mL), and dry over Na_2SO_4. Remove the solvent to yield the title compound as a light brown solid.

4. [2-(2-Benzyloxy-ethyl)-7-(3-trifluoromethyl-pyridiny-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine



Dissolve 2-(2-benzyloxy-ethyl)-4-chloro-7-(3-trifluoromethyl-pyridiny-2-yl)-quinazoline (2.47 g, 5.57 mmol) in a solution of acetonitrile (50 mL) and 4-trifluoromethyl-aniline (0.986 g, 6.12 mmol). Heat the mixture to 80°C for 2 hours. A white precipitate forms. Cool the solution in an ice bath and add diethyl ether (25 mL). Filter off the white precipitate and dry in a vacuum oven to yield the title compound as the mono-hydrochloride salt.

5. 2-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-ethanol



Dissolve [2-(2-benzyloxy-ethyl)-7-(3-trifluoromethyl-pyridiny-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine hydrochloride (2.96 g, 4.89 mmol) in MeOH (150 mL) and add 10% Pd/C (200 mg). Hydrogenate the mixture at 50 p.s.i. at 60°C for 8 hours. Quickly filter the mixture through Celite and wash the Celite filter cake with hot MeOH (200 mL). Remove the solvent under reduced pressure to yield the mono-hydrochloride salt of title compound as a white solid.

C. [2-(2-METHOXY-ETHYL)-7-(3-TRIFLUOROMETHYL-PYRIDIN-2-YL)-QUINAZOLIN-4-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE (COMPOUND 3)

1. 2-(2-methoxy-ethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ol



To a solution of 2-amino-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide (3.56 mmol) and pyridine (3.91 mmol) in THF (20 ml), add 4-methoxy-butyryl chloride (3.91 mmol). Stir the mixture 20 minutes at room temperature, add 20 ml of 20% NaOH, stir for 60 minutes at 50°C. Concentrate, add water, filter, acidify to pH=6, collect the precipitate to obtain 2-(3-benzyloxy-propyl)7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ol.

2. 2-(2-methoxy-ethyl)-4-chloro-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline



Using procedures analogous to those described above, 2-(2-methoxy-ethyl)-4-chloro-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline is prepared from 2-(2-methoxy-ethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ol.

3. [2-(2-methoxy-ethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine



Using procedures analogous to those described above, [2-(2-methoxy-ethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine is prepared from 2-(2-methoxy-ethyl)-4-chloro-7-(3-trifluoro-methyl-pyridin-2-yl)-quinazoline.

D. 3-[4-(4-TRIFLUOROMETHYL-PHENYLAMINO)-7-(3-TRIFLUORO-METHYL-PYRIDIN-2-YL)-QUINAZOLIN-2-YL]-PROPAN-1-OL (COMPOUND 4)

1. 2-(3-benzyloxy-propyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ol



To a solution of 2-amino-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide (3.56 mmol) and pyridine (3.91 mmol) in THF (20 ml) add 4-benzyloxy-butyryl chloride (3.91 mmol). Stir the mixture 20 minutes at room temperature, add 20 ml of 20% NaOH, stir for 60 minutes at 50°C. Concentrate, add water, filter, acidify to pH=6, collect the precipitate to obtain 2-(3-benzyloxy-propyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ol.

2. 2-(3-benzyloxy-propyl)-4-chloro-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline



Using procedures analogous to those already described 2-(3-benzyloxy-propyl)-4-chloro-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline can be prepared from 2-(3-benzyloxy-propyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ol.

3. *[2-(3-benzyloxy-propyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine*



Using procedures analogous to those already described, [2-(3-benzyloxy-propyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine is prepared from 2-(3-benzyloxy-propyl)-4-chloro-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline.

4. *3-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoro-methyl-pyridin-2-yl)-quinazolin-2-yl]-propan-1-ol*



Hydrogenate the mixture of 2-(3-benzyloxy-propyl)-4-chloro-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline (0.5 mmol) and 10% Pd-C in EtOH (100 ml) at 50 psi for 30 hours. Filter, concentrate, and chromatograph to give 3-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoro-methyl-pyridin-2-yl)-quinazolin-2-yl]-propan-1-ol.

E. [2-METHOXYMETHYL-7-(3-METHYLPYRIDIN-2-YL)-QUINAZOLIN-4-YL)-(4-TRIFLUOROMETHYLPHENYL)-AMINE (COMPOUND 5)

1. *7-bromo-2-methoxymethylquinazolin-4-yl)-(4-trifluoromethylphenyl)-amine*



Heat a mixture of 7-bromo-2-chloromethylquinazolin-4-yl)-(4-trifluoromethylphenyl)-amine (from Example C, 200 mg, 0.48 mmol), 4.4M sodium methoxide in methanol (2.4 mL), and methanol (1 mL) to 60°C for 4 hours. Cool to room temperature and evaporate the mixture. Dilute with EtOAc (10 mL) and wash 2X with water (10 mL each). Dry the organic layer (Na_2SO_4) and evaporate. Purify by preparative TLC (3:1 hexanes:EtOAc) to obtain 2-methoxymethyl-7-pyridin-4-yl-quinazolin-4-yl)-(4-trifluoromethylphenyl)-amine as a yellow solid.

2. *[2-Methoxymethyl-7-(3-methylpyridin-2-yl)-quinazolin-4-yl)-(4-trifluoromethyl phenyl)-amine*



Heat a mixture of 2-methoxymethyl-7-pyridin-4-yl-quinazolin-4-yl)-(4-trifluoromethylphenyl)-amine (100 mg, 0.243 mmol), 3-methyl-2-pyridylzinc bromide (1 mL of a 0.5M THF solution), tetrakis(triphenylphosphinepalladium(0) (50 mg, 0.043 mmol) in 1,2-dimethoxymethane (5 mL) for 3 hours at 80°C under nitrogen. Cool to room temperature and dilute with EtOAc (10 mL). Wash with water (2 x 10 mL) and dry the organic layer (Na_2SO_4) and evaporate. Purify by preparative TLC to obtain [2-methoxymethyl-7-(3-methylpyridin-2-yl)-quinazolin-4-yl)-(4-trifluoromethylphenyl)-amine as an off-white solid.

F. 7-(3-TRIFLUOROMETHYL-PYRIDIN-2-YL)-2-METHOXYMETHYL-PYRIDO[3,2-D]PYRIMIDIN-4-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE (COMPOUND 6)

1. *6'-Methoxy-3-trifluoromethyl-[2,3']bipyridinyl*



Heat a mixture of 2-chloro-3-trifluoromethylpyridine (37 g, 0.2 mol), 2-methoxypyridine-5-boronic acid (32 g, 0.21 mol), tetrakis(triphenylphosphine)palladium(0) (9 g, 7 mmol) and 2M potassium carbonate (150 mL) in toluene (500 mL) under a nitrogen atmosphere at 90°C for 8 hours. Cool the reaction mixture and separate the layers. Extract the aqueous layer with ethyl acetate (2 x 250 mL) and wash the combined organics with 4M sodium hydroxide (250 mL), water (250 mL), and brine (250 mL). Dry ($MgSO_4$) and concentrate under reduced pressure. Purify the resulting oil by flash chromatography on silica gel (50% ether/ 50% hexane) to give the title compound as a colorless oil.

2. *3-Trifluoromethyl-1'H-[2,3']bipyridinyl-6'-one*



Heat 6'-methoxy-3-trifluoromethyl-[2,3']bipyridinyl (41 g, 0.16 mol) in 30% HBr/AcOH (100 mL) to reflux for 1 hour. Cool the mixture, filter and wash the precipitate with ether (100 mL). Transfer the precipitate into 10M sodium hydroxide (500 mL) and stir for 1 hour. Treat the solution with hydrochloric acid until the solution is pH 7. Collect the white solid by filtration and air dry to give the title compound as a white solid.

3. 5'-Nitro-3-trifluoromethyl-1'H-[2,3']bipyridinyl-6'-one



To a solution of 3-trifluoromethyl-1'H-[2,3']bipyridinyl-6'-one (25 g, 0.1 mol) in concentrated sulfuric acid (100 mL) at 0°C, add dropwise a solution of fuming nitric acid (35 mL) and concentrated sulfuric acid (10 mL). Heat the reaction mixture to 70 °C for 1 hour, cool and pour onto ice (500 mL). Filter the mixture and treat the filtrate with 10 M sodium hydroxide until the solution is at pH 4-5. Collect the precipitate by filtration and air dry to give the title compound as a white solid.

4. 6'-Chloro-5'-nitro-3-trifluoromethyl-[2,3']bipyridinyl



Heat a solution of 5'-nitro-3-trifluoromethyl-1'H-[2,3']bipyridinyl-6'-one (25 g, 0.088 mol), thionyl chloride (300 mL) and DMF (3 mL) to reflux for 4 hours. Remove the volatiles by rotary evaporation and partition the residue between ethyl acetate (350 mL) and saturated sodium bicarbonate solution (250 mL). Extract the aqueous layer with further ethyl acetate (250 mL) and wash the combined organics with brine (250 mL). Dry ($MgSO_4$) and concentrate under reduced pressure to give the title compound as a yellow oil.

5. 6'-Chloro-3-trifluoromethyl-[2,3']bipyridinyl-5'-ylamine



To a solution of 6'-chloro-5'-nitro-3-trifluoromethyl-[2,3']bipyridinyl (25 g, 0.082 mol) and calcium chloride (11g, 0.1 mol) in ethanol (300 mL) and water (50 mL), add iron powder (45 g, 0.82 mol). Heat the solution to reflux for 1.5 hours, cool and filter through Celite. Concentrate the mixture under reduced pressure, re-dissolve in ethyl acetate (300 mL)

and wash with brine (200 mL). Concentrate the solution under reduced pressure and purify by flash chromatography on silica gel (50% ether/ 50% hexane) to give the title compound as a pale yellow solid.

6. 3-Amino-5-[3-(trifluoromethyl)(2-pyridyl)]pyridine-2-carboxamide



Heat a solution of 6'-chloro-3-trifluoromethyl-[2,3']bipyridinyl-5'-ylamine (25 g, 0.091 mol), zinc cyanide (6.75 g, 0.058 mol), $pd_2(dba)_3$ (2.63 g, 2.86 mmol), and DPPF (3.16g, 5.72 mmol) in DMF (250 mL) and water (2.5 mL), under a nitrogen atmosphere, at 120°C for 1 hour. Add water (30 mL) and heat the solution at 120°C for a further 4 hours to complete the hydrolysis. Cool the reaction to 0°C and add a solution of saturated ammonium chloride (200 ml), water (200 mL) and concentrated ammonium hydroxide (50 mL). After stirring at 0°C for 1 hour, filter the yellow precipitate, and wash with water (200 mL) and a 1:1 mixture of ether-hexane (200 mL). Air dry the solid, and then dry in a vacuum oven to give the title compound.

7. 2-(Chloromethyl)-7-[3-(trifluoromethyl)(2-pyridyl)]-3-hydropyridino[3,2-d]pyrimidin-4-one



Heat a solution of 3-amino-5-[3-(trifluoromethyl)(2-pyridyl)]pyridine-2-carboxamide (23 g, 81.5 mmol) and 2-chloro1,1,1-trimethoxyethane (250 mL) at 130°C for 1 hour. Remove the volatiles by evaporation and triturate the solid (50% ether/ 50% hexane) to give the title compound as a light brown solid.

8. 4-Chloro-2-chloromethyl-7-(3-chloro-pyridin-2-yl) -pyrido[3,2-d]pyrimidine



Heat a solution of 2-(chloromethyl)-7-[3-(trifluoromethyl)(2-pyridyl)]-3-hydropyridino[3,2-d]pyrimidin-4-one (2.49 g, 7.31 mmol), phosphorous oxychloride (10 mL), 2,6-lutidine (2.13 mL, 18.3 mmol) and toluene to reflux for 8 hours. Remove the

solvent and partition the crude residue between EtOAc (150 mL) and H_2O (150 mL). Remove the organic phase and extract the aqueous phase with EtOAc (150 mL). Combine the organic extractions, wash with saturated $NaHCO_3$(aq) (150 mL) and brine (150 mL), and dry over Na_2SO_4. Remove the solvent to yield the title compound as a light brown solid.

9. [2-(2-Chloromethyl)-7-(3-trifluoromethyl-pyridiny-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine



Dissolve 4-chloro-2-chloro-methyl-7-(3-chloro-pyridin-2-yl)-pyrido[3,2-d]pyrimidine (2.30 g, 6.40 mmol) in a solution of acetonitrile (20 mL) and 4-trifluoromethyl aniline (1.13 g, 7.04 mmol). Heat the mixture at 80°C for 18 hours. Cool the mixture to 0°C and dilute with diethyl ether (20 mL). The mono-hydrochloride salt of the title compound forms a light brown precipitate, which is removed by filtration and dried in a vacuum oven.

10. 7-(3-trifluoromethyl-pyridin-2-yl)-2-methoxymethyl-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine



Treat [2-(2-chloromethyl)-7-(3-trifluoromethyl-pyridiny-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine with NaOMe as described in Example 1A, step 9, above. This affords 7-(3-trifluoromethyl-pyridin-2-yl)-2-methoxymethyl-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine as a solid.

G. 7-(3-METHYL-PYRIDIN-2-YL)-2-METHOXYMETHYL-PYRIDO[3,2-D]PYRIMIDIN-4-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE (COMPOUND 7)

1. 5-Bromo-3-nitropyridine-2-carbonitrile



Heat a solution of 2-amino-5-bromo-3-nitropyridine (2.18 g, 10 mmol), cuprous cyanide (1.33 g, 15 mmol) and *tert*-butylnitrite (2.0 mL, 15 mmol) in acetonitrile (50 mL) at

60°C for 2 hours. Cool the solution and partitioned between ethyl acetate (100 mL) and saturated aqueous $NaHCO_3$ (100 mL). Extract the aqueous layer with ethyl acetate (2 x 50 mL), wash with water (100 mL) and brine (100 mL), dry ($MgSO_4$) and evaporate. Purify the solid by flash chromatography on silica gel (25% ether / 75% hexane) to give the title compound as a pale yellow solid.

2. 5-(3-Methyl(2-pyridyl))-3-nitropyridine-2-carbonitrile

Heat a solution of 5-bromo-3-nitropyridine-2-carbonitrile (228 mg, 1.0 mmol), tetrakis(triphenylphosphine)palladium(0) (15 mg), 3-methyl-2-pyridylzinc bromide (0.5 M in THF, 3 mL, 1.5 mmol) in THF (5 mL) at 60°C for 2 hours. Cool the solution and partition between ethyl acetate (10 mL) and saturated aqueous $NaHCO_3$ (10 mL). Extract the aqueous layer with ethyl acetate (2 x 15 mL), wash with water (10 mL) and brine (10 mL), dry ($MgSO_4$) and evaporate to give the title compound as a pale yellow solid.

3. 3-Amino-5-(3-methyl(2-pyridyl))pyridine-2-carboxamide



Heat a solution of 5-(3-methyl(2-pyridyl))-3-nitropyridine-2-carbonitrile (1 g, 4.1 mmol), iron (2.3 g, 40 mmol) and calcium chloride (560 mg, 5 mmol) in ethanol (15 mL) and water (4 mL) to reflux for 1 hour. Cool the mixture, filter through Celite and wash with ethyl acetate. Evaporate the filtrate and re-dissolve the residue in ethyl acetate. Wash with water and brine, dry ($MgSO_4$) and evaporate to give the title compound as a pale yellow solid.

4. 7-(3-methyl-pyridin-2-yl)-2-methoxymethyl-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine



The title compound is prepared from 3-amino-5-(3-methyl(2-pyridyl))pyridine-2-carboxamide using procedures analogous to those described in the foregoing examples.

H. 7-(3-TRIFLUOROMETHYL-PYRIDIN-2-YL)-2-METHOXYMETHYL-PYRIDO[3,2-D]PYRIMIDIN-4-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE (COMPOUND 6)

1. 7-(3-trifluoromethyl-pyridin-2-yl)-2-methoxymethyl-3H-pyrido[3,2-d]pyrimidin-4-one



Treat a solution of 3-amino-5-[3-(chloro-pyridin-2-yl)]pyridine-2-carboxamide (340 mg, 1.21 mmol) in THF (5 mL) and pyridine (0.11 mL) with methoxy-acetyl chloride (0.11mL, 144 mg, 1.33 mmol). Stir the mixture for 3 hours at room temperature. Then, add 5 N NaOH (10 mL) and stir the solution for an additional 18 hours. Concentrate the solution (~ 5 mL) and acidify with conc. HCl. Extract the aqueous mixture with EtOAc (3 x 25 mL), and dry the combined organic extracts over Na_2SO_4. Remove the solvent under reduced pressure to yield the title compound as a white solid.

2. 4-Chloro-7-(3-trifluoromethyl-pyridin-2-yl)-2-methoxymethyl-pyrido[3,2-d]pyrimidine



Dissolve 7-(3-trifluoromethyl-pyridin-2-yl)-2-methoxymethyl-3*H*-pyrido[3,2-d]pyrimidin-4-one (276 mg, 0.822 mmol) in $CHCl_3$ (25 mL) and 2,6-lutidine (294 mg, 2.74 mmol). Add phosphorous oxycloride (0.255 mL, 2.74 mmol) dropwise and heat the resulting solution to reflux for 24 hours. Cool the solution and remove the solvent under reduced pressure. Partition the crude residue between EtOAc (50 mL) and saturated $NaHCO_{3(aq)}$ (50 mL). Remove the organic phase and extract the aqueous phase with additional EtOAc (50 mL). Combine the two organic extracts, wash with brine (100 mL), and dry over Na_2SO_4. Remove the solvent to yield the title compound as a light brown solid.

3. 7-(3-trifluoromethyl-pyridin-2-yl)-2-methoxymethyl-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine



Dissolve 4-chloro-7-(3-trifluoromethyl-pyridin-2-yl)-2-methoxymethyl-pyrido[3,2-d]pyrimidine (30 mg, 0.0934 mmol) into a solution of acetonitrile (3 mL) and 4-trifluoromethyl-aniline (18.0 mg, 0.112 mmol). Heat the mixture to 80°C for 16 hours. Cool the reaction mixture in an ice bath and add diethyl ether (3 mL). Filter off the off-white precipitate and dry in a vacuum oven to yield the title compound as the mono-hydrochloride salt.

I. [7-(3-CHLORO-PYRIDIN-2-YL)-2-METHOXYMETHYL-PYRIDO[2,3-D]PYRIMIDIN-4-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE (COMPOUND 8)

1. 2-Acetyl-3-chloropyridine



Dissolve 3-chloro-2-cyanopyridine (10.0 g, 0.072 mol, *Chem. Pharm. Bull.* (1985) 33:565-571) in anhydrous THF (200 mL) under N_2 atmosphere and cool in an ice bath. Add drop wise 3.0 M MeMgI in diethyl ether (48 ml, 0.14 mol) to the reaction mixture and stir in an ice bath for 2 hours. Pour the reaction mixture over ice cold water, acidify the mixture with 2.0 N aq. HCl to pH 2 to 3. Extract the reaction mixture with EtOAc (3 x 100 mL) and dry over anhydrous $MgSO_4$. Filter, concentrate under vacuum and then filter through a pad of silica gel using 20% ethyl acetate / hexane as eluent. Removal of solvent under reduced pressure gives pure 2-acetyl-3-chloropyridine as oil.

2. 1-(3-Chloro-pyridin-2-yl)-3-dimethylaminopropenone



Heat 2-acetyl-3-chloropyridine (0.77 g, 5.0 mmol) with N,N-dimethylformamide dimetylacetal (3.0 g) at 105°C for 20 hours. Concentrate under reduced pressure to give 1-(3-chloro-pyridin-2-yl)-3-dimethylaminopropenone as oil.

3. 2-Amino-4-(3-chloro-pyridin-2-yl)-benzonitrile



Heat a solution of 1-(3-Chloro-pyridin-2-yl)-3-dimethylaminopropenone (1.05 g, 5 mmol), 3-amino-3-methoxy-acrylonitrile hydrochloride (1.35 g, 10 mmol) and ammonium

acetate (2.2 g, 15.0 mmol) in ethanol (25 mL) at reflux for 20 hours. Cool the mixture and concentrate under reduced pressure to give dark oil. Dissolve the residue in EtOAc / water (100 mL). Extract the aqueous solution with EtOAc, wash the EtOAc with brine, dry ($MgSO_4$) and concentrate under reduced pressure to give 2-amino-4-(3-chloro-pyridin-2-yl)-benzonitrile as a brown solid.

4. 6-Amino-3'-chloro-[2,2']bipyridinyl-5-carboxylic acid amide



Cool concentrated sulfuric acid (10 mL) in an ice bath under nitrogen atmosphere. Add in portions 2-amino-4-(3-chloro-pyridin-2-yl)-benzonitrile (1.0 g, 4.3 mmol) over a period of 15 minutes. Stir at room temperature overnight. Pour the reaction mixture over ice, adjust the pH to 10 using 10 N aq. NaOH, filter the solid, wash the solid with water and dry under vacuum to give 6-amino-3'-chloro-[2,2']bipyridinyl-5-carboxylic acid amide as a yellow solid.

5. 7-(3-Chloro-pyridin-2-yl)-2-methoxymethyl-3H-pyrido[2,3-d]pyrimidin-4-one



Dissolve 6-amino-3'-chloro-[2,2']bipyridinyl-5-carboxylic acid amide (0.5 g, 2.02 mmol) in anhydrous THF (10 mL) under N_2 atmosphere. Add dropwise pyridine (0.36 g, 4.04 mmol) and methoxyacetyl chloride (0.48 g, 4.04 mmol) to the reaction mixture and stir at room temperature overnight. Add 10% aq. NaOH (10 mL) and reflux for 4 hours. Concentrate in vacuum, adjust the pH to 6.0 using AcOH, collect the solid by filtration and dry under vacuum to give 7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-3H-pyrido[2,3-d]pyrimidin-4-one as a white solid.

6. 4-Chloro-7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidine



Reflux a mixture of 7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-3H-pyrido[2,3-d]pyrimidin-4-one (0.25 g), 2,6-lutidine (0.44 g), and $POCl_3$ (0.51 g) in $CHCl_3$ (5 mL) for 20

hours. Cool the mixture and concentrate under reduced pressure. Partition the residue between EtOAc and saturated $NaHCO_3$ solution. Wash the EtOAc portion with additional $NaHCO_3$ and then dry (Na_2SO_4) and concentrate under reduced pressure. Filter the brown residue through 2 inches of silica gel (1:1 EtOAc/hexanes eluent) and concentrate under reduced pressure to give 4-chloro-7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidine.

7. [7-(3-Chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine



Heat a mixture of 4-chloro-7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidine (0.1 mmol) and 4-trifluoromethyl-aniline (16.1 mg, 0.1mmol) in AcCN (1 mL) at 80°C for 24 hours. Cool the mixture and wash the precipitate with ether to give [7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine as the mono-HCl salt.

EXAMPLE 2

Additional Representative Substituted 2-Hydroxyalkyl-Quinazolin-4-ylamine Analogues

Using routine modifications, the starting materials may be varied and additional steps employed to produce other compounds provided herein. Compounds listed in Table II were prepared using the above methods, with readily apparent modifications. In the column labeled K_i in Table II, * indicates that the K_i for the compound determined as described in Example 5, herein, is 1 micromolar or less. Mass Spectrometry data was obtained as described above and is given as M+1.

Table II

Representative Substituted 2-Hydroxyalkyl-Quinazoline-4-ylamine Analogues

Compound		Name	MS (M+1)	K_i
9.		Acetic acid 4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl ester		*

	Compound	Name	MS (M+1)	K_i
10.		[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-methanol	465.13	*
11.		[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	479.33	*
12.		[2-(3-Benzyloxy-propyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	583.32	*
13.		[2-(3-Benzyloxy-propyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	584.32	*
14.		3-[7-(3-Trifluoromethyl-pyridin-2-yl)-4-(6-trifluoromethyl-pyridin-3-ylamino)-quinazolin-2-yl]-propan-1-ol	494.26	*
15.		[2-(3-Benzyloxy-propyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-*tert*-butyl-pyridin-3-yl)-amine	572.37	*
16.		3-[4-(6-*tert*-Butyl-pyridin-3-ylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propan-1-ol	482.29	*
17.		3-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propionic acid methyl ester	521.27	*

	Compound	Name	MS (M+1)	K_i
18.		3-[7-(3-Trifluoromethyl-pyridin-2-yl)-4-(6-trifluoromethyl-pyridin-3-ylamino)-quinazolin-2-yl]-propionic acid methyl ester	522.26	*
19.		3-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propionic acid	507.20	*
20.		[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-acetic acid ethyl ester	521.23	*
21.		Acetic acid 7-(3-trifluoromethyl-pyridin-2-yl)-4-(6-trifluoromethyl-pyridin-3-ylamino)-quinazolin-2-ylmethyl ester	508.20	*
22.		[7-(3-Trifluoromethyl-pyridin-2-yl)-4-(6-trifluoromethyl-pyridin-3-ylamino)-quinazolin-2-yl]-methanol	466.17	*
23.		[2-Benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(2,2,2-trifluoro-1-methyl-ethyl)-phenyl]-amine	583.28	*
24.		[2-Benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	555.28	*
25.		[2-Benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	556.28	*

Compound	Name	MS (M+1)	K_i
26. 	[2-Benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine	556.28	*
27. 	[2-Benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethoxy-phenyl)-amine	571.29	*
28. 	[2-Benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine		*
29. 	[2-(2-Diethylamino-ethoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	565.14	*
30. 	[2-(2-Piperidin-1-yl-ethoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	577.15	*
31. 	[2-(1-Methyl-piperidin-4-yloxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	563.13	*
32. 	(4-Methanesulfonyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	489.18	*
33. 	[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	480.18	*

Compound		Name	MS (M+1)	K_i
34.		2-{4-[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ylamino]-phenyl}-2-methyl-propionitrile	478.24	*
35.		[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine	543.18	*
36.		[4-(2-Methoxy-1,1-dimethyl-ethyl)-phenyl]-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	497.26	*
37.		N-*tert*-Butyl-4-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ylamino]-benzenesulfonamide	546.26	*
38.		4-[2-Benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ylamino]-N-*tert*-butyl-benzenesulfonamide	622.32	*
39.		[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine	480.19	*
40.		[2-Benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-methanesulfonyl-phenyl)-amine	565.33	*

Compound		Name	MS (M+1)	K_i
41.		2-{4-[2-Benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ylamino]-phenyl}-2-methyl-propionitrile	554.38	*
42.		[2-Benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(2-methoxy-1,1-dimethyl-ethyl)-phenyl]-amine	573.39	*
43.		[2-Benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-*tert*-butyl-phenyl)-amine	543.38	*
44.		[2-Benzyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(1-methanesulfonyl-2,3-dihydro-1H-indol-5-yl)-amine	606.39	*
45.		[2-(Pyridin-3-ylmethoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	557.09	*
46.		[2-(Pyridin-4-ylmethoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	557.09	*
47.		(4-*tert*-Butyl-phenyl)-[2-(2-methoxy-ethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	481.13	*

Compound		Name	MS (M+1)	K_i
48.		(4-Isopropyl-phenyl)-[2-(2-methoxy-ethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	467.11	*
49.		(6-*tert*-Butyl-pyridin-3-yl)-[2-(2-methoxy-ethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	482.13	*
50.		(4-*tert*-Butyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-amine	468.11	*
51.		(4-Isopropyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-amine	454.09	*
52.		(4-Ethyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-amine	440.07	*
53.		[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	481.04	*
54.		1-{4-[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-ylamino]-phenyl}-ethanone	454.06	*

Compound		Name	MS (M+1)	K_i
55.		4-[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-ylamino]-benzonitrile	437.04	*
56.		(4-Cyclohexyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-amine	494.13	*
57.		1-{4-[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-ylamino]-phenyl}-butan-1-one	482.10	*
58.		[4-(2-Methoxy-1,1-dimethyl-ethyl)-phenyl]-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido [3,2-d]pyrimidin-4-yl]-amine	498.12	*
59.		(4-*tert*-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-amine	434.08	*
60.		[7-(3-Chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-isopropyl-phenyl)-amine	420.18	*
61.		[7-(3-Chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-[4-(2-methoxy-1,1-dimethyl-ethyl)-phenyl]-amine	464.23	*

Compound		Name	MS (M+1)	K_i
62.		2-{4-[7-(3-Chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-2-methyl-propionitrile	445.20	*
63.		(4-*sec*-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-amine	434.20	*
64.		[7-(3-Chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	446.20	
65.		(4-*tert*-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[3,2-d]pyrimidin-4-yl]-amine	434.27	*
66.		[7-(3-Chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[3,2-d]pyrimidin-4-yl]-(4-isopropyl-phenyl)-amine	420.25	*
67.		[2-Ethoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	493.30	*
68.		(6-*tert*-Butyl-pyridin-3-yl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-quinazolin-4-yl]-amine	434.32	*

	Compound	Name	MS (M+1)	K_i
69.		[7-(3-Chloro-pyridin-2-yl)-2-methoxymethyl-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	419.30	*
70.		[7-(3-Chloro-pyridin-2-yl)-2-methoxymethyl-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	445.26	*
71.		(4-*tert*-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-quinazolin-4-yl]-amine	433.33	*
72.		(4-Isopropyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	453.35	*
73.		(4-*tert*-Butyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	467.38	*
74.		(6-*tert*-Butyl-pyridin-3-yl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	468.38	*
75.		(4-*tert*-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-(2-methoxy-ethoxymethyl)-pyrido[2,3-d]pyrimidin-4-yl]-amine		*

	Compound	Name	MS (M+1)	K_i
76.		[7-(3-Chloro-pyridin-2-yl)-2-(2-methoxy-ethoxymethyl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine		*
77.		[7-(3-Chloro-pyridin-2-yl)-2-(2-methoxy-ethoxymethyl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-isopropyl-phenyl)-amine	464.36	*
78.		(4-Isopropyl-phenyl)-[2-methoxymethyl-7-(3-methyl-pyridin-2-yl)-quinazolin-4yl]-amine	399.33	*
79.		(4-*tert*-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-ethoxymethyl-quinazolin-4-yl]-amine	447.40	*
80.		[7-(3-Chloro-pyridin-2-yl)-2-ethoxymethyl-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	433.37	*
81.		[7-(3-Chloro-pyridin-2-yl)-2-ethoxymethyl-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	459.33	*
82.		(6-*tert*-Butyl-pyridin-3-yl)-[7-(3-chloro-pyridin-2-yl)-2-ethoxymethyl-quinazolin-4-yl]-amine	448.39	*

Compound		Name	MS (M+1)	K_i
83.		2-{4-[7-(3-Chloro-pyridin-2-yl)-2-(2-methoxy-ethoxymethyl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-2-methyl-propionitrile	489.42	*
84.		(4-*sec*-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-(2-methoxy-ethoxymethyl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	478.43	*
85.		[7-(3-Chloro-pyridin-2-yl)-2-(2-methoxy-ethyl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine		*
86.		[2-(Tetrahydro-pyran-4-yloxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	549.47	*
87.		[2-(2-Dimethylamino-ethoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	536.47	*
88.		[2-Methoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	426.33	*
89.		[2-(3-Dimethylamino-propoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	550.47	*
90.		[2-Ethoxymethyl-7-(3-methyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	439.36	*

Compound		Name	MS (M+1)	K_i
91.		[2-Isopropoxymethyl-7-(3-methyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	453.39	*
92.		[7-(3-Methyl-pyridin-2-yl)-2-(tetrahydro-pyran-4-yloxymethyl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	495.45	*
93.		(4-*sec*-Butyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	468.20	*
94.		[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-[4-(2,2,2-trifluoro-1-methyl-ethyl)-phenyl]-amine	508.16	*
95.		(4-*tert*-Butyl-phenyl)-[2-methoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	414.36	*
96.		(4-Isopropyl-phenyl)-[2-methoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	400.34	*
97.		(4-*sec*-Butyl-phenyl)-[2-methoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	414.35	*

Compound		Name	MS (M+1)	K_i
98.		2-{4-[2-Methoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-2-methyl-propionitrile	425.35	*
99.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline-2-carboxylic acid ethyl ester	507.33	*
100.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline-2-carboxylic acid	479.28	*
101.		(4-Isopropyl-phenyl)-[2-(tetrahydro-pyran-4-yloxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	523.45	*
102.		[7-(3-Chloro-pyridin-2-yl)-2-(tetrahydro-pyran-4-yloxymethyl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	515.37	*
103.		[7-(3-Chloro-pyridin-2-yl)-2-(tetrahydro-pyran-4-yloxymethyl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	489.41	*
104.		[2-Ethoxymethyl-7-(3-methyl-pyridin-2-yl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	413.38	*
105.		[2-Isopropoxymethyl-7-(3-methyl-pyridin-2-yl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	427.43	*

Compound		Name	MS (M+1)	K_i
106.		(4-Isopropyl-phenyl)-[7-(3-methyl-pyridin-2-yl)-2-(tetrahydro-pyran-4-yloxymethyl)-quinazolin-4-yl]-amine	469.49	*
107.		(4-*tert*-Butyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	468.20	*
108.		(4-Isopropyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	454.19	*
109.		[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	480.13	*
110.		(4-Cyclopentyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	480.21	*
111.		(4-*tert*-Butyl-phenyl)-[2-(4-dimethylamino-butoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	552.31	*
112.		(4-Methanesulfonyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine		*

Compound		Name	MS (M+1)	K_i
113.		[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine		*
114.		[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-[4-(morpholine-4-sulfonyl)-phenyl]-amine		*
115.		[2-(3-Diethylamino-propoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	578.57	*
116.		(4-*tert*-Butyl-phenyl)-[2-(3-dimethylamino-propoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	538.57	*
117.		(4-*tert*-Butyl-phenyl)-[2-(3-diethylamino-propoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	566.64	*
118.		(4-Cyclopropyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	451.38	*
119.		[7-(3-Methyl-pyridin-2-yl)-4-(4-trifluoromethyl-phenylamino)-pyrido[2,3-d]pyrimidin-2-yl]-methanol	412.28	*

	Compound	Name	MS (M+1)	K_i
120.		[7-(3-Chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[3,2-d]pyrimidin-4-yl]-[4-(morpholine-4-sulfonyl)-phenyl]-amine	527.15	*
121.		[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-2-yl]-methanol	466.10	*
122.		[7-(3-Chloro-pyridin-2-yl)-4-(4-trifluoromethyl-phenylamino)-pyrido[3,2-d]pyrimidin-2-yl]-methanol	432.07	*
123.		[2-(3-Dimethylamino-2,2-dimethyl-propoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	578.25	*
124.		(4-*tert*-Butyl-phenyl)-[2-(3-morpholin-4-yl-propoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	580.32	*
125.		(4-*tert*-Butyl-phenyl)-[2-(4-morpholin-4-yl-butoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	594.32	*
126.		[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(morpholine-4-sulfonyl)-phenyl]-amine	560.21	*

Compound	Name	MS (M+1)	K_i
127. 	[2-Ethoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(morpholine-4-sulfonyl)-phenyl]-amine	574.22	*
128. 	[2-Isopropoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(morpholine-4-sulfonyl)-phenyl]-amine	588.24	*
129. 	(4-*tert*-Butyl-phenyl)-[2-isobutoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	456.30	*
130. 	[2-Isobutoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-isopropyl-phenyl)-amine	442.28	*
131. 	[2-Isobutoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	468.22	*
132. 	(4-*tert*-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-ethoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-amine	448.22	*
133. 	[7-(3-Chloro-pyridin-2-yl)-2-ethoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-isopropyl-phenyl)-amine	434.20	*

	Compound	Name	MS (M+1)	K_i
134.		[7-(3-Chloro-pyridin-2-yl)-2-ethoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	460.15	*
135.		[7-(3-Chloro-pyridin-2-yl)-2-ethoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine		*
136.		[7-(3-Chloro-pyridin-2-yl)-2-ethoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-[4-(2,2,2-trifluoro-1-methyl-ethyl)-phenyl]-amine	488.17	*
137.		[7-(3-Chloro-pyridin-2-yl)-2-ethoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-cyclopentyl-phenyl)-amine	460.22	*
138.		[2-Ethoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	440.19	*
139.		[2-Ethoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-isopropyl-phenyl)-amine	414.25	*
140.		[2-Ethoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine		*

	Compound	Name	MS (M+1)	K_i
141.		[4-(Morpholine-4-sulfonyl)-phenyl]-[2-(tetrahydro-pyran-4-yloxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	630.26	*
142.		[2-Cyclopropylmethoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(morpholine-4-sulfonyl)-phenyl]-amine	600.25	*
143.		[2-Cyclopentyloxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(morpholine-4-sulfonyl)-phenyl]-amine	614.26	*
144.		1-Dimethylamino-3-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethoxy]-propan-2-ol	566.24	*
145.		(4-*tert*-Butyl-phenyl)-[2-(3-diethylamino-1-methyl-propoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	580.38	*
146.		[7-(3-Chloro-pyridin-2-yl)-2-ethoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine		*
147.		[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	481.17	*

Compound		Name	MS (M+1)	K_i
148.		[2-Methoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	427.19	*
149.		1-{4-[2-Methoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-cyclobutanecarbonitrile	437.22	*
150.		1-{4-[7-(3-Chloro-pyridin-2-yl)-2-ethoxymethyl-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-cyclobutanecarbonitrile	471.19	*
151.		1-{4-[2-Isobutoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-cyclobutanecarbonitrile	479.42	*
152.		[2-Ethoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	494.31	*
153.		[2-Isopropoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	508.18	*
154.		[2-(Tetrahydro-pyran-4-yloxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	550.21	*

Compound	Name	MS (M+1)	K_i
155. 	[4-(4-*tert*-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-methanol	453.20	*
156. 	[4-(4-Isopropyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-methanol	439.18	*
157. 	[4-(4-*tert*-Butyl-phenylamino)-7-(3-chloro-pyridin-2-yl)-quinazolin-2-yl]-methanol	419.17	*
158. 	[7-(3-Chloro-pyridin-2-yl)-4-(4-isopropyl-phenylamino)-quinazolin-2-yl]-methanol	405.15	*
159. 	[2-Methoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine	490.08	*
160. 	(2,6-Dimethyl-morpholin-4-yl)-(1-{4-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-cyclobutyl)-methanone	607.22	*
161. 	2-{4-[2-Isobutoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-2-methyl-propionitrile	467.21	*

Compound	Name	MS (M+1)	K_i
162. 	(4-*tert*-Butyl-phenyl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	510.44	*
163. 	[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-isopropyl-phenyl)-amine	496.42	*
164. 	[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	522.27	*
165. 	[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	523.16	*
166. 	[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(3-methyl-4-trifluoromethyl-phenyl)-amine	536.42	*
167. 	2-{4-[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-2-methyl-propionitrile	521.44	*
168. 	[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine	586.39	*

Compound	Name	MS (M+1)	K_i
169. 	[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethoxy]-acetic acid ethyl ester	551.39	*
170. 	[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethoxy]-acetic acid	523.34	*
171. 	[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-2-yl]-methanol	466.29	*
172. 	7-(3-Methyl-pyridin-2-yl)-4-(4-trifluoromethyl-phenylamino)-pyrido[2,3-d]pyrimidine-2-carboxylic acid ethyl ester	454.32	*
173. 	4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid ethyl ester	508.32	*
174. 	[7-(3-Methyl-pyridin-2-yl)-2-(tetrahydro-furan-3-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	452.16	*
175. 	2-Methyl-2-{4-[7-(3-methyl-pyridin-2-yl)-2-(tetrahydro-furan-3-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-propionitrile	451.22	*
176. 	[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	488.13	*

Compound	Name	MS (M+1)	K_i
177. 	[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	489.13	*
178. 	[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(3-methyl-4-trifluoromethyl-phenyl)-amine	502.16	*
179. 	2-{4-[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-2-methyl-propionitrile	487.20	*
180. 	[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethoxy-phenyl)-amine	504.13	*
181. 	[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine	552.10	*
182. 	[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(3-methyl-4-trifluoromethyl-phenyl)-amine	494.13	*
183. 	[2-Isobutoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(3-methyl-4-trifluoromethyl-phenyl)-amine	482.20	*

Compound	Name	MS (M+1)	K_i
184. 	[7-(3-Chloro-pyridin-2-yl)-2-ethoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(3-methyl-4-trifluoromethyl-phenyl)-amine	474.13	*
185. 	4-(4-*tert*-Butyl-phenylamino)-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid ethyl ester	442.23	*
186. 	[4-[4-(Piperidine-1-sulfonyl)-phenylamino]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-methanol	544.18	*
187. 	N-*tert*-Butyl-4-[2-hydroxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-ylamino]-N-methyl-benzenesulfonamide	546.20	*
188. 	[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethoxy-phenyl)-amine	496.12	*
189. 	[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethoxy-phenyl)-amine	538.17	*
190. 	[2-Isobutoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethoxy-phenyl)-amine	484.20	*

	Compound	Name	MS (M+1)	K_i
191.		(6-*tert*-Butyl-pyridin-3-yl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	469.21	*
192.		(6-*tert*-Butyl-pyridin-3-yl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	511.25	*
193.		(6-*tert*-Butyl-pyridin-3-yl)-[2-isobutoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	457.29	*
194.		(6-*tert*-Butyl-pyridin-3-yl)-[7-(3-chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-amine	477.24	*
195.		[7-(3-Chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethoxy-phenyl)-amine	462.11	*
196.		[2-Methoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethoxy-phenyl)-amine	442.16	*
197.		[7-(3-Chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(3-methyl-4-trifluoromethyl-phenyl)-amine	460.13	*

Compound	Name	MS (M+1)	K_i
198. 	[2-Methoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(3-methyl-4-trifluoromethyl-phenyl)-amine	440.18	*
199. 	(6-*tert*-Butyl-pyridin-3-yl)-[7-(3-chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-amine	435.19	*
200. 	(6-*tert*-Butyl-pyridin-3-yl)-[2-methoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	415.24	*
201. 	[4-(4-*tert*-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-2-yl]-methanol	454.35	*
202. 	[4-[4-(Piperidine-1-sulfonyl)-phenylamino]-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-2-yl]-methanol	545.42	*
203. 	N-*tert*-Butyl-4-[2-hydroxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide	547.43	*
204. 	[4-(4-*tert*-Butyl-phenylamino)-7-(3-methyl-pyridin-2-yl)-pyrido[2,3d]pyrimidin-2-yl]-methanol	400.34	*

Compound		Name	MS (M+1)	K_i
205.		7-(3-Methyl-pyridin-2-yl)-4-(4-trifluoromethyl-phenylamino)-pyrido[2,3-d]pyrimidine-2-carboxylic acid		*
206.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid		*
207.		4-(4-*tert*-Butyl-phenylamino)-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid		*
208.		3-{4-[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-3-methyl-butan-2-one	496.19	*
209.		3-{4-[2-Isobutoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-3-methyl-butan-2-one	484.27	*
210.		3-{4-[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-3-methyl-butan-2-one	504.22	*
211.		3-{4-[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-3-methyl-butan-2-one	538.24	*

Compound	Name	MS (M+1)	K_i
212. 	3-{4-[2-Methoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-3-methyl-butan-2-one	442.23	*
213. 	3-{4-[7-(3-Chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-3-methyl-butan-2-one	462.18	*
214. 	[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-methanesulfonyl-phenyl)-amine	532.39	*
215. 	[2-Isobutoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-[4-(2-methoxy-1,1-dimethyl-ethyl)-phenyl]-amine	486.47	*
216. 	[2-Isobutoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-methanesulfonyl-phenyl)-amine	478.37	*
217. 	2-[4-(4-*tert*-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-2-methyl-propan-1-ol	495.42	*
218. 	2-Methyl-2-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propan-1-ol	507.36	*

Compound		Name	MS (M+1)	K_i
219.		4-(4-*tert*-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid ethyl ester	496.39	*
220.		4-(4-*tert*-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid	468.35	*
221.		N,N-Diethyl-2-{4-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-isobutyramide	553.50	*
222.		N,N-Diethyl-2-{4-[2-isobutoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-isobutyramide	541.56	*
223.		[2-Ethoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl -phenyl)-amine	494.34	*
224.		[2-Ethoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	495.34	*
225.		2-{4-[2-Ethoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-2-methyl-propionitrile	493.40	*

Compound		Name	MS (M+1)	K_i
226.		[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-methanesulfonyl-phenyl)-amine	498.36	*
227.		[4-(2-Diethylamino-1,1-dimethyl-ethyl)-phenyl]-[2-methoxymethyl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	243.21	*
228.		2-[4-(4-*tert*-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethoxy]-3-methyl-butyric acid methyl ester (S)	567.26	*
229.		(R)-2-[4-(4-*tert*-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethoxy]-propionic acid (chiral)	525.23	*
230.		(S)-2-[4-(4-*tert*-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethoxy]-3-methyl-butyric acid	553.25	*
231.		[2-Ethoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-[4-(2,2,2-trifluoro-1-methyl-ethyl)-phenyl]-amine	522.17	*
232.		[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-[4-(2,2,2-trifluoro-1-methyl-ethyl)-phenyl]-amine	550.20	*

	Compound	Name	MS (M+1)	K_i
233.		[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-[4-(2,2,2-trifluoro-1-methyl-ethyl)-phenyl]-amine	516.19	*
234.		2-[4-(4-*tert*-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethoxy]-3-methyl-butyric acid (R)	553.48	*
235.		[7-(3-Chloro-pyrazin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	447.26	*
236.		(4-*tert*-Butyl-phenyl)-[7-(3-chloro-pyrazin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-amine	435.28	*
237.		[7-(3-Chloro-pyrazin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-isopropyl-phenyl)-amine	421.26	*
238.		2-{4-[7-(3-Chloro-pyrazin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-2-methyl-propionitrile	446.27	*
239.		[7-(3-Chloro-pyrazin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine	511.24	*

Compound		Name	MS (M+1)	K_i
240.		(4-Difluoromethyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	462.31	*
241.		(4-Difluoromethyl-phenyl)-[2-ethoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	476.33	*
242.		(4-Difluoromethyl-phenyl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	504.39	*
243.		[7-(3-Chloro-pyridin-2-yl)-2-methoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-difluoromethyl-phenyl)-amine	428.26	*
244.		[7-(3-Chloro-pyridin-2-yl)-2-ethoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-difluoromethyl-phenyl)-amine	442.29	*
245.		(R)-[7-(3-Chloro-pyridin-2-yl)-2-(1-methoxy-ethyl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	460.30	*
246.				

	Compound	Name	MS (M+1)	K_i
247.		[2-(1-Methyl-piperidin-4-ylmethoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	576.51	*
248.		(4-Fluoro-phenyl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	472.24	*
249.		(4-Chloro-phenyl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	488.22	*
250.		1-{4-[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-ethanone	496.27	*
251.		(4-Ethoxy-phenyl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	498.29	*
252.		(3,4-Difluoro-phenyl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	490.23	*
253.		(4-Fluoro-3-methyl-phenyl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	486.26	*

Compound	Name	MS (M+1)	K_i
254. 	(4-Fluoro-3-trifluoromethyl-phenyl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	540.26	*
255. 	(4-Chloro-3-trifluoromethyl-phenyl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	556.25	*
256. 	[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-methoxy-3-trifluoromethyl-phenyl)-amine	552.29	*
257. 	(3,4-Dimethyl-phenyl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	482.28	*
258. 	(3-Fluoro-4-methoxy-phenyl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	502.27	*
259. 	[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-fluoro-phenyl)-amine	438.20	*
260. 	(4-Chloro-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-amine	454.19	*

Compound	Name	MS (M+1)	K_i
261. 	4-[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-ylamino]-benzonitrile	445.22	*
262. 	1-{4-[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-ethanone	462.25	*
263. 	[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-morpholin-4-yl-phenyl)-amine	505.32	*
264. 	[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-ethoxy-phenyl)-amine	464.26	*
265. 	[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-ethyl-phenyl)-amine	448.25	*
266. 	[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-propyl-phenyl)-amine	462.28	*
267. 	4-[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-ylamino]-benzoic acid methyl ester	478.25	*

Compound		Name	MS (M+1)	K_i
268.		[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(3,4-difluoro-phenyl)-amine	456.21	*
269.		[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-fluoro-3-methyl-phenyl)-amine	452.23	*
270.		[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(3-trifluoromethyl-phenyl)-amine	522.27	*
271.		(3-Chloro-phenyl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	488.23	*
272.		4-[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-benzonitrile	479.26	*
273.		(4-Chloro-3-fluoro-phenyl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	506.23	*
274.		(4-Chloro-3-methyl-phenyl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	502.26	*

Compound		Name	MS (M+1)	K_i
275.		(3-Chloro-4-fluoro-phenyl)-[2-isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	506.23	*
276.		[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-methyl-3-trifluoromethyl-phenyl)-amine	536.29	*
277.		{4-[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-methanol	450.24	*
278.		(4-Butoxy-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-amine	492.31	*
279.		4-[7-(3-Chloro-pyridin-2-yl)-2-isopropoxymethyl-pyrido[2,3-d]pyrimidin-4-ylamino]-benzenesulfonamide	499.24	*
280.		1-{4-[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-butan-1-one	490.30	*
281.		[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-ethynyl-phenyl)-amine	444.23	*

Compound		Name	MS (M+1)	K_i
282.		5-(4-Trifluoromethyl-phenylamino)-2-(3-trifluoromethyl-pyridin-2-yl)-[1,6]naphthyridine-7-carboxylic acid ethyl ester	507.22	*
283.		{4-[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-acetic acid ethyl ester	506.30	*
284.		{4-[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-acetic acid	478.25	*
285.		[7-(3-Chloro-pyridin-2-yl)-2-isobutoxymethyl-pyrido[2,3-d]pyrimidin-4-yl]-(4-fluoro-3-methoxy-phenyl)-amine	468.24	*
286.		[5-(4-Trifluoromethyl-phenylamino)-2-(3-trifluoromethyl-pyridin-2-yl)-[1,6]naphthyridin-7-yl]-methanol	465.19	*
287.		(4-Chloro-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	446.10	*
288.		4-[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-benzonitrile	437.13	*
289.		1-{4-[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-ethanone	454.15	*

Compound		Name	MS (M+1)	K_i
290.		2-{4-[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-ylamino]-phenyl}-2-methyl-propionitrile	479.18	*
291.		(3,4-Difluoro-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	448.12	*
292.		(4-Chloro-3-fluoro-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	464.09	*
293.		(4-Chloro-3-methyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	460.12	*
294.		(4-Chloro-3-trifluoromethyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	514.09	*
295.		[7-Methoxymethyl-2-(3-trifluoromethyl-pyridin-2-yl)-[1,6]naphthyridin-5-yl]-(4-trifluoromethyl-phenyl)-amine	479.13	*
296.		[7-Isobutoxymethyl-2-(3-trifluoromethyl-pyridin-2-yl)-[1,6]naphthyridin-5-yl]-(4-trifluoromethyl-phenyl)-amine	521.18	*

	Compound	Name	MS (M+1)	K_i
297.		[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	479.16	*
298.		(4-tert-Butyl-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-amine	467.20	*
299.		2-Methoxymethyl-4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridine-3-carboxylic acid methyl ester	537.23	*
300.		[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-2-yl]-methanol	465.20	*
301.		[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	521.25	*
302.		(4-Chloro-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-amine	445.19	*
303.		(4-Fluoro-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-amine	429.21	*
304.		(4-Chloro-3-fluoro-phenyl)-[2-methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-amine	463.19	*

	Compound	Name	MS (M+1)	K_i
305.		4-[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-ylamino]-benzonitrile	436.22	*
306.		[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-[4-(propane-2-sulfonyl)-phenyl]-amine	517.29	*
307.		[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine	480.26	*
308.		[2-Methoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine	543.24	*
309.		[2-(2-Dimethylamino-ethoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	536.22	*
310.		[2-Ethoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	493.19	*
311.		[2-Isopropoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	507.19	*
312.		[2-(3-Methyl-butoxymethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	535.23	*

Compound		Name	MS (M+1)	K_i
313.		[2-Propoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	507.19	*
314.		[2-Isobutoxymethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine	522.20	*

EXAMPLE 3

Preparation of Representative Compounds

This Example illustrates the preparation of representative substituted 2-aminoalkyl-quinazolin-4-ylamine analogues.

A. [2-PYRROLIDIN-1-YLMETHYL-7-(3-TRIFLUOROMETHYL-PYRIDIN-2-YL)-QUINAZOLIN-4-YL]-(4-TRIFLUORO METHYL-PHENYL)-AMINE (COMPOUND 315)

1. *[2-chloromethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoro methyl-phenyl)-amine*



This compound is prepared as described in Example 1A.

2. *[2-Pyrrolidin-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine*



Heat a solution of [2-chloromethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine HCl (30 mg, 0.058 mmol) in pyrrolidine (1mL) at 100°C for 1 hour. Remove the excess pyrrolidine under reduced pressure and partition the residue between EtOAc and 10% NaOH solution. Dry the EtOAc layer (Na_2SO_4) and

concentrate under reduced pressure to give [2-pyrrolidin-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine as a foam. Mass Spec 517.2.

B. [2-(2,6-DIMETHYL-MORPHOLIN-4-YLMETHYL)-7-(2-TRIFLUOROMETHYL-PHENYL)-PYRIDO[4,3-D]PYRIMIDIN-4-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE (CIS) (COMPOUND 316)

1. 4-Hydroxy-6-(2-trifluoromethyl-phenyl)-nicotinic acid ethyl ester



Dissolve LiHMDS (34 g, 0.20 mol) in dry THF (150 mL) and cool to -70°C under N_2 atm. Add 4-dimethylamino-3-ethoxy-but-3-en-2-one (15 g, 0.081 mol; *see J. Heterocyclic Chem.* (1987) *24*:1669) and 2-(trifluoromethyl)benzoyl chloride (20.0 g, 0.097 mol) in THF (50 mL) into the solution for 10 minutes. Remove the cooling bath and stir for 10 minutes. Add ammonium acetate (10 g) and acetic acid (200 mL) to the reaction mixture and distil THF under reduced pressure. Heat the mixture at 60-65°C for 18 hours, cool and add water (250 mL) and CH_2Cl_2 (250 mL). Separate the CH_2Cl_2 layer, and extract the aqueous layer twice with CH_2Cl_2 (2 x 250 mL each). Combine the CH_2Cl_2 extracts, dry ($MgSO_4$), and evaporate. Purify by silica gel chromatography to provide 4-hydroxy-6-(2-trifluoromethyl-phenyl)-nicotinic acid ethyl ester as a yellow solid.

2. 4-Chloro-6-(2-trifluoromethyl-phenyl)-nicotinic acid ethyl ester



Heat a mixture of 4-Hydroxy-6-(2-trifluoromethyl-phenyl)-nicotinic acid ethyl ester (9.0 g, 0.029 mol) in $POCl_3$ (22 g) at 110°C for 2 hours. Evaporate the $POCl_3$, and add ice (100 g) followed by careful addition of saturated $NaHCO_3$. Extract with EtOAc, dry ($MgSO_4$), and evaporate to provide 4-chloro-6-(2-trifluoromethyl-phenyl)-nicotinic acid ethyl ester as a brown oil.

3. *4-Amino-6-(2-trifluoromethyl-phenyl)-nicotinamide*



Heat a mixture of 4-Chloro-6-(2-trifluoromethyl-phenyl)-nicotinic acid ethyl ester (5.2 g) and 28% aq. NH_4OH (100 mL) in a 350 ml resealable pressure vessel for 60 hours. Cool, extract with EtOAc (3 x 100 mL each), dry ($MgSO_4$), and evaporate to provide the crude product. Purify by silica gel chromatography to provide 4-amino-6-(2-trifluoromethyl-phenyl)-nicotinamide as a solid.

4. *2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(2-trifluoromethyl-phenyl)-pyrido[4,3-d]pyrimidin-4-ol*



Heat a solution of 4-amino-6-(2-trifluoromethyl-phenyl)-nicotinamide (1 g, 3.5 mmol), 2,6-dimethyl-morpholin-4-yl)-acetic acid ethyl ester (2.85 g, 14 mmol), NaOEt (5.0 eq.) in EtOH (10 mL) for 20 hours. After cooling, concentrate the reaction mixture under reduced pressure, dilute the mixture with water (25 mL) and extract with EtOAc (3 x 25 mL each), then wash twice with water (25 mL each) and dry with $MgSO_4$. Evaporate, and purify by flash chromatography to obtain 2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(2-trifluoromethyl-phenyl)-pyrido[4,3-d]- pyrimidin-4-ol.

5. *4-Chloro-2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(2-trifluoromethyl-phenyl)-pyrido[4,3-d]pyrimidine*



Reflux a mixture of 2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(2-trifluoromethyl-phenyl)-pyrido[4,3-d]- pyrimidin-4-ol (0.6 g), 2,6-lutidine (0.62 g), and $POCl_3$ (1.1 g) in $CHCl_3$ (15 mL) for 20 hours. Cool the mixture and concentrate under reduced pressure. Partition the residue between EtOAc and saturated $NaHCO_3$ solution. Wash the EtOAc portion with additional $NaHCO_3$ and then dry (Na_2SO_4) and concentrate under reduced pressure. Filter the brown residue through 2 inches of silica gel (1:1 EtOAc/hexanes eluent)

and concentrate under reduced pressure to give 4-chloro-2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(2-trifluoromethyl-phenyl)-pyrido[4,3-d]pyrimidine.

6. *[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(2-trifluoromethyl-phenyl)-pyrido[4,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)*



Heat a mixture of 4-chloro-2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(2-trifluoromethyl-phenyl)-pyrido[4,3-d]pyrimidine (43.7 mg, 0.1 mmol) and 4-trifluoromethyl-aniline (16.1 mg, 0.1mmol) in AcCN (1 mL) at 80°C for 24 hours. Cool the mixture and wash the precipitate with ether to give 4-chloro-2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(2-trifluoromethyl-phenyl)-pyrido[4,3-d]pyrimidine as the mono-HCl salt. Mass Spec 561.2.

C. [2-MORPHOLIN-4-YLMETHYL-7(3-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PYRIDO[3,2-A]PYRIMIDIN-4-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE (COMPOUND 317)

1. *2-(Chloromethyl)-7-[3-(trifluoromethyl)(2-pyridyl)]-3-hydropyridino[3,2-d]pyrimidin-4-one*



This compound is prepared as described above (Example 1F).

2. *2-(Morpholin-4-ylmethyl)-7-[3-(trifluoromethyl)(2-pyridyl)]-3-hydropyridino[3,2-d]pyrimidin-4-one*



Heat a solution of 2-(chloromethyl)-7-[3-(trifluoromethyl)(2-pyridyl)]-3-hydropyridino[3,2-d]pyrimidin-4-one (20 g, 0.058 mol), morpholine (15.66 g, 0.18 mol) in acetonitrile (500 mL) at 80°C for 12 hours. Evaporate the solution and partition the residue between ethyl acetate (500 mL) and saturated sodium bicarbonate solution (500 mL). Extract the aqueous layer with further ethyl acetate (250 mL) and wash the combined organics with brine (500 mL). Dry ($MgSO_4$) and concentrate under reduced pressure to give the title compound as a brown solid.

3. *4-({4-Chloro-7-[3-(trifluoromethyl)(2-pyridyl)]pyridino[3,2-d]pyrimidin-2-yl}methyl)-methylmorpholine*



Heat a solution of 2-(morpholin-4-ylmethyl)-7-[3-(trifluoromethyl)(2-pyridyl)]-3-hydropyridino[3,2-d]pyrimidin-4-one (11.73 g, 0.03 mol), $POCl_3$ (13.8 g, 0.09 mol) and 2,6-lutidine (9.63 g, 0.09 mol) in chloroform (500 mL) at 60°C for 12 hours. Evaporate the solution and partition the residue between ethyl acetate (500 mL) and saturated sodium bicarbonate solution (500 mL). Extract the aqueous layer with further ethyl acetate (250 mL) and wash the combined organics with brine (500 mL). Dry ($MgSO_4$) and concentrate under reduced pressure to give the title compound as a brown solid.

4. *[2-Morpholin-4-ylmethyl-7(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-a]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine*



Heat a solution of 4-({4-chloro-7-[3-(trifluoromethyl)(2-pyridyl)]pyridino[3,2-d]pyrimidin-2-yl}methyl)-methylmorpholine (12.2 g, 0.03 mol), 4-(trifluoromethyl)aniline (4.8 g, 0.03 mol) in acetonitrile (500 mL) at 80°C for 12 hours. Evaporate the solution and partition the residue between ethyl acetate (500 mL) and saturated sodium bicarbonate solution (500 mL). Extract the aqueous layer with further ethyl acetate (2 x 250 mL) and wash the combined organics with brine (500 mL). Dry ($MgSO_4$) and concentrate under reduced pressure. Purify the residue by flash chromatography on silica gel (90% ether/ 10% hexane then 100% ether) to give the title compound. Mass Spec. 534.2.

D. [2-(2-PYRROLIDIN-1-YL-ETHYL)-7-(3-TRIFLUOROMETHYL-PYRIDINY-2-YL)-QUINAZOLIN-4-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE (COMPOUND 318)

1. *2-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-ethanol*



This compound is prepared as described above (Example 1B).

2. *[2-(2-Chloro-ethyl)-7-(3-trifluoromethyl-pyridiny-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine*



Dissolve 2-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-ethanol hydrochloride (1.54 g, 2.99 mmol) in thionyl chloride (20 mL) and heat to 60°C for 1 hour. Remove the excess thionyl chloride under reduced pressure and triturate the residue with diethyl ether to yield the mono-hydrochloride salt of the title compound as a light brown solid.

3. *[2-(2-Pyrrolidin-1-yl-ethyl)-7-(3-trifluoromethyl-pyridiny-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine*



Dissolve [2-(2-chloro-ethyl)-7-(3-trifluoromethyl-pyridiny-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine hydrochloride (20 mg, 0.0375 mmol) in CH_3CN / 10% diisopropylethylamine (0.187 mL) and add a 0.2 N solution of pyrrolidine in acetonitrile (0.281 mL). Heat the mixture at 70°C for 18 hours. Remove the solvent under reduced pressure and partition the crude reaction mixture between EtOAc (1 mL) and 1 N (NaOH). Remove the organic extract and extract the aqueous phase again with EtOAc (1 mL).

Chromatograph the combined organic extracts through a small pad of silica gel, eluting with acetone to yield the title compound as a light brown solid.

E. [2-(3-MORPHOLIN-4-YL-PROPYL)7-(3-TRIFLUOROMETHYL-PYRIDIN-2-YL)-QUINAZOLIN-4-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE HYDROCHLORIDE (COMPOUND 320)

1. *3-[4-hydroxy-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propionic acid ethyl ester*



To a solution of 2-amino-4-(3-trifluoromethyl-pyridin-2-yl)-benzamide (0.5 mmol) and pyridine (0.55 mmol) in THF (5 ml), add 3-chlorocarbonyl-propionic acid ethyl ester chloride (0.55 mmol). Stir the mixture for 20 minutes at room temperature, add 20 ml of 21% NaOEt in EtOH, and stir for 30 minutes at 50°C. Concentrate, add water, filter, acidify to pH 6, and collect the precipitate to give 3-[4-hydroxy-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propionic acid ethyl ester.

2. *3-[4-chloro-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propionic acid ethyl ester*



Using procedures analogous to those already described, 3-[4-chloro-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propionic acid ethyl ester is prepared from 3-[4-hydroxy-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propionic acid ethyl ester.

3. *3-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propionic acid ethyl ester*



Using procedures analogous to those already described, 3-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propionic acid ethyl ester is prepared from 3-[4-chloro-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propionic acid ethyl ester.

4. *3-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propionic acid*



To a mixture of 3-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoro-methyl-pyridin-2-yl)-quinazolin-2-yl]-propionic acid ethyl ester (0.5 mmol) in THF (20 ml) and H_2O (20 ml), add LiOH (1.5 mmol). Stir the mixture for 2 hours at 60°C. Concentrate, add water, extract with ether, acidify the aqueous layer to pH 4-5, extract with EtOAc, and concentrate to give 3-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoro-methyl-pyridin-2-yl)-quinazolin-2-yl]-propionic acid.

5. *1-morpholin-4-yl-3-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propan-1-one (compound 319)*



To a solution of 3-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoro-methyl-pyridin-2-yl)-quinazolin-2-yl]-propionic acid (0.5 mmol) and triethylamine (0.5 mmol) in DMF (10 ml), add BOP (0.5 mmol). Stir the mixture for 18 hours at room temperature, dilute with water, extract with EtOAc, and wash with brine. Concentrate to give 1-morpholin-4-yl-3-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propan-1-one. Mass Spec. 575.2.

6. *[2-(3-morpholin-4-yl-propyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine hydrochloride (compound 320)*



To a solution of 1-morpholin-4-yl-3-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propan-1-one (0.14 mmol) in THF (20 ml), add LAH (0.67 mmol). Stir the mixture for 6 hours at room temperature, quench with 10%

NaOH, extract with EtOAc, dry over Na_2SO_4, and add HCl-EtOAc. Collect the precipitate to give [2-(3-morpholin-4-yl-propyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine hydrochloride. Mass Spec. 561.2.

F. 4-TRIFLUOROMETHYLPHENYL-[2-(2,6-DIMETHYLMORPHONLI-4-YLMETHYL)-7-(2-TRIFLUOROMETHYL PHENYL)-QUINAZOLIN-4-YL]-AMINE (COMPOUND 321)

1. *7-Bromo-2-chloromethyl-3H-quinazolin-4-one*



Reflux a solution of 2-amino-4-bromobenzamide (27 g, 0.13 mol; *see* Joshi and Chaudhari (1987) *Indian J. Chem., Sect. B, 26B(6)*:602-4) in 2-chloro-1,1,1-trimethoxyethane (50 mL) for 30 minutes, during which time a large precipitate appears. Evaporate the mixture fully and triturate with ether to collect 7-bromo-2-chloromethyl-*3H*-quinazolin-4-one as a white solid.

2. *7-Bromo-4-chloro-2-chloromethylquinazoline*



Heat a mixture of 7-bromo-2-chloromethyl-*3H*-quinazolin-4-one (5 g, 18.2 mmol), 2,6-lutidine (5 g), and phosphorus oxychloride (5 mL) in 1,2-dimethoxyethane (500 mL) at 80°C for 16 hours. Cool the mixture to room temperature and fully evaporate the mixture, then dilute with ether and wash with water. Dry the solvent (Na_2SO_4) and evaporate the ether to obtain 7-bromo-4-chloro-2-chloromethylquinazoline as a yellow solid.

3. *7-Bromo-2-chloromethylquinazolin-4-yl)-(4-trifluoromethylphenyl)-amine*



Heat a mixture of 7-bromo-4-chloro-2-chloromethylquinazoline (1168 mg, 4.0 mmol) and 4-(trifluoromethyl)aniline (644 mg, 4.0 mmol) in chloroform (50 mL) at 60°C for 16 hours. Cool and collect the precipitated product 7-bromo-2-chloromethylquinazolin-4-yl)-(4-trifluoromethylphenyl)-amine as the HCL salt.

4. *[7-Bromo-2-(cis-2,6-dimethylmorpholin-4-ylmethyl)-quinazolin-4-yl]-4-(trifluoromethylphenyl)-amine*



Heat a mixture of 7-bromo-2-chloromethylquinazolin-4-yl)-(4-trifluoromethylphenyl)-amine (416 mg, 1.0 mmol), *cis*-2,6-dimethylmorpholine (150 mg, 1.3 mmol), and triethylamine (202 mg, 2.0 mmol) in N,N-dimethylacetamide (7 mL) for 1 hour. Cool to room temperature, dilute with EtOAc (50 mL), and wash four times with water (25 mL each). Dry (Na_2SO_4) and evaporate. Triturate with ether to give [7-bromo-2-(*cis*-2,6-dimethylmorpholin-4-ylmethyl)-quinazolin-4-yl]-4-(trifluoromethylphenyl)-amine as a yellow solid.

5. *[2-(cis-2,6-dimethylmorpholin-4-yloxymethyl)-7-(2-trifluoromethylphenyl)-quinazolin-4-yl]-(4-trifluoromethylphenyl)-amine*



Under nitrogen, heat a mixture of [7-bromo-2-(cis-2,6-dimethylmorpholin-4-ylmethyl)-quinazolin-4-yl]-4-(trifluoromethylphenyl)-amine (75 mg, 0.15 mmol), 2-(trifluoromethyl phenyl)boronic acid (45 mg, 0.23 mmol), tetrakis(triphenylphosphine)palladium(0) (21 mg, 0.018 mmol), 2M Na_2CO_3 in water (1mL), and 1,2-dimethoxyethane (5 mL) at 60°C for 16 hours. Cool the mixture to room temperature, dilute with EtOAc, and wash twice with water (10 mL each). Dry the organic layer (Na_2SO_4) and evaporate. Purify by preparative TLC (9:1 CH_2CL_2:MeOH) to obtain [2-(*cis*-2,6-dimethylmorpholin-4-yloxymethyl)-7-(2-trifluoromethylphenyl)-quinazolin-4-yl]-(4-trifluoromethylphenyl)-amine as a yellow solid. Mass Spec. 560.2.

G. [7-(3-METHYL-PYRIDIN-2-YL)-2-PYRROLIDIN-1-YLMETHYL-PYRIDO[3,2-D]PYRIMIDIN-4-YL]-(4-TRIFLUOROMETHYL-PHENYL)-AMINE (COMPOUND 322)

1. *3-Amino-5-(3-methyl(2-pyridyl))pyridine-2-carboxamide*



This compound is prepared as described above (Example 1G).

2. *[7-(3-Methyl-pyridin-2-yl)-2-pyrrolidin-1-ylmethyl-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine*



This compound is prepared from 3-amino-5-(3-methyl(2-pyridyl))pyridine-2-carboxamide in a manner analogous to that used to prepare [2-pyrrolidin-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine (Example 3A).

H. ADDITIONAL REPRESENTATIVE SUBSTITUTED 2-AMINOALKYL-QUINAZOLIN-4-YLAMINE ANALOGUES

Those having skill in the art will recognize that the starting materials may be varied and additional steps employed to produce other compounds encompassed by the present invention. Compounds listed in Table III were prepared using the above methods, with readily apparent modifications. In the column labeled K_i in Table III, * indicates that the K_i for the compound is 1 micromolar or less. Mass Spectrometry data was obtained as described above and is given as M+1.

Table III

Representative Substituted 2-Aminoalkyl-quinazolin-4-ylamine Analogues

Compound		Name	MS (M+1)	K_i
323.		[2-{[Methyl-(1-phenyl-ethyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	582.29	*
324.		[2-[(Indan-1-yl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	594.30	*

	Compound	Name	MS (M+1)	K_i
325.		[2-{[Methyl-(1-phenyl-propyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	596.31	
326.		[2-(1-Methyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	594.30	
327.		[2-[(Benzyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	568.28	
328.		[2-(3,4-Dihydro-1H-isoquinolin-2-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	580.28	
329.		[2-{[(3-Fluoro-benzyl)-methyl-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	586.27	
330.		[2-{[Methyl-(2-methyl-benzyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	582.29	
331.		[2-{[(2-Fluoro-benzyl)-methyl-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	586.27	
332.		[2-[(Benzyl-cyclopropyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	594.31	

	Compound	Name	MS (M+1)	K_i
333.		[2-{[Methyl-(2-phenyl-ethyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	582.29	
334.		[2-Piperidin-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	532.27	
335.		[2-(4-Methyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	546.29	
336.		[2-Azepan-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	546.30	
337.		[2-Azocan-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.32	*
338.		(4-Trifluoromethyl-phenyl)-[7-(3-trifluoromethyl-pyridin-2-yl)-2-(3,3,5-trimethyl-azepan-1-ylmethyl)-quinazolin-4-yl]-amine	588.36	*
339.		[2-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	590.30	*
340.		[2-(Octahydro-quinolin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	586.34	*

Compound		Name	MS (M+1)	K_i
341.		[2-Dimethylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	492.25	*
342.		[2-[(Allyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	518.26	*
343.		[2-Diethylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	520.27	*
330.		[2-[(Methyl-propyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	520.27	*
331.		[2-[(Butyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	534.28	*
332.		[2-[(Ethyl-isopropyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	534.30	*
333.		[2-Diallylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	544.27	*
334.		[2-[(Butyl-ethyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	548.31	*

Compound	Name	MS (M+1)	K_i
335. 	[2-[(Cyclopropylmethyl-propyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.31	*
336. 	[2-[(Hexyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	562.32	*
337. 	[2-Dibutylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	576.34	*
338. 	[2-[(Isopropyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	520.27	*
339. 	[2-(2-Methyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	546.28	*
340. 	[2-{[Ethyl-(2-methyl-allyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	546.28	*
341. 	[2-[(Cyclohexyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.31	*
342. 	[2-(2-Ethyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.30	*

	Compound	Name	MS (M+1)	K_i
343.		[2-[(Cyclohexyl-ethyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	574.33	*
344.		[2-{[Bis-(2-methoxy-ethyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	580.30	*
345.		[2-Dipentylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	604.38	*
346.		[2-Dihexylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	632.43	*
347.		[2-(3,5-Dimethyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.30	*
348.		[2-{[Methyl-(1-phenyl-ethyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	583.34	*
349.		[2-[(Indan-1-yl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	595.35	*
350.		[2-{[Methyl-(1-phenyl-propyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	597.36	*

	Compound	Name	MS (M+1)	K_i
351.		[2-(1-Methyl-3,4-dihydro-1H-isoquinolin-2-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	595.35	*
352.		[2-(3,4-Dihydro-1H-isoquinolin-2-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	581.34	*
353.		[2-{[(3-Fluoro-benzyl)-methyl-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	587.33	*
354.		[2-{[Methyl-(2-methyl-benzyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	583.34	*
355.		[2-{[(2-Fluoro-benzyl)-methyl-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	587.32	*
356.		[2-[(Benzyl-cyclopropyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	595.35	*
357.		[2-[(Methyl-phenethyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	583.35	*
358.		[2-Pyrrolidin-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	519.31	*

Compound		Name	MS (M+1)	K_i
359.		[2-Piperidin-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	533.32	*
360.		[2-(4-Methyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	547.34	*
361.		[2-Azepan-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	547.34	*
362.		[2-Azocan-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	561.36	*
363.		(6-Trifluoromethyl-pyridin-3-yl)-[7-(3-trifluoromethyl-pyridin-2-yl)-2-(3,3,5-trimethyl-azepan-1-ylmethyl)-quinazolin-4-yl]-amine	589.40	*
364.		[2-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	591.35	*
365.		[2-(Octahydro-quinolin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	587.38	*
366.		[2-Dimethylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	493.35	*

Compound		Name	MS (M+1)	K_i
367.		[2-[(Allyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	519.30	*
368.		[2-Diethylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	521.32	*
369.		[2-[(Methyl-propyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	521.32	*
370.		[2-[(Butyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	535.34	*
371.		[2-[(Ethyl-isopropyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	535.35	*
372.		[2-Diallylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	545.33	*
373.		[2-Dipropylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	549.36	*
374.		[2-[(Butyl-ethyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	549.36	*

Compound		Name	MS (M+1)	K_i
375.		[2-[(Cyclopropylmethyl-propyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	561.36	*
376.		[2-[(Hexyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	563.37	*
377.		[2-Dibutylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	577.39	*
378.		[2-[(Isopropyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	521.32	*
379.		[2-(2-Methyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	547.34	*
380.		[2-{[Ethyl-(2-methyl-allyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	547.34	*
381.		[2-[(Cyclohexyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	561.36	*

	Compound	Name	MS (M+1)	K_i
382.		[2-(2-Ethyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	561.36	*
383.		[2-[(Cyclohexyl-ethyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	575.38	*
384.		[2-{[Bis-(2-methoxy-ethyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	581.36	*
385.		[2-Dipentylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	605.43	*
386.		[2-Dihexylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	633.47	*
387.		[2-(3,5-Dimethyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	561.36	*
388.		[2-{2-[Methyl-(1-phenyl-ethyl)-amino]-ethyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	596.33	*
389.		[2-[2-(Indan-1-yl-methyl-amino)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	608.34	*

	Compound	Name	MS (M+1)	K_i
390.		[2-{2-[Methyl-(1-phenyl-propyl)-amino]-ethyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	610.35	*
391.		[2-[2-(1-Methyl-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	608.34	*
392.		[2-[2-(Benzyl-methyl-amino)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	582.31	*
393.		[2-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	594.32	*
394.		[2-{2-[(3-Fluoro-benzyl)-methyl-amino]-ethyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	600.30	*
395.		[2-{2-[Methyl-(2-methyl-benzyl)-amino]-ethyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	596.33	*
396.		[2-{2-[(2-Fluoro-benzyl)-methyl-amino]-ethyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	600.30	*

Compound		Name	MS (M+1)	K_i
397.		[2-[2-(Benzyl-cyclopropyl-amino)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	608.32	*
398.		[2-[2-(Methyl-phenethyl-amino)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	596.31	*
399.		[2-Piperidin-1-ylethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	546.30	*
400.		[2-Morpholin-4-ylethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	548.27	*
401.		[2-(4-Methyl-piperidin-1-ylethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.30	*
402.		[2-Azepan-1-ylethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.30	*
403.		[2-Thiomorpholin-4-ylethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	564.23	*
404.		[2-(3,3-Dimethyl-piperidin-1-ylethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	574.31	*

	Compound	Name	MS (M+1)	K_i
405.		[2-Azocan-1-ylethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	574.31	*
406.		(4-Trifluoromethyl-phenyl)-{7-(3-trifluoromethyl-pyridin-2-yl)-2-[2-(3,3,5-trimethyl-azepan-1-yl)-ethyl]-quinazolin-4-yl}-amine	602.34	*
407.		[2-[2-(1,4-Dioxa-8-aza-spiro[4.5]dec-8-yl)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	604.29	*
408.		[2-(Octahydro-quinolin-1-ylethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	600.35	*
409.		[2-Dimethylaminoethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine		*
410.		[2-[(Allyl-methyl-amino)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	532.25	*
411.		[2-Diethylaminoethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	534.28	*
412.		[2-[(Propyl-methyl-amino)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	534.27	*

Compound		Name	MS (M+1)	K_i
413.		[2-[(Butyl-methyl-amino)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	548.29	*
414.		[2-[(Isopropyl-ethyl-amino)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	548.31	*
415.		[2-Diallylaminoethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	558.27	*
416.		[2-Dipropylaminoethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	562.31	*
417.		[2-[(Butyl-ethyl-amino)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	562.31	*
418.		[2-[(Cyclopropylmethyl-propyl-amino)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	574.15	*
419.		[2-[(Hexyl-methyl-amino)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	576.32	*
420.		[2-Dibutylaminoethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	590.33	*

Compound		Name	MS (M+1)	K_i
421.		[2-[(Isopropyl-methyl-amino)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	534.29	*
422.		[2-(2-Methyl-piperidin-1-ylethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.30	*
423.		[2-{2-[Ethyl-(2-methyl-allyl)-amino]-ethyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.29	*
424.		[2-[(Cyclohexyl-methyl-amino)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	574.32	*
425.		[2-(2-Ethyl-piperidin-1-ylethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	574.31	*
426.		[2-[(Cyclohexyl-ethyl-amino)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	588.34	*
427.		[2-{2-[Bis-(2-methoxy-ethyl)-amino]-ethyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	594.30	*
428.		[2-Dipentylaminoethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	618.37	*

	Compound	Name	MS (M+1)	K_i
429.		[2-Dihexylaminoethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	646.40	*
430.		[2-(3,5-Dimethyl-piperidin-1-ylethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	574.30	*
431.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (1-ethyl-pyrrolidin-2-ylmethyl)-amide	590.21	*
432.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (3-pyrrolidin-1-yl-propyl)-amide	590.20	*
433.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide		*
434.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (3-dimethylamino-2,2-dimethyl-propyl)-amide	592.22	*
435.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (2-dimethylamino-ethyl)-amide	550.17	*

Compound		Name	MS (M+1)	K_i
436.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (3-dimethylamino-propyl)-amide	564.19	*
437.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide	576.19	*
438.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (2-diethylamino-ethyl)-amide	578.21	*
439.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (2-piperidin-1-yl-ethyl)-amide	590.21	*
440.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid [2-(1-methyl-pyrrolidin-2-yl)-ethyl]-amide	590.22	*
441.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (3-diethylamino-propyl)-amide	592.23	*
442.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide	592.19	*

Compound		Name	MS (M+1)	K_i
443.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (3-morpholin-4-yl-propyl)-amide	606.21	*
444.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (2-dimethylamino-1-methyl-ethyl)-amide	564.20	*
445.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide		*
446.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (4-diethylamino-1-methyl-butyl)-amide	620.26	*
447.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (1,2,2,6,6-pentamethyl-piperidin-4-yl)-amide	632.27	*
448.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (1-methyl-piperidin-4-yl)-amide		*
449.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid methylamide	493.13	*

	Compound	Name	MS (M+1)	K_i
450.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid ethylamide	507.15	*
451.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid allylamide	519.15	*
452.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid propylamide	521.16	*
453.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid cyclopropylmethyl-amide	533.17	*
454.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (2-ethoxy-ethyl)-amide	551.18	*
455.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (2-methoxy-ethyl)-amide	537.16	*
456.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (3-methoxy-propyl)-amide	551.18	*

Compound	Name	MS (M+1)	K_i
457. 	4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide	563.18	*
458. 	4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (2,2-dimethyl-propyl)-amide	549.20	*
459. 	Pyrrolidin-1-yl-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-2-yl]-methanone	533.17	*
460. 	Piperidin-1-yl-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-2-yl]-methanone	547.19	*
461. 	Morpholin-4-yl-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-2-yl]-methanone	549.17	*
462. 	(4-Methyl-piperidin-1-yl)-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-2-yl]-methanone	561.21	*
463. 	Thiomorpholin-4-yl-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-2-yl]-methanone	565.15	*
464. 	4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid allyl-methyl-amide	533.17	*

Compound		Name	MS (M+1)	K_i
465.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid diallylamide	559.19	*
466.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid dipropylamide	563.22	*
467.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid dimethylamide		*
468.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (3,3-dimethyl-cyclohexyl)-amide	575.23	*
469.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid bis-(2-methoxy-ethyl)-amide	595.22	*
470.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carboxylic acid (3,5-dimethyl-cyclohexyl)-amide	575.24	*
471.		(4-Isopropyl-piperazin-1-yl)-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-2-yl]-methanone	590.25	*
472.		(4-Methyl-piperazin-1-yl)-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-2-yl]-methanone	562.21	*

Compound	Name	MS (M+1)	K_i
473. 	(4-Cyclopentyl-piperazin-1-yl)-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-2-yl]-methanone	616.27	*
474. 	(4-Cycloheptyl-piperazin-1-yl)-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-2-yl]-methanone	644.30	*
475. 	(4-*tert*-Butyl-phenyl)-[2-pyrrolidin-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	506.37	*
476. 	(4-*tert*-Butyl-phenyl)-[2-piperidin-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	520.39	*
477. 	[2-Morpholin-4-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	534.29	*
478. 	1-Pyrrolidin-1-yl-3-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propan-1-one	560.14	*
479. 	[2-(3-Pyrrolidin-1-yl-propyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	546.16	*
480. 	[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	563.30	*

Compound	Name	MS (M+1)	K_i
481. 	2-{1-[7-(3-Trifluoromethyl-pyridin-2-yl)-4-(6-trifluoromethyl-pyridin-3-ylamino)-quinazolin-2-ylmethyl]-piperidin-4-yl}-ethanol	577.32	*
482. 	{1-[7-(3-Trifluoromethyl-pyridin-2-yl)-4-(6-trifluoromethyl-pyridin-3-ylamino)-quinazolin-2-ylmethyl]-piperidin-4-yl}-methanol	563.30	*
483. 	4-[7-(3-Trifluoromethyl-pyridin-2-yl)-4-(6-trifluoromethyl-pyridin-3-ylamino)-quinazolin-2-ylmethyl]-piperazine-1-carboxylic acid ethyl ester		*
484. 	1-[7-(3-Trifluoromethyl-pyridin-2-yl)-4-(6-trifluoromethyl-pyridin-3-ylamino)-quinazolin-2-ylmethyl]-piperidin-4-ol	549.13	*
485. 	[2-(3-Methyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	547.29	*
486. 	1-[7-(3-Trifluoromethyl-pyridin-2-yl)-4-(6-trifluoromethyl-pyridin-3-ylamino)-quinazolin-2-ylmethyl]-piperidin-3-ol	549.28	*
487. 	1-[7-(3-Trifluoromethyl-pyridin-2-yl)-4-(6-trifluoromethyl-pyridin-3-ylamino)-quinazolin-2-ylmethyl]-piperidine-4-carboxylic acid amide	576.30	*
488. 	1-[7-(3-Trifluoromethyl-pyridin-2-yl)-4-(6-trifluoromethyl-pyridin-3-ylamino)-quinazolin-2-ylmethyl]-piperidine-3-carboxylic acid ethyl ester	605.32	*

	Compound	Name	MS (M+1)	K_i
489.		1-{4-[7-(3-Trifluoromethyl-pyridin-2-yl)-4-(6-trifluoromethyl-pyridin-3-ylamino)-quinazolin-2-ylmethyl]-piperazin-1-yl}-ethanone	576.15	*
490.		{1-[7-(3-Trifluoromethyl-pyridin-2-yl)-4-(6-trifluoromethyl-pyridin-3-ylamino)-quinazolin-2-ylmethyl]-piperidin-3-yl}-methanol	563.38	*
491.		1-[7-(3-Trifluoromethyl-pyridin-2-yl)-4-(6-trifluoromethyl-pyridin-3-ylamino)-quinazolin-2-ylmethyl]-piperidine-4-carboxylic acid ethyl ester	605.41	*
492.		2-{4-[7-(3-Trifluoromethyl-pyridin-2-yl)-4-(6-trifluoromethyl-pyridin-3-ylamino)-quinazolin-2-ylmethyl]-piperazin-1-yl}-ethanol	578.17	*
493.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	562.14	*
494.		2-{1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-piperidin-4-yl}-ethanol	576.32	*
495.		{1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-piperidin-4-yl}-methanol	562.15	*
496.		1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-piperidin-4-ol	548.12	*

	Compound	Name	MS (M+1)	K_i
497.		{1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-piperidin-2-yl}-methanol	562.30	*
498.		[2-(3-Methyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	546.39	*
499.		1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-piperidin-3-ol	548.37	*
500.		1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-piperidine-4-carboxylic acid amide	575.15	*
501.		1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-piperidine-3-carboxylic acid ethyl ester	604.43	*
502.		{1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-piperidin-3-yl}-methanol	562.39	*
503.		1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-piperidine-4-carboxylic acid ethyl ester	604.43	*
504.		2-{4-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-piperazin-1-yl}-ethanol	577.42	*

Compound	Name	MS (M+1)	K_i
505. 	[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)	562.12	*
506. 	N-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-methanesulfonamide	542.27	*
507. 	[2-Pyridin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine		*
508. 	[2-Pyridin-3-yl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine		*
509. 	[2-(6-Methoxy-pyridin-3-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	542.08	*
510. 	[2-(5H-Tetrazol-5-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine		*
511. 	[2-Morpholin-4-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine	535.35	*
512. 	[2-(4-Isopropyl-piperazin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	575.18	*

	Compound	Name	MS (M+1)	K_i
513.		[2-(4-Cyclopentyl-piperazin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	601.20	*
514.		[2-[4-(2-Methoxy-ethyl)-piperazin-1-ylmethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	591.17	*
515.		[2-[4-(2-Dimethylamino-ethyl)-piperazin-1-ylmethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	604.22	*
516.		[2-[4-(2-Diethylamino-ethyl)-piperazin-1-ylmethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	632.26	*
517.		[2-[4-(2-Pyrrolidin-1-yl-ethyl)-piperazin-1-ylmethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	630.25	*
518.		[2-[4-(2-Morpholin-4-yl-ethyl)-piperazin-1-ylmethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	646.24	*
519.		[2-[4-(3-Dimethylamino-propyl)-piperazin-1-ylmethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	618.24	*

Compound		Name	MS (M+1)	K_i
520.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine	563.14	*
521.		[2-{[Bis-(2-methoxy-ethyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine	581.15	*
522.		[2-(4-Methyl-piperazin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine	548.13	*
523.		[2-Piperidin-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(2,2,2-trifluoro-1-methyl-ethyl)-phenyl]-amine	560.15	*
524.		[2-Morpholin-4-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(2,2,2-trifluoro-1-methyl-ethyl)-phenyl]-amine	562.13	*
525.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(2,2,2-trifluoro-1-methyl-ethyl)-phenyl]-amine	590.17	*
526.		[2-(4-Methyl-piperazin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(2,2,2-trifluoro-1-methyl-ethyl)-phenyl]-amine	575.17	*
527.		[2-{[Bis-(2-methoxy-ethyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(2,2,2-trifluoro-1-methyl-ethyl)-phenyl]-amine	608.19	*

Compound		Name	MS (M+1)	K_i
528.		[2-Morpholin-4-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	535.08	*
529.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine (cis)	563.12	*
530.		[2-Methylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	478.05	*
531.		[2-Ethylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	492.07	*
532.		[2-(Isopropylamino-methyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	506.08	*
533.		[2-(*tert*-Butylamino-methyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	520.10	*
534.		2-{[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-amino}-ethanol	508.07	*
535.		[2-[(2-Methoxy-ethylamino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	522.09	*

Compound	Name	MS (M+1)	K_i
536. 	[2-(Isobutylamino-methyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	520.11	*
537. 	[2-[(3-Methyl-butylamino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	534.14	*
538. 	[2-Cyclohexylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	546.14	*
539. 	[2-Hexylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	548.15	*
540. 	[2-Octylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	576.19	*
541. 	[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine (cis)	563.33	*
542. 	[2-Morpholin-4-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	536.28	*
543. 	[2-(6-Pyrrolidin-1-yl-pyridin-3-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoro methyl-phenyl)-amine	581.34	*

Compound		Name	MS (M+1)	K_i
544.		[2-[3-(2,6-Dimethyl-morpholin-4-yl)-propyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	591.39	*
545.		[2-Morpholin-4-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(6-trifluoromethyl-pyridin-2-yl)-amine	536.28	*
546.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)	563.33	*
547.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine (cis)	564.32	*
548.		[2-Thiomorpholin-4-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	550.27	*
549.		[2-(3,3-Dimethyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.34	*
550.		[2-Dipropylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	548.33	*
551.		[2-[(Cyclopropylmethyl-propyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.34	*

Compound	Name	MS (M+1)	K_i
552. 	[2-(3,5-Dimethyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.35	*
553. 	[2-(1,1-Dioxo-1λ⁶-thiomorpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	583.28	*
554. 	[2-[(Tetrahydro-thiopyran-4-ylamino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	565.30	*
555. 	[2-Thiomorpholin-4-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	551.27	*
556. 	[2-(3,3-Dimethyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	561.36	*
557. 	[2-Dipropylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	549.34	*
558. 	[2-[(Cyclopropylmethyl-propyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	561.34	*
559. 	[2-(3,5-Dimethyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	561.35	*

Compound	Name	MS (M+1)	K_i
560. 	[2-(Benzylamino-methyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(5-trifluoromethyl-pyridin-2-yl)-amine	555.30	*
561. 	[2-[2-(2,6-Dimethyl-morpholin-4-yl)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine		*
562. 	4-{2-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-ethyl}-piperazine-1-carbaldehyde	575.34	*
563. 	[2-[2-(4-Methyl-piperazin-1-yl)-ethyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	561.36	*
564. 	[2-(4-Ethoxy-piperidin-1-ylethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	590.39	*
565. 	[2-(4-Methoxy-piperidin-1-ylethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	576.37	*
566. 	[2-[3-(2,6-Dimethyl-morpholin-4-yl)-propyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	590.37	*
567. 	[2-[3-(2,6-Dimethyl-morpholin-4-yl)-propyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)	590.35	*

Compound		Name	MS (M+1)	K_i
568.		2-(1-{3-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propyl}-piperidin-4-yl)-ethanol	604.39	*
569.		(1-{3-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propyl}-piperidin-4-yl)-methanol	590.37	*
570.		1-{3-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propyl-piperidin-4-ol	576.36	*
571.		1-{3-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-propyl}piperidin-3-ol	576.35	*
572.		[2-[3-(3-Methyl-piperidin-1-yl)-propyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	574.17	*
573.		[2-[3-(4-Methyl-piperazin-1-yl)-propyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	575.36	*
574.		[2-(Benzylamino-methyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine		*
575.		[2-[(Benzyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	569.31	*

Compound	Name	MS (M+1)	K_i
576. 	[2-[(2-Methoxy-benzylamino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	585.31	*
577. 	[2-[(4-Methoxy-benzylamino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine		*
578. 	[2-{[(Pyridin-2-ylmethyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine		*
579. 	[2-Imidazol-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	516.24	*
580. 	[2-Morpholin-4-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine	598.34	*
581. 	[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine	626.40	*
582. 	[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine (cis)	626.40	*
583. 	(4-*tert*-Butyl-phenyl)-[2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-amine (cis)	551.42	*

	Compound	Name	MS (M+1)	K_i
584.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-methanesulfonyl-phenyl)-amine (cis)	573.38	*
585.		4-{2-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-ethyl}-piperazine-1-carboxylic acid propyl ester	633.41	*
586.		[2-(4-Hydroxy-piperidin-1-ylethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	562.35	*
587.		[2-(3-Methyl-piperidin-1-ylethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.36	*
588.		[2-(3-Hydroxy-piperidin-1-ylethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	562.34	*
589.		1-{2-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-ethyl}-piperidine-4-carboxylic acid amide	589.37	*
590.		1-{2-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-ethyl}-piperidine-3-carboxylic acid ethyl ester	618.39	*
591.		[2-(3-Methoxy-piperidin-1-ylethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	576.36	*

Compound		Name	MS (M+1)	K_i
592.		1-{2-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-ethyl}-piperidine-4-carboxylic acid ethyl ester	618.39	*
593.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine (cis)		*
594.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-[4-(propane-1-sulfonyl)-phenyl]-amine (cis)	601.40	*
595.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-[4-(propane-2-sulfonyl)-phenyl]-amine (cis)	601.40	*
596.		(R,R)-[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	562.14	*
597.		(S,S)-[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	562.27	*
598.		[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)	528.12	*
599.		[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine (cis)	529.11	*

	Compound	Name	MS (M+1)	K_i
600.		(R,R)-[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	563.14	*
601.		(S,S)-[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	563.37	*
602.		[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine (cis)	592.10	*
603.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-methyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)	509.15	*
604.		(S,S)-[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	528.12	*
605.		(S,S)-(6-*tert*-Butyl-pyridin-3-yl)-[7-(3-chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-amine	517.19	*
606.		(R,R)-[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	528.11	*
607.		(R,R)-(6-*tert*-Butyl-pyridin-3-yl)-[7-(3-chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-amine	517.18	*

Compound		Name	MS (M+1)	K_i
608.		(S,S)-[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	529.11	*
609.		(S,S)-(6-*tert*-Butyl-pyridin-3-yl)-[2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	551.22	*
610.		(R,R)-[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine	529.11	*
611.		(R,R)-(6-*tert*-Butyl-pyridin-3-yl)-[2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	551.22	*
612.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(2-trifluoromethyl-phenyl)-pyrido[4,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)	562.14	*
613.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-isopropyl-phenyl)-amine (cis)	537.18	*
614.		(4-*tert*-Butyl-phenyl)-[2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(2-trifluoromethyl-phenyl)-pyrido[4,3-d]pyrimidin-4-yl]-amine (cis)	550.22	*
615.		[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)	529.10	*

Compound	Name	MS (M+1)	K_i
616. 	[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-pyrido[3,2-d]pyrimidin-4-yl]-(6-trifluoromethyl-pyridin-3-yl)-amine (cis)	530.10	*
617. 	[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethanesulfonyl-phenyl)-amine (cis)	593.09	*
618. 	[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-methyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)	508.16	*
619. 	[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-pyridin-2-yl-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)	494.14	*
620. 	[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(2-trifluoromethyl-phenyl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)	561.15	*
621. 	(R,R)-(4-*tert*-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-amine	516.36	*
622. 	(R,R)-(4-Fluoro-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-amine	478.25	*
623. 	(R,R)-1-{4-[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-ylamino]-phenyl}-ethanone	502.29	*

Compound	Name	MS (M+1)	K_i
624. 	(R,R)-(4-Chloro-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-amine	494.24	*
625. 	(R,R)-(4-Isopropyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-amine	502.32	*
626. 	(R,R)-(4-Ethyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-amine	488.30	*
627. 	[2-(4-Methyl-piperazin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	547.33	*
628. 	[2-(4-Ethyl-piperazin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	561.35	*
629. 	(R,R)-[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-(6-isopropoxy-pyridin-3-yl)-amine	519.33	*
630. 	(R,R)-4-[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-ylamino]-benzonitrile	485.25	*
631. 	(R,R)-[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-[4-(propane-2-sulfonyl)-phenyl]-amine	566.30	*

Compound	Name	MS (M+1)	K_i
632. 	(6-*tert*-Butyl-pyridin-3-yl)-[7-(3-chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-pyrido[3,2-d]pyrimidin-4-yl]-amine (cis)	518.32	*
633. 	(4-*tert*-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-pyrido[3,2-d]pyrimidin-4-yl]-amine (cis)	517.33	*
634. 	[7-(3-Chloro-pyridin-2-yl)-2-(3,5-dimethyl-piperazin-1-ylmethyl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	527.27	*
635. 	(4-*tert*-Butyl-phenyl)-[2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(3-methyl-pyridin-2-yl)-quinazolin-4-yl]-amine (cis)	496.37	*
636. 	(4-*tert*-Butyl-phenyl)-[2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-pyridin-2-yl-quinazolin-4-yl]-amine (cis)	482.35	*
637. 	(4-*tert*-Butyl-phenyl)-[2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(6-methyl-pyridin-2-yl)-quinazolin-4-yl]-amine (cis)	496.38	*
638. 	[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(2-methoxy-phenyl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)		*
639. 	1-{2-[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-4-(4-trifluoromethyl-phenylamino)-quinazolin-7-yl]-phenyl}-ethanone (cis)		*

	Compound	Name	MS (M+1)	K_i
640.		(S,S)-[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	536.17	*
641.		(S,S)-[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-ethyl-phenyl)-amine	522.15	*
642.		(S,S)-(4-Chloro-phenyl)-[2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	528.08	*
643.		(S,S)-[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(propane-2-sulfonyl)-phenyl]-amine	600.16	*
644.		(S,S)-(4-Chloro-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-amine	494.05	*
645.		(S,S)-[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-[4-(propane-2-sulfonyl)-phenyl]-amine	566.12	*
646.		(S)-[7-(3-Chloro-pyridin-2-yl)-2-(2-methyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-[4-(propane-2-sulfonyl)-phenyl]-amine	552.10	*
647.		(S)-(4-*tert*-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-(2-methyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-amine	502.14	*

Compound		Name	MS (M+1)	K_i
648.		(S)-[7-(3-Chloro-pyridin-2-yl)-2-(2-methyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	488.12	*
649.		(S,S)-(4-*tert*-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-amine	516.16	*
650.		(S,S)-[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	502.14	*
651.		(S,S)-[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-(4-ethyl-phenyl)-amine	488.12	*
652.		(R,R)-[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	536.17	*
653.		(R,R)-[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-ethyl-phenyl)-amine	522.15	*
654.		(R,R)-(4-Chloro-phenyl)-[2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	528.08	*
655.		(R,R)-[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(propane-2-sulfonyl)-phenyl]-amine	600.16	*

Compound	Name	MS (M+1)	K_i
656. 	(S)-2-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-pyrrolidine-1-carboxylic acid benzyl ester	638.51	*
657. 	(R,R)-[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	563.34	*
658. 	(S,S)-[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	563.34	*
659. 	[2-Azepan-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	547.34	*
660. 	[2-Thiomorpholin-4-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	551.28	*
661. 	[2-(3,3-Dimethyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	561.37	*
662. 	[2-[(Allyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	519.28	*
663. 	[2-Diallylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	545.32	*

Compound		Name	MS (M+1)	K_i
664.		[2-Dipropylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	549.36	*
665.		[2-[(Cyclopropylmethyl-propyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	561.37	*
666.		[2-Dibutylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	577.41	*
667.		[2-{[Ethyl-(2-methyl-allyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	547.34	*
668.		[2-(3,5-Dimethyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)	561.37	*
669.		[2-(3-Methyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	547.34	*
670.		[2-{[Bis-(2-methoxy-ethyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	581.36	*
671.		[2-(5,6-Dihydro-4H-pyrimidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	531.12	*

Compound		Name	MS (M+1)	K_i
672.		(R)-(4-*tert*-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-(2-methyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-amine	502.17	*
673.		(R)-[7-(3-Chloro-pyridin-2-yl)-2-(2-methyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	488.15	*
674.		(R)-[7-(3-Chloro-pyridin-2-yl)-2-(2-methyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	514.09	*
675.		(4-*tert*-Butyl-phenyl)-[2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-pyridin-4-yl-quinazolin-4-yl]-amine (cis)	482.43	*
676.		(4-*tert*-Butyl-phenyl)-[2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-pyridin-3-yl-quinazolin-4-yl]-amine (cis)	482.43	*
677.		(4-*tert*-Butyl-phenyl)-[2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-pyrimidin-5-yl-quinazolin-4-yl]-amine (cis)	483.43	*
678.		(4-*tert*-Butyl-phenyl)-[7-(2,4-dimethoxy-pyrimidin-5-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-amine (cis)	543.50	*
679.		[2-Piperidin-4-yl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	518.35	*

Compound		Name	MS (M+1)	K_i
680.		(4-*sec*-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-amine (cis)	516.46	*
681.		[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine (cis)	502.44	*
682.		(R)-(4-*tert*-Butyl-phenyl)-[2-(2-methyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	536.49	*
683.		(R)-[2-(2-Methyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	548.43	*
684.		(R)-(4-Isopropyl-phenyl)-[2-(2-methyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	522.47	*
685.		(S)-(4-*tert*-Butyl-phenyl)-[2-(2-methyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	536.50	*
686.		(S)-[2-(2-Methyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	548.43	*
687.		(S)-(4-Isopropyl-phenyl)-[2-(2-methyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	522.47	*

Compound		Name	MS (M+1)	K_i
688.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine (cis)	536.50	*
689.		[2-(1-Ethyl-piperidin-4-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	546.45	*
690.		[2-(1-Propyl-piperidin-4-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.48	*
691.		[2-(1-Pyridin-4-ylmethyl-piperidin-4-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	609.52	*
692.		[2-[1-(1-Methyl-1H-imidazol-2-ylmethyl)-piperidin-4-yl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	612.54	*
693.		1-{4-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-piperidin-1-yl}-ethanone	560.45	*
694.		1-{4-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-piperidin-1-yl}-propan-1-one	574.47	*
695.		(S)-[2-Pyrrolidin-2-yl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	504.37	*

Compound		Name	MS (M+1)	K_i
696.		(S)-[2-(1-Propyl-pyrrolidin-2-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	546.50	*
697.		(4-*tert*-Butyl-phenyl)-[2-(1,1-dioxo-1λ⁶-isothiazolidin-2-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	556.46	*
698.		1-{4-[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-ylamino]-phenyl}-ethanone (cis)	537.51	*
699.		[2-Imidazol-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	516.41	*
700.		[7-(3-Chloro-pyridin-2-yl)-2-imidazol-1-ylmethyl-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	482.35	*
701.		[2-Imidazol-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	515.41	*
702.		(2,6-Dimethyl-morpholin-4-yl)-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-methanone (cis)	576.46	*
703.		[2-(1-Methanesulfonyl-piperidin-4-yl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	596.15	*

	Compound	Name	MS (M+1)	K_i
704.		2-Methyl-2-{[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-amino}-propan-1-ol	536.19	*
705.		[2-(4-Methyl-[1,4]diazepan-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	561.23	*
706.		N,N,N'-Trimethyl-N'-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-propane-1,3-diamine	563.25	*
707.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline-2-carboxylic acid dimethylamide	506.40	*
708.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline-2-carboxylic acid methylamide		*
709.		4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline-2-carboxylic acid (2-morpholin-4-yl-ethyl)-amide	591.55	*
710.		(4-Cyclopropyl-phenyl)-[2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine (cis)	534.53	*
711.		[2-Dimethylaminomethyl-7-(3-methyl-pyridin-2-yl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	412.25	*

Compound		Name	MS (M+1)	K_i
712.		(4-Isopropyl-phenyl)-[7-(3-methyl-pyridin-2-yl)-2-morpholin-4-ylmethyl-quinazolin-4-yl]-amine	454.25	*
713.		(4-Isopropyl-phenyl)-[7-(3-methyl-pyridin-2-yl)-2-thiomorpholin-4-ylmethyl-quinazolin-4-yl]-amine	470.23	*
714.		[2-(3,3-Dimethyl-piperidin-1-ylmethyl)-7-(3-methyl-pyridin-2-yl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	480.30	*
715.		[2-[(Ethyl-propyl-amino)-methyl]-7-(3-methyl-pyridin-2-yl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	440.27	*
716.		(4-Isopropyl-phenyl)-[2-[(methyl-propyl-amino)-methyl]-7-(3-methyl-pyridin-2-yl)-quinazolin-4-yl]-amine	440.27	*
717.		[2-[(Ethyl-isopropyl-amino)-methyl]-7-(3-methyl-pyridin-2-yl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	454.30	*
718.		[2-[(Isopropyl-methyl-amino)-methyl]-7-(3-methyl-pyridin-2-yl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	440.27	*
719.		[2-{[Bis-(2-methoxy-ethyl)-amino]-methyl}-7-(3-methyl-pyridin-2-yl)-quinazolin-4-yl]-(4-isopropyl-phenyl)-amine	500.31	*

Compound	Name	MS (M+1)	K_i
720. 	[7-(3-Chloro-pyridin-2-yl)-2-(2,6-dimethyl-morpholin-4-ylmethyl)-pyrido[3,2-d]pyrimidin-4-yl]-[4-(morpholine-4-sulfonyl)-phenyl]-amine (cis)		*
721. 	[2-Dimethylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(morpholine-4-sulfonyl)-phenyl]-amine	573.21	*
722. 	[2-[(Methyl-propyl-amino)-methyl]-7-(3-*trifluoromethyl-pyridin-2-*yl)-quinazolin-4-yl]-[4-(morpholine-4-sulfonyl)-phenyl]-amine	601.26	*
723. 	[2-[(Isopropyl-methyl-*amino*)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(morpholine-4-sulfonyl)-phenyl]-amine	601.26	*
724. 	[2-[(Ethyl-propyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-[4-(morpholine-4-*sulfonyl*)-phenyl]-amine	601.24	*
725. 	[2-[(Bis-ethoxymethyl-amino)-methyl]-7-(3-methyl-pyridin-2-yl)-*quinazolin-4-yl*]-(4-trifluoromethyl-phenyl)-amine	526.23	*
726. 	[2-Dipropylaminomethyl-7-(3-methyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	494.24	*
727. 	3-[7-(3-Methyl-pyridin-2-yl)-4-(4-trifluoromethyl-phenylamino)-pyrido[2,3-d]pyrimidin-2-yl]-azetidine-1-carboxylic acid tert-butyl ester	537.19	*

Compound		Name	MS (M+1)	K_i
728.		1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-piperidine-4-carboxylic acid	576.18	*
729.		1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-piperidine-3-carboxylic acid	576.18	*
730.		(S)-1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-pyrrolidine-2-carboxylic acid	562.16	*
731.		[2-(3,3-Dimethyl-piperidin-1-ylmethyl)-7-(3-methyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	506.24	*
732.		(R)-1-[7-(3-Methyl-pyridin-2-yl)-4-(4-trifluoromethyl-phenylamino)-quinazolin-2-ylmethyl]-pyrrolidin-3-ol	480.20	*
733.		(R)-{1-[7-(3-Methyl-pyridin-2-yl)-4-(4-trifluoromethyl-phenylamino)-quinazolin-2-ylmethyl]-pyrrolidin-3-yl}-methanol	494.21	*
734.		(S)-{1-[7-(3-Methyl-pyridin-2-yl)-4-(4-trifluoromethyl-phenylamino)-quinazolin-2-ylmethyl]-pyrrolidin-3-yl}-methanol	494.21	*
735.		[2-Azetidin-3-yl-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	437.32	*

	Compound	Name	MS (M+1)	K_i
736.		1-{2-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-ethyl}-piperidine-4-carboxylic acid ethyl ester	586.39	*
737.		1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-piperidine-2-carboxylic acid	576.45	*
738.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)	509.23	*
739.		[2-(2,2-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	562.22	*
740.		[7-(3-Chloro-pyridin-2-yl)-2-(2,2-dimethyl-morpholin-4-ylmethyl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	528.42	*
741.		(4-Cyclopropyl-phenyl)-[2-(2,2-dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-amine	534.48	*
742.		[2-(2,2-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	563.44	*
743.		[2-{[Bis-(2-methoxy-ethyl)-amino]-methyl}-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	527.47	*

	Compound	Name	MS (M+1)	K_i
744.		(S)-1-[4-(4-tert-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-pyrrolidine-2-carboxylic acid	550.50	*
745.		(R)-1-[4-(4-tert-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-pyrrolidine-2-carboxylic acid	550.49	*
746.		[2-(3,3-Dimethyl-piperidin-1-ylmethyl)-7-(3-methyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	507.25	*
747.		(S)-1-[7-(3-Methyl-pyridin-2-yl)-4-(4-trifluoromethyl-phenylamino)-pyrido[2,3-d]pyrimidin-2-ylmethyl]-pyrrolidine-2-carboxylic acid		*
748.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)	563.20	*
749.		[2-{[Bis-(2-methoxy-ethyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	581.21	*
750.		[2-(3,3-Dimethyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	561.23	*

	Compound	Name	MS (M+1)	K_i
751.		(S)-1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-2-ylmethyl]-pyrrolidine-2-carboxylic acid		*
752.		(S)-1-[4-(4-tert-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[3,2-d]pyrimidin-2-ylmethyl]-pyrrolidine-2-carboxylic acid	551.24	*
753.		(R,S)-1-[4-(4-tert-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-4-hydroxy-pyrrolidine-2-carboxylic acid	566.50	*
754.		2-{[4-(4-*tert*-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-propyl-amino}-ethanol	538.50	*
755.		{1-[4-(4-*tert*-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-ylmethyl]-pyrrolidin-2-yl}-methanol	536.49	*
756.		[2-(1,1-Dioxo-1λ⁶-[1,2]thiazinan-2-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-4-yl]-(4-trifluoromethyl-phenyl)-amine	582.41	*
757.		(4-*tert*-Butyl-phenyl)-[2-(2,6-dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine (cis)	551.54	*

Compound	Name	MS (M+1)	K_i
758. 	(S)-1-[4-(4-tert-Butyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-2-ylmethyl]-pyrrolidine-2-carboxylic acid	551.51	
759. 	Piperidin-1-yl-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-methanone	546.42	*
760. 	(4-Cyclopentyl-piperazin-1-yl)-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazolin-2-yl]-methanone		*
761. 	4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline-2-carboxylic acid (3-methyl-butyl)-amide	548.43	*
762. 	4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline-2-carboxylic acid (2-methoxy-ethyl)-amide	536.39	*
763. 	4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-quinazoline-2-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide	575.47	*
764. 	{[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carbonyl]-amino}-acetic acid	537.37	*
765. 	3-{[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carbonyl]-amino}-propionic acid	551.40	*

	Compound	Name	MS (M+1)	K_i
766.		4-{[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carbonyl]-amino}-butyric acid	565.42	*
767.		1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carbonyl]-piperidine-4-carboxylic acid	591.46	*
768.		(S)-1-[4-(4-Trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidine-2-carbonyl]-pyrrolidine-2-carboxylic acid	577.44	*
769.		(4-tert-Butyl-phenyl)-[7-(3-chloro-pyridin-2-yl)-2-(1-methyl-piperidin-4-yl)-pyrido[2,3-d]pyrimidin-4-yl]-amine	487.46	*
770.		[7-(3-Chloro-pyridin-2-yl)-2-(1-methyl-piperidin-4-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-isopropyl-phenyl)-amine	473.43	*
771.		[7-(3-Chloro-pyridin-2-yl)-2-(1-methyl-piperidin-4-yl)-pyrido[2,3-d]pyrimidin-4-yl]-(4-trifluoromethyl-phenyl)-amine	499.39	*
772.		(R)-2-[4-(4-Chloro-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-pyrido[2,3-d]pyrimidin-2-yl]-pyrrolidine-1-carboxylic acid methyl ester	529.26	*

Compound		Name	MS (M+1)	K_i
773.		[2-(2,6-Dimethyl-morpholin-4-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine (cis)	562.2	*
774.		[2-(2-Methyl-pyrrolidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		*
775.		[2-{[Bis-(2-methoxy-ethyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	580.3	*
776.		[2-Propylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
777.		[2-[(2-Methyl-butylamino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
778.		[2-[(Cyclopropylmethyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
779.		[2-(Isobutylamino-methyl)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
780.		[2-[(Cyclohexylmethyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		

Compound	Name	MS (M+1)	K_i
781. 	[2-[(2,2-Dimethyl-propylamino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
782. 	[2-[(2-Ethoxy-ethylamino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
783. 	[2-[(2-Isopropoxy-ethylamino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
784. 	[2-{[(1-Ethyl-pyrrolidin-2-ylmethyl)-amino]-methyl}-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
785. 	N,N-Dimethyl-N'-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-2-ylmethyl]-ethane-1,2-diamine		
786. 	[2-Cyclopropylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
787. 	[2-Cyclohexylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
788. 	[2-Cyclobutylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		

Compound		Name	MS (M+1)	K_i
789.		[2-Cyclopentylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
790.		[2-[(4-Methyl-cyclohexylamino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
791.		[2-[(2-Methyl-cyclohexylamino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
792.		[2-(Isopropylamino-methyl)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
793.		[2-(sec-Butylamino-methyl)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
794.		[2-[(1,2-Dimethyl-propylamino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
795.		[2-[(2-Methoxy-1-methyl-ethylamino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
796.		[2-(tert-Butylamino-methyl)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		

Compound		Name	MS (M+1)	K_i
797.		N1,N1-Dimethyl-N2-[4-(4-trifluoromethyl-phenylamino)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-2-ylmethyl]-propane-1,2-diamine		
798.		[2-Pyrrolidin-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
799.		[2-Piperidin-1-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	532.22	*
800.		[2-Morpholin-4-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	534.20	*
801.		[2-(4-Methyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	546.23	
802.		[2-Thiomorpholin-4-ylmethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	550.17	*
803.		[2-Diethylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	520.22	
804.		[2-[(Methyl-propyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	520.22	

	Compound	Name	MS (M+1)	K_i
805.		[2-[(Butyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	534.23	
806.		[2-[(Ethyl-isopropyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
807.		[2-Dipropylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	548.25	
808.		[2-Dimethylaminomethyl-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
809.		[2-[(Isopropyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	520.22	
810.		[2-(2-Methyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	546.23	*
811.		[2-[(Cyclohexyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.25	
812.		[2-(2-Ethyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.24	*

Compound		Name	MS (M+1)	K_i
813.		[2-[(Cyclohexyl-ethyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	574.26	*
814.		[2-(3,5-Dimethyl-piperidin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	560.25	
815.		[2-(2,5-Dihydro-pyrrol-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
816.		[2-(3,6-Dihydro-2H-pyridin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	530.20	*
817.		[2-(4-Methyl-piperazin-1-ylmethyl)-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	547.22	*
818.		[2-[(Diisopropylamino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine		
819.		[2-[(Benzyl-methyl-amino)-methyl]-7-(3-trifluoromethyl-pyridin-2-yl)-[1,8]naphthyridin-4-yl]-(4-trifluoromethyl-phenyl)-amine	568.22	

EXAMPLE 4

VR1-Transfected Cells and Membrane Preparations

This Example illustrates the preparation of VR1-transfected cells and VR1-containing membrane preparations for use in capsaicin binding assays (Example 5).

A cDNA encoding full length human capsaicin receptor (SEQ ID NO:1, 2 or 3 of U.S. Patent No. 6,482,611) was subcloned in the plasmid pBK-CMV (Stratagene, La Jolla, CA) for recombinant expression in mammalian cells.

Human embryonic kidney (HEK293) cells were transfected with the pBK-CMV expression construct encoding the full length human capsaicin receptor using standard methods. The transfected cells were selected for two weeks in media containing G418 (400 μg/ml) to obtain a pool of stably transfected cells. Independent clones were isolated from this pool by limiting dilution to obtain clonal stable cell lines for use in subsequent experiments.

For radioligand binding experiments, cells were seeded in T175 cell culture flasks in media without antibiotics and grown to approximately 90% confluency. The flasks were then washed with PBS and harvested in PBS containing 5 mM EDTA. The cells were pelleted by gentle centrifugation and stored at –80°C until assayed.

Previously frozen cells were disrupted with the aid of a tissue homogenizer in ice-cold HEPES homogenization buffer (5mM KCl 5, 5.8mM NaCl, 0.75mM $CaCl_2$, 2mM $MgCl_2$, 320 mM sucrose, and 10 mM HEPES pH 7.4). Tissue homogenates were first centrifuged for 10 minutes at 1000 x g (4°C) to remove the nuclear fraction and debris, and then the supernatant from the first centrifugation is further centrifuged for 30 minutes at 35,000 x g (4°C) to obtain a partially purified membrane fraction. Membranes were resuspended in the HEPES homogenization buffer prior to the assay. An aliquot of this membrane homogenate was used to determine protein concentration via the Bradford method (BIO-RAD Protein Assay Kit, #500-0001, BIO-RAD, Hercules, CA).

EXAMPLE 5

Capsaicin Receptor Binding Assay

This Example illustrates a representative assay of capsaicin receptor binding that may be used to determine the binding affinity of compounds for the capsaicin (VR1) receptor.

Binding studies with [^{3}H] Resiniferatoxin (RTX) are carried out essentially as described by Szallasi and Blumberg (1992) *J. Pharmacol. Exp. Ter. 262*:883-888. In this protocol, non-specific RTX binding is reduced by adding bovine alpha$_1$ acid glycoprotein (100 μg per tube) after the binding reaction has been terminated.

[^{3}H] RTX (37 Ci/mmol) is synthesized by and obtained from the Chemical Synthesis and Analysis Laboratory, National Cancer Institute-Frederick Cancer Research and

Development Center, Frederick, MD. [^{3}H] RTX may also be obtained from commercial vendors (*e.g.*, Amersham Pharmacia Biotech, Inc.; Piscataway, NJ).

The membrane homogenate of Example 4 is centrifuged as before and resuspended to a protein concentration of 333μg/ml in homogenization buffer. Binding assay mixtures are set up on ice and contain [^{3}H]RTX (specific activity 2200 mCi/ml), 2 μl non-radioactive test compound, 0.25 mg/ml bovine serum albumin (Cohn fraction V), and 5 x 10^4 - 1 x 10^5 VR1-transfected cells. The final volume is adjusted to 500 μl (for competition binding assays) or 1,000 μl (for saturation binding assays) with the ice-cold HEPES homogenization buffer solution (pH 7.4) described above. Non-specific binding is defined as that occurring in the presence of 1 μM non-radioactive RTX (Alexis Corp.; San Diego, CA). For saturation binding, [^{3}H]RTX is added in the concentration range of 7-1,000 pM, using 1 to 2 dilutions. Typically 11 concentration points are collected per saturation binding curve.

Competition binding assays are performed in the presence of 60 pM [^{3}H]RTX and various concentrations of test compound. The binding reactions are initiated by transferring the assay mixtures into a 37°C water bath and are terminated following a 60 minute incubation period by cooling the tubes on ice. Membrane-bound RTX is separated from free, as well as any alpha$_1$-acid glycoprotein-bound RTX, by filtration onto WALLAC glass fiber filters (PERKIN-ELMER, Gaithersburg, MD) which were pre-soaked with 1.0% PEI (polyethyleneimine) for 2 hours prior to use. Filters are allowed to dry overnight then counted in a WALLAC 1205 BETA PLATE counter after addition of WALLAC BETA SCINT scintillation fluid.

Equilibrium binding parameters are determined by fitting the allosteric Hill equation to the measured values with the aid of the computer program FIT P (Biosoft, Ferguson, MO) as described by Szallasi, *et al.* (1993) *J. Pharmacol. Exp. Ther.* 266:678-683. Compounds provided herein generally exhibit K_i values for capsaicin receptor of less than 1 μM, 100 nM, 50 nM, 25 nM, 10 nM, or 1nM in this assay.

EXAMPLE 6

Calcium Mobilization Assay

This Example illustrates representative calcium mobilization assays for use in evaluating test compounds for agonist and antagonist activity.

Cells transfected with expression plasmids (as described in Example 4) and thereby expressing human capsaicin receptor are seeded and grown to 70-90% confluency in

FALCON black-walled, clear-bottomed 96-well plates (#3904, BECTON-DICKINSON, Franklin Lakes, NJ). The culture medium is emptied from the 96 well plates and FLUO-3 AM calcium sensitive dye (Molecular Probes, Eugene, OR) is added to each well (dye solution: 1 mg FLUO-3 AM, 440 µL DMSO and 440 µl 20% pluronic acid in DMSO, diluted 1:250 in Krebs-Ringer HEPES (KRH) buffer (25 mM HEPES, 5 mM KCl, 0.96 mM NaH_2PO_4, 1 mM $MgSO_4$, 2 mM $CaCl_2$, 5 mM glucose, 1 mM probenecid, pH 7.4), 50 µl diluted solution per well). Plates are covered with aluminum foil and incubated at 37°C for 1-2 hours in an environment containing 5% CO_2. After the incubation, the dye is emptied from the plates, and the cells are washed once with KRH buffer, and resuspended in KRH buffer.

DETERMINATION CAPSAICIN EC_{50}

To measure the ability of a test compound to agonize or antagonize a calcium mobilization response in cells expressing capsaicin receptors to capsaicin or other vanilloid agonist, the EC_{50} of the agonist capsaicin is first determined. An additional 20 µl of KRH buffer and 1 µl DMSO is added to each well of cells, prepared as described above. 100 µl capsaicin in KRH buffer is automatically transferred by the FLIPR instrument to each well. Capsaicin-induced calcium mobilization is monitored using either FLUOROSKAN ASCENT (Labsystems; Franklin, MA) or FLIPR (fluorometric imaging plate reader system; Molecular Devices, Sunnyvale, CA) instruments. Data obtained between 30 and 60 seconds after agonist application are used to generate an 8-point concentration response curve, with final capsaicin concentrations of 1 nM to 3 µM. KALEIDAGRAPH software (Synergy Software, Reading, PA) is used to fit the data to the equation:

$$y=a*(1/(1+(b/x)^c))$$

to determine the 50% excitatory concentration (EC_{50}) for the response. In this equation, y is the maximum fluorescence signal, x is the concentration of the agonist or antagonist (in this case, capsaicin), a is the E_{max}, b corresponds to the EC_{50} value and c is the Hill coefficient.

DETERMINATION OF AGONIST ACTIVITY

Test compounds are dissolved in DMSO, diluted in KRH buffer, and immediately added to cells prepared as described above. 100 nM capsaicin (an approximate EC_{90} concentration) is also added to cells in the same 96-well plate as a positive control. The final concentration of test compounds in the assay wells is between 0.1 nM and 5 µM.

The ability of a test compound to act as an agonist of the capsaicin receptor is determined by measuring the fluorescence response of cells expressing capsaicin receptors

elicited by the compound as function of compound concentration. This data is fit as described above to obtain the EC_{50}, which is generally less than 1 micromolar, preferably less than 100 nM, and more preferably less than 10 nM. The extent of efficacy of each test compound is also determined by calculating the response elicited by a concentration of test compound (typically 1 μM) relative to the response elicited by 100 nM capsaicin. This value, called Percent of Signal (POS), is calculated by the following equation:

POS=100*test compound response /100 nM capsaicin response

This analysis provides quantitative assessment of both the potency and efficacy of test compounds as human capsaicin receptor agonists. Agonists of the human capsaicin receptor generally elicit detectable responses at concentrations less than 100 μM, or preferably at concentrations less than 1 μM, or most preferably at concentrations less than 10 nM. Extent of efficacy at human capsaicin receptor is preferably greater than 30 POS, more preferably greater than 80 POS at a concentration of 1 μM. Certain agonists are essentially free of antagonist activity as demonstrated by the absence of detectable antagonist activity in the assay described below at compound concentrations below 4 nM, more preferably at concentrations below 10 μM and most preferably at concentrations less than or equal to 100 μM.

DETERMINATION OF ANTAGONIST ACTIVITY

Test compounds are dissolved in DMSO, diluted in 20 μl KRH buffer so that the final concentration of test compounds in the assay well is between 1 μM and 5 μM, and added to cells prepared as described above. The 96 well plates containing prepared cells and test compounds are incubated in the dark, at room temperature for 0.5 to 6 hours. It is important that the incubation not continue beyond 6 hours. Just prior to determining the fluorescence response, 100 μl capsaicin in KRH buffer at twice the EC_{50} concentration determined as described above is automatically added by the FLIPR instrument to each well of the 96 well plate for a final sample volume of 200 μl and a final capsaicin concentration equal to the EC_{50}. The final concentration of test compounds in the assay wells is between 1 μM and 5 μM. Antagonists of the capsaicin receptor decrease this response by at least about 20%, preferably by at least about 50%, and most preferably by at least 80%, as compared to matched control (*i.e.*, cells treated with capsaicin at twice the EC_{50} concentration in the absence of test compound), at a concentration of 10 micromolar or less, preferably 1 micromolar or less. The concentration of antagonist required to provide a 50% decrease,

relative to the response observed in the presence of capsaicin and without antagonist, is the IC_{50} for the antagonist, and is preferably below 1 micromolar, 100 nanomolar, 10 nanomolar or 1 nanomolar.

Certain preferred VR1 modulators are antagonists that are essentially free of agonist activity as demonstrated by the absence of detectable agonist activity in the assay described above at compound concentrations below 4 nM, more preferably at concentrations below 10 μM and most preferably at concentrations less than or equal to 100 μM.

EXAMPLE 7

Microsomal *in vitro* half-life

This Example illustrates the evaluation of compound half-life values ($t_{1/2}$ values) using a representative liver microsomal half-life assay.

Pooled human liver microsomes are obtained from XenoTech LLC (Kansas City, KS). Such liver microsomes may also be obtained from In Vitro Technologies (Baltimore, MD) or Tissue Transformation Technologies (Edison, NJ). Six test reactions are prepared, each containing 25 μl microsomes, 5 μl of a 100 μM solution of test compound, and 399 μl 0.1 M phosphate buffer (19 mL 0.1 M NaH_2PO_4, 81 mL 0.1 M Na_2HPO_4, adjusted to pH 7.4 with H_3PO_4). A seventh reaction is prepared as a positive control containing 25 μl microsomes, 399 μl 0.1 M phosphate buffer, and 5 μl of a 100 μM solution of a compound with known metabolic properties (*e.g.*, DIAZEPAM or CLOZAPINE). Reactions are preincubated at 39°C for 10 minutes.

CoFactor Mixture is prepared by diluting 16.2 mg NADP and 45.4 mg Glucose-6-phosphate in 4 mL 100 mM $MgCl_2$. Glucose-6-phosphate dehydrogenase solution is prepared by diluting 214.3 μl glucose-6-phosphate dehydrogenase suspension (Roche Molecular Biochemicals; Indianapolis, IN) into 1285.7 μl distilled water. 71 μl Starting Reaction Mixture (3 mL CoFactor Mixture; 1.2 mL Glucose-6-phosphate dehydrogenase solution) is added to 5 of the 6 test reactions and to the positive control. 71 μl 100 mM $MgCl_2$ is added to the sixth test reaction, which is used as a negative control. At each time point (0, 1, 3, 5, and 10 minutes), 75 μl of each reaction mix is pipetted into a well of a 96-well deep-well plate containing 75 μl ice-cold acetonitrile. Samples are vortexed and centrifuged 10 minutes at 3500 rpm (Sorval T 6000D centrifuge, H1000B rotor). 75 μl of supernatant from each reaction is transferred to a well of a 96-well plate containing 150 μl of a 0.5 μM solution of a compound with a known LCMS profile (internal standard) per well. LCMS analysis of each sample is carried out and the amount of unmetabolized test compound is measured as AUC,

compound concentration vs. time is plotted, and the $t_{1/2}$ value of the test compound is extrapolated.

Preferred compounds provided herein exhibit *in vitro* $t_{1/2}$ values of greater than 10 minutes and less than 4 hours, preferably between 30 minutes and 1 hour, in human liver microsomes.

EXAMPLE 8
MDCK Toxicity Assay

This Example illustrates the evaluation of compound toxicity using a Madin Darby canine kidney (MDCK) cell cytotoxicity assay.

1 μL of test compound is added to each well of a clear bottom 96-well plate (PACKARD, Meriden, CT) to give final concentration of compound in the assay of 10 micromolar, 100 micromolar or 200 micromolar. Solvent without test compound is added to control wells.

MDCK cells, ATCC no. CCL-34 (American Type Culture Collection, Manassas, VA), are maintained in sterile conditions following the instructions in the ATCC production information sheet. Confluent MDCK cells are trypsinized, harvested, and diluted to a concentration of 0.1 x 10^6 cells/ml with warm (37°C) medium (VITACELL Minimum Essential Medium Eagle, ATCC catalog # 30-2003). 100 μL of diluted cells is added to each well, except for five standard curve control wells that contain 100 μL of warm medium without cells. The plate is then incubated at 37°C under 95% O_2, 5% CO_2 for 2 hours with constant shaking. After incubation, 50 μL of mammalian cell lysis solution (from the PACKARD (Meriden, CT) ATP-LITE-M Luminescent ATP detection kit) is added per well, the wells are covered with PACKARD TOPSEAL stickers, and plates are shaken at approximately 700 rpm on a suitable shaker for 2 minutes.

Compounds causing toxicity will decrease ATP production, relative to untreated cells. The ATP-LITE-M Luminescent ATP detection kit is generally used according to the manufacturer's instructions to measure ATP production in treated and untreated MDCK cells. PACKARD ATP LITE-M reagents are allowed to equilibrate to room temperature. Once equilibrated, the lyophilized substrate solution is reconstituted in 5.5 mL of substrate buffer solution (from kit). Lyophilized ATP standard solution is reconstituted in deionized water to give a 10 mM stock. For the five control wells, 10 μL of serially diluted PACKARD standard is added to each of the standard curve control wells to yield a final concentration in each subsequent well of 200 nM, 100 nM, 50 nM, 25 nM and 12.5 nM. PACKARD substrate

solution (50 μL) is added to all wells, which are then covered, and the plates are shaken at approximately 700 rpm on a suitable shaker for 2 minutes. A white PACKARD sticker is attached to the bottom of each plate and samples are dark adapted by wrapping plates in foil and placing in the dark for 10 minutes. Luminescence is then measured at 22°C using a luminescence counter (*e.g.,* PACKARD TOPCOUNT Microplate Scintillation and Luminescence Counter or TECAN SPECTRAFLUOR PLUS), and ATP levels calculated from the standard curve. ATP levels in cells treated with test compound(s) are compared to the levels determined for untreated cells. Cells treated with 10 μM of a preferred test compound exhibit ATP levels that are at least 80%, preferably at least 90%, of the untreated cells. When a 100 μM concentration of the test compound is used, cells treated with preferred test compounds exhibit ATP levels that are at least 50%, preferably at least 80%, of the ATP levels detected in untreated cells.

EXAMPLE 9

Dorsal Root Ganglion Cell Assay

This Example illustrates a representative dorsal root ganglian cell assay for evaluating VR1 antagonist or agonist activity of a compound.

DRG are dissected from neonatal rats, dissociated and cultured using standard methods (Aguayo and White (1992) *Brain Research 570*:61-67). After 48 hour incubation, cells are washed once and incubated for 30-60 minutes with the calcium sensitive dye Fluo 4 AM (2.5-10 ug/ml; TefLabs, Austin, TX). Cells are then washed once. Addition of capsaicin to the cells results in a VR1-dependent increase in intracellular calcium levels which is monitored by a change in Fluo-4 fluorescence with a fluorometer. Data are collected for 60-180 seconds to determine the maximum fluorescent signal.

For antagonist assays, various concentrations of compound are added to the cells. Fluorescent signal is then plotted as a function of compound concentration to identify the concentration required to achieve a 50% inhibition of the capsaicin-activated response, or IC_{50}. Antagonists of the capsaicin receptor preferably have an IC_{50} below 1 micromolar, 100 nanomolar, 10 nanomolar or 1 nanomolar.

For agonist assays, various concentrations of compound are added to the cells without the addition of capsaicin. Compounds that are capsaicin receptor agonists result in a VR1-dependent increase in intracellular calcium levels which is monitored by a change in Fluo-4 fluorescence with a fluorometer. The EC_{50}, or concentration required to achieve 50% of the

maximum signal for a capsaicin-activated response, is preferably below 1 micromolar, below 100 nanomolar or below 10 nanomolar.

EXAMPLE 10

Animal Models for Determining Pain Relief

This Example illustrates representative methods for assessing the degree of pain relief provided by a compound.

A. Pain Relief Testing

The following methods may be used to assess pain relief.

MECHANICAL ALLODYNIA

Mechanical allodynia (an abnormal response to an innocuous stimulus) is assessed essentially as described by Chaplan *et al.* (1994) *J. Neurosci. Methods* 53:55-63 and Tal and Eliav (1998) *Pain* 64(3):511-518. A series of von Frey filaments of varying rigidity (typically 8-14 filaments in a series) are applied to the plantar surface of the hind paw with just enough force to bend the filament. The filaments are held in this position for no more than three seconds or until a positive allodynic response is displayed by the rat. A positive allodynic response consists of lifting the affected paw followed immediately by licking or shaking of the paw. The order and frequency with which the individual filaments are applied are determined by using Dixon up-down method. Testing is initiated with the middle hair of the series with subsequent filaments being applied in consecutive fashion, ascending or descending, depending on whether a negative or positive response, respectively, is obtained with the initial filament.

Compounds are effective in reversing or preventing mechanical allodynia-like symptoms if rats treated with such compounds require stimulation with a Von Frey filament of higher rigidity strength to provoke a positive allodynic response as compared to control untreated or vehicle treated rats. Alternatively, or in addition, testing of an animal in chronic pain may be done before and after compound administration. In such an assay, an effective compound results in an increase in the rigidity of the filament needed to induce a response after treatment, as compared to the filament that induces a response before treatment or in an animal that is also in chronic pain but is left untreated or is treated with vehicle. Test compounds are administered before or after onset of pain. When a test compound is administered after pain onset, testing is performed 10 minutes to three hours after administration.

MECHANICAL HYPERALGESIA

Mechanical hyperalgesia (an exaggerated response to painful stimulus) is tested essentially as described by Koch et al. (1996) *Analgesia* 2(3):157-164. Rats are placed in individual compartments of a cage with a warmed, perforated metal floor. Hind paw withdrawal duration (*i.e.,* the amount of time for which the animal holds its paw up before placing it back on the floor) is measured after a mild pinprick to the plantar surface of either hind paw.

Compounds produce a reduction in mechanical hyperalgesia if there is a statistically significant decrease in the duration of hindpaw withdrawal. Test compound may be administered before or after onset of pain. For compounds administered after pain onset, testing is performed 10 minutes to three hours after administration.

THERMAL HYPERALGESIA

Thermal hyperalgesia (an exaggerated response to noxious thermal stimulus) is measured essentially as described by Hargreaves *et al.* (1988) *Pain.* 32(1):77-88. Briefly, a constant radiant heat source is applied the animals' plantar surface of either hind paw. The time to withdrawal *(i.e.,* the amount of time that heat is applied before the animal moves its paw), otherwise described as thermal threshold or latency, determines the animal's hind paw sensitivity to heat.

Compounds produce a reduction in thermal hyperalgesia if there is a statistically significant increase in the time to hindpaw withdrawal (*i.e.,* the thermal threshold to response or latency is increased). Test compound may be administered before or after onset of pain. For compounds administered after pain onset, testing is performed 10 minutes to three hours after administration.

B. Pain Models

Pain may be induced using any of the following methods, to allow testing of analgesic efficacy of a compound. In general, compounds provided herein result in a statistically significant reduction in pain as determined by at least one of the previously described testing methods, using male SD rats and at least one of the following models.

ACUTE INFLAMMATORY PAIN MODEL

Acute inflammatory pain is induced using the carrageenan model essentially as described by Field *et al.* (1997) *Br. J. Pharmacol.* 121(8):1513-1522. 100-200 μl of 1-2% carrageenan solution is injected into the rats' hind paw. Three to four hours following

injection, the animals' sensitivity to thermal and mechanical stimuli is tested using the methods described above. A test compound (0.01 to 50 mg/kg) is administered to the animal, prior to testing, or prior to injection of carrageenan. The compound can be administered orally or through any parenteral route, or topically on the paw. Compounds that relieve pain in this model result in a statistically significant reduction in mechanical allodynia and/or thermal hyperalgesia.

CHRONIC INFLAMMATORY PAIN MODEL

Chronic inflammatory pain is induced using one of the following protocols:

1. Essentially as described by Bertorelli *et al.* (1999) *Br. J. Pharmacol.* 128(6):1252-1258, and Stein *et al.* (1998) *Pharmacol. Biochem. Behav.* 31(2):455-51, 200 µl Complete Freund's Adjuvant (0.1 mg heat killed and dried *M. Tuberculosis*) is injected to the rats' hind paw: 100 µl into the dorsal surface and 100 µl into the plantar surface.
2. Essentially as described by Abbadie *et al.* (1994) *J Neurosci.* 14(10):5865-5871 rats are injected with 150 µl of CFA (1.5 mg) in the tibio-tarsal joint.

Prior to injection with CFA in either protocol, an individual baseline sensitivity to mechanical and thermal stimulation of the animals' hind paws is obtained for each experimental animal.

Following injection of CFA, rats are tested for thermal hyperalgesia, mechanical allodynia and mechanical hyperalgesia as described above. To verify the development of symptoms, rats are tested on days 5, 6, and 7 following CFA injection. On day 7, animals are treated with a test compound, morphine or vehicle. An oral dose of morphine of 1-5 mg/kg is suitable as positive control. Typically, a dose of 0.01-50 mg/kg of test compound is used. Compounds can be administered as a single bolus prior to testing or once or twice or three times daily, for several days prior to testing. Drugs are administered orally or through any parenteral route, or applied topically to the animal.

Results are expressed as Percent Maximum Potential Efficacy (MPE). 0% MPE is defined as analgesic effect of vehicle, 100% MPE is defined as an animal's return to pre-CFA baseline sensitivity. Compounds that relieve pain in this model result in a MPE of at least 30%.

CHRONIC NEUROPATHIC PAIN MODEL

Chronic neuropathic pain is induced using the chronic constriction injury (CCI) to the rat's sciatic nerve essentially as described by Bennett and Xie (1988) *Pain* 33:87-107. Rats

are anesthetized (*e.g.* with an intraperitoneal dose of 50-65 mg/kg pentobarbital with additional doses administered as needed). The lateral aspect of each hind limb is shaved and disinfected. Using aseptic technique, an incision is made on the lateral aspect of the hind limb at the mid thigh level. The biceps femoris is bluntly dissected and the sciatic nerve is exposed. On one hind limb of each animal, four loosely tied ligatures are made around the sciatic nerve approximately 1-2 mm apart. On the other side the sciatic nerve is not ligated and is not manipulated. The muscle is closed with continuous pattern and the skin is closed with wound clips or sutures. Rats are assessed for mechanical allodynia, mechanical hyperalgesia and thermal hyperalgesia as described above.

Compounds that relieve pain in this model result in a statistically significant reduction in mechanical allodynia, mechanical hyperalgesia and/or thermal hyperalgesia when administered (0.01-50 mg/kg, orally, parenterally or topically) immediately prior to testing as a single bolus, or for several days: once or twice or three times daily prior to testing.

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

What is claimed is:

1. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

X, V, W, Y and Z are each independently N or CR_1, with the proviso that at least one of V and X is N;

R_1 is independently selected at each occurrence from hydrogen, halogen, hydroxy, cyano, amino, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkoxy, haloC_1-C_6alkoxy, C_1-C_4alkoxycarbonyl and mono- and di-(C_1-C_6alkyl)amino;

R is -O-R_7 or $-N\begin{matrix}R_4\\R_3\end{matrix}$;

R_7 is:

(i) hydrogen;

(ii) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, C_2-C_8alkanoyl, C_3-C_8alkanone, C_2-C_8alkyl ether, C_6-C_{10}arylC_0-C_8alkyl or (5- to 10-membered heterocycle)C_0-C_8alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from R_b; or

(iii) taken together with an R_5 or R_6 to form a 4- to 10-membered heterocycle that is substituted with from 0 to 4 substituents independently chosen from R_b;

R_3 and R_4 are:

(i) each independently selected from:

(a) hydrogen;

(b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, C_3-C_8alkanone, C_2-C_8alkanoyl, C_2-C_8alkyl ether, C_6-C_{10}arylC_0-C_8alkyl, (5- to 10-membered heterocycle)C_0-C_8alkyl and -(SO_2)C_1-C_8alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from R_b; and

(c) groups that are taken together with an R_5 or R_6 to form a 4- to 10-membered heterocycle that is substituted with from 0 to 4 substituents independently chosen from R_b; or

(ii) taken together to form a 4- to 10-membered heterocycle that is substituted with from 0 to 4 substituents independently chosen from R_b;

R_5 and R_6 are, independently at each occurrence:

(i) each independently hydrogen, C_1-C_8alkyl substituted with from 0 to 2 substituents independently chosen from R_b, or taken together with R_3, R_4 or R_7 to form a 4- to 10-membered heterocyclic group that is substituted with from 0 to 4 substituents independently chosen from R_b;

(ii) taken together to form a keto group; or

(iii) taken together to form a 3- to 7-membered carbocyclic or heterocyclic ring that is substituted with from 0 to 4 substituents independently chosen from R_b;

n is 1, 2 or 3;

Ar_1 and Ar_2 are independently selected from 6- to 10-membered aryl groups and 5- to 10-membered heterocycles, each of which is substituted with from 0 to 3 substituents independently selected from groups of the formula LR_a;

L is independently selected at each occurrence from a bond, O, $S(O)_m$, C(=O), OC(=O), C(=O)O, O-C(=O)O, $N(R_x)$, $C(=O)N(R_x)$, $N(R_x)C(=O)$, $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl;

R_a is independently selected at each occurrence from: (i) hydrogen, halogen, cyano and nitro; and (ii) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, C_2-C_8alkyl ether, (4- to 10-membered heterocycle)C_0-C_8alkyl and mono- and di-(C_1-C_8alkyl)amino, each of which is substituted with from 0 to 4 substituents independently selected from hydroxy, halogen, amino, cyano, nitro, oxo, –COOH, C_1-C_4alkyl, C_1-C_4alkoxy, haloC_1-C_4alkyl, haloC_1-C_4alkoxy, hydroxyC_1-C_4alkyl, and mono- and di-(C_1-C_6alkyl)amino; and

R_b is independently chosen at each occurrence from:

(i) hydroxy, halogen, amino, aminocarbonyl, cyano, nitro, oxo and –COOH; and

(ii) C_1-C_8alkyl, C_1-C_8haloalkyl, C_1-C_8alkoxy, C_1-C_8haloalkoxy, C_1-C_8alkanoyl, C_2-C_8alkoxycarbonyl, C_2-C_8alkanoyloxy, C_1-C_8alkylthio, C_2-C_8alkyl ether, phenylC_0-C_8alkyl, phenylC_0-C_8alkoxy, mono- and di-(C_1-C_6alkyl)aminoC_0-C_6alkyl, -(SO_2)C_1-C_8alkyl and (4- to 7-membered heterocycle)(C_0-C_8alkyl); each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy, hydroxyC_1-C_4alkyl, haloC_1-C_4alkyl, and mono- and di-(C_1-C_4alkyl)amino.

2. A compound or form thereof according to claim 1, wherein V and X are N.

3. A compound or form thereof according to claim 1, wherein V is N and X is CH.

4. A compound or form thereof according to claim 1, wherein X is N and V is CH.

5. A compound or form thereof according to any one of claims 1-4, wherein Y is N and W and Z are each CH.

6. A compound or form thereof according to any one of claims 1-4, wherein Z is N and W and Y are each CH.

7. A compound or form thereof according to any one of claims 1-4, wherein W, Y and Z are each CH.

8. A compound or form thereof according to claim 1, wherein Ar_1 and Ar_2 are independently selected from phenyl and 6-membered aromatic heterocycles, each of which is substituted with 0, 1 or 2 substituents independently selected from groups of the formula LR_a.

9. A compound or form thereof according to claim 8, wherein:

Ar_1 is phenyl or pyridyl, each of which is substituted with from 0 to 2 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkoxy and haloC_1-C_6alkoxy; and

Ar_2 is phenyl or pyridyl, each of which is substituted with from 0 to 2 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkyl, haloC_1-C_6alkyl, cyanoC_1-C_6alkyl, C_1-C_6alkoxy, haloC_1-C_6alkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoyl, $-(SO_2)R_d$, - $N(R_x)S(O)_mR_d$, and $-N[S(O_m)R_x]S(O)_mR_d$; wherein m is 1 or 2, R_x is hydrogen or C_1-C_6alkyl, and R_d is C_1-C_6alkyl, haloC_1-C_6alkyl, amino, mono- or di-(C_1-C_6alkyl)amino or a 5- to 10-membered, N-linked heterocyclic group, each of which R_d is substituted with from 0 to 2 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, mono- and di-(C_1-C_6alkyl)amino, C_1-C_4alkyl, haloC_1-C_4alkyl, C_1-C_4alkoxy and haloC_1-C_4alkoxy.

10. A compound or form thereof according to claim 9, wherein:

Ar_1 is pyridyl, unsubstituted or substituted with halogen, cyano, C_1-C_4alkyl or haloC_1-C_4alkyl; and

Ar_2 is phenyl or pyridyl, substituted with from 0 to 2 substituents independently chosen from halogen, C_1-C_4alkyl, cyanoC_1-C_4alkyl, haloC_1-C_4alkyl, C_2-C_6alkyl ether and groups of the formula $-(SO_2)R_d$, wherein R_d is C_1-C_4alkyl or haloC_1-C_4alkyl.

11. A compound or form thereof according to claim 9, wherein:

Ar_1 is phenyl, unsubstituted or substituted with halogen, cyano, C_1-C_4alkyl or haloC_1-C_4alkyl; and

Ar_2 is phenyl or pyridyl, substituted with from 0 to 2 substituents independently chosen from halogen, C_1-C_4alkyl, cyanoC_1-C_4alkyl, haloC_1-C_4alkyl, C_2-C_6alkyl ether and groups of the formula $-(SO_2)R_d$, wherein R_d is C_1-C_4alkyl or haloC_1-C_4alkyl.

12. A compound or form thereof according to claim 9, wherein:

Ar_1 is pyridin-2-yl, 3-methyl-pyridin-2-yl, 3-trifluoromethyl-pyridin-2-yl or 3-halo-pyridin-2-yl; and

Ar_2 is phenyl, pyridin-2-yl or pyridin-3-yl, each of which is substituted at the *para*-position with halogen, cyano, methyl, ethyl, propyl, isopropyl, *t*-butyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2,2,2-trifluoro-1-methyl-ethyl, methanesulfonyl, ethanesulfonyl, propanesulfonyl, propane-2-sulfonyl, trifluoromethanesulfonyl or 2,2,2-trifluoroethanesulfonyl.

13. A compound or form thereof according to claim 9, wherein:

Ar_1 is phenyl, 2-methyl-phenyl, 2-trifluoromethyl-phenyl or 2-halo-phenyl; and

Ar_2 is phenyl, pyridin-2-yl or pyridin-3-yl, each of which is substituted at the *para*-position with halogen, cyano, methyl, ethyl, propyl, isopropyl, *t*-butyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2,2,2-trifluoro-1-methyl-ethyl, methanesulfonyl, ethanesulfonyl, propanesulfonyl, propane-2-sulfonyl, trifluoromethanesulfonyl or 2,2,2-trifluoroethanesulfonyl.

14. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

V, X, W, Y and Z are each independently N or CR_1, with the proviso that at least one of V and X is N;

R_1 is independently selected at each occurrence from hydrogen, halogen, hydroxy, cyano, amino, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkoxy, haloC_1-C_6alkoxy, C_1-C_4alkoxycarbonyl and mono- and di-(C_1-C_6alkyl)amino;

R_7 is:

(i) hydrogen;

(ii) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, C_2-C_8alkanoyl, C_3-C_8alkanone, C_2-C_8alkyl ether, C_6-C_{10}arylC_0-C_8alkyl or (5- to 10-membered heterocycle)C_0-C_8alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from R_b; or

(iii) taken together with an R_5 or R_6 to form a 4- to 10-membered heterocycle that is substituted with from 0 to 4 substituents independently chosen from R_b;

R_5 and R_6 are, independently at each occurrence:

(i) each independently hydrogen, C_1-C_8alkyl substituted with from 0 to 2 substituents independently chosen from R_b, or taken together with R_7 to form a 4- to 10-membered heterocyclic group that is substituted with from 0 to 4 substituents independently chosen from R_b;

(ii) taken together to form a keto group; or

(iii) taken together to form a 3- to 7-membered carbocyclic or heterocyclic ring that is substituted with from 0 to 4 substituents independently chosen from R_b;

n is 1, 2 or 3;

Ar_1 and Ar_2 are independently selected from 6- to 10-membered aryl groups and 5- to 10-membered heterocycles, each of which is substituted with from 0 to 3 substituents independently selected from groups of the formula LR_a;

L is independently selected at each occurrence from a bond, O, $S(O)_m$, C(=O), OC(=O), C(=O)O, O-C(=O)O, $N(R_x)$, $C(=O)N(R_x)$, $N(R_x)C(=O)$, $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl;

R_a is independently selected at each occurrence from: (i) hydrogen, halogen, cyano and nitro; and (ii) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, C_2-C_8alkyl ether, (4- to 10-membered heterocycle)C_0-C_8alkyl and mono- and di-(C_1-C_8alkyl)amino, each of which is substituted with from 0 to 4 substituents independently selected from hydroxy, halogen, amino, cyano, nitro, oxo, –COOH, C_1-C_4alkyl, C_1-C_4alkoxy, haloC_1-C_4alkyl, haloC_1-C_4alkoxy, hydroxyC_1-C_4alkyl, and mono- and di-(C_1-C_6alkyl)amino; and

R_b is independently chosen at each occurrence from:

(i) hydroxy, halogen, amino, aminocarbonyl, cyano, nitro, oxo and –COOH; and

(ii) C_1-C_8alkyl, C_1-C_8haloalkyl, C_1-C_8alkoxy, C_1-C_8haloalkoxy, C_1-C_8alkanoyl, C_2-C_8alkoxycarbonyl, C_2-C_8alkanoyloxy, C_1-C_8alkylthio, C_2-C_8alkyl ether, phenylC_0-C_8alkyl, phenylC_0-C_8alkoxy, mono- and di-(C_1-C_6alkyl)aminoC_0-C_6alkyl, -(SO_2)C_1-C_8alkyl and (4- to 7-membered heterocycle)(C_0-C_8alkyl); each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy, hydroxyC_1-C_4alkyl, haloC_1-C_4alkyl, and mono- and di-(C_1-C_4alkyl)amino.

15. A compound or form thereof according to claim 14, wherein V and X are N.

16. A compound or form thereof according to claim 14, wherein V is N and X is CH.

17. A compound or form thereof according to claim 14, wherein X is N and V is CH.

18. A compound or form thereof according to any one of claims 14-17, wherein Y is N and W and Z are each CH.

19. A compound or form thereof according to any one of claims 14-17, wherein Z is N and W and Y are each CH.

20. A compound or form thereof according to any one of claims 14-17, wherein W, Y and Z are each CH.

21. A compound or form thereof according to claim 14, wherein Ar_1 and Ar_2 are independently selected from phenyl and 6-membered aromatic heterocycles, each of which is substituted with 0, 1 or 2 substituents independently selected from groups of the formula LR_a.

22. A compound or form thereof according to claim 21, wherein:

Ar_1 is phenyl or pyridyl, each of which is substituted with from 0 to 2 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkoxy and haloC_1-C_6alkoxy; and

Ar_2 is phenyl or pyridyl, each of which is substituted with from 0 to 2 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkyl, haloC_1-C_6alkyl, cyanoC_1-C_6alkyl, C_1-C_6alkoxy, haloC_1-C_6alkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoyl, $-(SO_2)R_d$, $N(R_x)S(O)_mR_d$, and $-N[S(O_m)R_x]S(O)_mR_d$; wherein m is 1 or 2, R_x is hydrogen or C_1-C_6alkyl, and R_d is C_1-C_6alkyl, haloC_1-C_6alkyl, amino, mono- or di-(C_1-C_6alkyl)amino or a 5- to 10-membered, N-linked heterocyclic group, each of which R_d is substituted with from 0 to 2 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, mono- and di-(C_1-C_6alkyl)amino, C_1-C_4alkyl, haloC_1-C_4alkyl, C_1-C_4alkoxy and haloC_1-C_4alkoxy.

23. A compound or form thereof according to claim 22, wherein:

Ar_1 is pyridyl, unsubstituted or substituted with halogen, cyano, C_1-C_4alkyl or haloC_1-C_4alkyl; and

Ar_2 is phenyl or pyridyl, substituted with from 0 to 2 substituents independently chosen from halogen, C_1-C_4alkyl, cyanoC_1-C_6alkyl, haloC_1-C_4alkyl, C_2-C_6alkyl ether and groups of the formula $-(SO_2)R_d$, wherein R_d is C_1-C_4alkyl or haloC_1-C_4alkyl.

24. A compound or form thereof according to claim 22, wherein:

Ar_1 is phenyl, unsubstituted or substituted with halogen, cyano, C_1-C_4alkyl or haloC_1-C_4alkyl; and

Ar_2 is phenyl or pyridyl, substituted with from 0 to 2 substituents independently chosen from halogen, C_1-C_4alkyl, cyanoC_1-C_6alkyl, haloC_1-C_4alkyl, C_2-C_6alkyl ether and groups of the formula $-(SO_2)R_d$, wherein R_d is C_1-C_4alkyl or haloC_1-C_4alkyl.

25. A compound or form thereof according to claim 22, wherein:

Ar_1 is pyridin-2-yl, 3-methyl-pyridin-2-yl, 3-trifluoromethyl-pyridin-2-yl or 3-halo-pyridin-2-yl; and

Ar_2 is phenyl, pyridin-2-yl or pyridin-3-yl, each of which is substituted at the *para*-position with halogen, cyano, methyl, ethyl, propyl, isopropyl, *t*-butyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2,2,2-trifluoro-1-methyl-ethyl, methanesulfonyl, ethanesulfonyl,

propanesulfonyl, propane-2-sulfonyl, trifluoromethanesulfonyl or 2,2,2-trifluoroethanesulfonyl.

26. A compound or form thereof according to claim 22, wherein:

Ar_1 is phenyl, 3-methyl-phenyl, 3-trifluoromethyl-phenyl or 3-halo-phenyl; and

Ar_2 is phenyl, pyridin-2-yl or pyridin-3-yl, each of which is substituted at the *para*-position with halogen, cyano, methyl, ethyl, propyl, isopropyl, *t*-butyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2,2,2-trifluoro-1-methyl-ethyl, methanesulfonyl, ethanesulfonyl, propanesulfonyl, propane-2-sulfonyl, trifluoromethanesulfonyl or 2,2,2-trifluoroethanesulfonyl.

27. A compound or form thereof according to claim 14, having the formula:



wherein A, B, C, X, Y and Z are each independently CH or N, and wherein each "$(LR_a)_{1-3}$" represents from 1 to 3 substituents independently chosen from groups of the formula LR_a.

28. A compound or form thereof according to claim 27, wherein X is CH.

29. A compound or form thereof according to claim 27, wherein X is N.

30. A compound or form thereof according to claim 14 or claim 27, wherein R_7 is:

(i) hydrogen; or

(ii) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, C_2-C_8alkanoyl, C_3-C_8alkanone, C_2-C_8alkyl ether, C_6-C_{10}arylC_0-C_8alkyl or (5- to 10-membered heterocycle)C_0-C_8alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from R_b.

31. A compound or form thereof according to claim 30, wherein R_7 is:

(i) hydrogen; or

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkanoyl, C_2-C_6alkyl ether, mono- or di-(C_1-C_6alkyl)aminoC_1-C_6alkyl, phenylC_0-C_4alkyl, (5- to 6-membered heteroaryl)C_0-C_4alkyl or (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is

substituted with from 0 to 4 substituents independently chosen from hydroxy, halogen, amino, C_1-C_4alkyl, haloC_1-C_4alkyl, C_1-C_4alkoxy and haloC_1-C_4alkoxy.

32. A compound or form thereof according to claim 30, wherein R_7 is C_1-C_4alkyl, C_2-C_4alkyl ether, mono- or di-(C_1-C_4alkyl)aminoC_1-C_6alkyl, a 6-membered heterocycle or benzyl, each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen and C_1-C_4alkyl.

33. A compound or form thereof according to claim 14 or claim 27, wherein each R_5 and R_6 is independently selected from hydrogen and C_1-C_4alkyl.

34. A compound or form thereof according to claim 33, wherein each R_5 and R_6 is hydrogen.

35. A compound or form thereof according to claim 14 or claim 27, wherein one R_5 and one R_6 attached to the same carbon atom are taken together to form a keto group.

36. A compound or form thereof according to claim 14 or claim 27, wherein n is 1.

37. A compound or form thereof according to claim 14, having the formula:



wherein:

X, Y and Z are independently CH or N;

Ar_1 is phenyl or pyridyl, unsubstituted or substituted with halogen, cyano, C_1-C_4alkyl or haloC_1-C_4alkyl;

Ar_2 is phenyl or pyridyl, unsubstituted or substituted with C_1-C_4alkyl, cyanoC_1-C_4alkyl, haloC_1-C_4alkyl, C_2-C_6alkyl ether or a group of the formula -(SO_2)R_d, wherein R_d is C_1-C_4alkyl or haloC_1-C_4alkyl;

R_5 and R_6 are independently selected from hydrogen and C_1-C_4alkyl; and

R_7 is (a) hydrogen; or (b) C_1-C_6alkyl, C_2-C_6alkenyl or phenylC_0-C_4alkyl, each of which is substituted with 0, 1 or 2 substituents independently selected from hydroxy, halogen, C_1-C_4alkyl and haloC_1-C_4alkyl.

38. A compound or form thereof according to claim 27, having the formula:



wherein:

A, B, C, Y and Z are each independently CH or N;

R_7 is (a) hydrogen; or (b) C_1-C_6alkyl, C_2-C_6alkenyl or phenylC_0-C_4alkyl, each of which is substituted with 0, 1 or 2 substituents independently chosen from hydroxy, halogen, C_1-C_4alkyl and haloC_1-C_4alkyl; and

each R_6 is independently hydrogen or methyl.

39. A compound or form thereof according to claim 27, having the formula:



wherein:

A, B, C, Y and Z are each independently CH or N;

R_7 is (a) hydrogen; or (b) C_1-C_6alkyl, C_2-C_6alkenyl or phenylC_0-C_4alkyl, each of which is substituted with 0, 1 or 2 substituents independently chosen from hydroxy, halogen, C_1-C_4alkyl and haloC_1-C_4alkyl; and

each R_6 is independently hydrogen or methyl.

40. A compound or form thereof according to claim 14, wherein the compound is selected from compounds listed in Table II.

41. A compound of the formula:



or a pharmaceutically acceptable form thereof, wherein:

V, X, W, Y and Z are each independently N or CR_1, with the proviso that at least one of V and X is N;

R_1 is independently selected at each occurrence from hydrogen, halogen, hydroxy, cyano, amino, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkoxy, haloC_1-C_6alkoxy, C_1-C_4alkoxycarbonyl and mono- and di-(C_1-C_6alkyl)amino;

R_3 and R_4 are:

(i) each independently selected from:

(a) hydrogen;

(b) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, C_3-C_8alkanone, C_2-C_8alkanoyl, C_2-C_8alkyl ether, (C_6-C_{10}aryl)C_0-C_8alkyl, (5- to 10-membered heterocycle)C_0-C_8alkyl and -(SO_2)C_1-C_8alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from R_b; and

(c) groups that are taken together with an R_5 or R_6 to form a 4- to 10-membered heterocycle that is substituted with from 0 to 4 substituents independently chosen from R_b; or

(ii) taken together to form a 4- to 10-membered heterocycle that is substituted with from 0 to 4 substituents independently chosen from R_b;

R_5 and R_6 are, independently at each occurrence:

(i) each independently hydrogen, C_1-C_8alkyl substituted with from 0 to 2 substituents independently chosen from R_b, or taken together with R_3 or R_4 to form a 4- to 10-membered heterocyclic group that is substituted with from 0 to 4 substituents independently chosen from R_b;

(ii) taken together to form a keto group; or

(iii) taken together to form a 3- to 7-membered carbocyclic or heterocyclic ring that is substituted with from 0 to 4 substituents independently chosen from R_b;

n is 1, 2 or 3;

Ar_1 and Ar_2 are independently selected from 6- to 10-membered aryl groups and 5- to 10-membered heterocycles, each of which is substituted with from 0 to 3 substituents independently selected from groups of the formula LR_a;

L is independently selected at each occurrence from a bond, O, $S(O)_m$, C(=O), OC(=O), C(=O)O, O-C(=O)O, $N(R_x)$, C(=O)$N(R_x)$, $N(R_x)$C(=O), $N(R_x)S(O)_m$, $S(O)_mN(R_x)$ and $N[S(O)_mR_x]S(O)_m$; wherein m is independently selected at each occurrence from 0, 1 and 2; and R_x is independently selected at each occurrence from hydrogen and C_1-C_8alkyl;

R_a is independently selected at each occurrence from: (i) hydrogen, halogen, cyano and nitro; and (ii) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, C_2-C_8alkyl ether, (4- to 10-membered heterocycle)C_0-C_8alkyl and mono- and di-(C_1-C_8alkyl)amino, each of which is substituted with from 0 to 4 substituents independently selected from hydroxy, halogen, amino, cyano, nitro, oxo, –COOH, C_1-C_4alkyl, C_1-C_4alkoxy, haloC_1-C_4alkyl, haloC_1-C_4alkoxy, hydroxyC_1-C_4alkyl, and mono- and di-(C_1-C_6alkyl)amino; and

R_b is independently chosen at each occurrence from:

(i) hydroxy, halogen, amino, aminocarbonyl, cyano, nitro, oxo and –COOH; and

(ii) C_1-C_8alkyl, C_1-C_8haloalkyl, C_1-C_8alkoxy, C_1-C_8haloalkoxy, C_1-C_8alkanoyl, C_2-C_8alkoxycarbonyl, C_2-C_8alkanoyloxy, C_1-C_8alkylthio, C_2-C_8alkyl ether, phenylC_0-C_8alkyl, phenylC_0-C_8alkoxy, mono- and di-(C_1-C_6alkyl)aminoC_0-C_6alkyl, -(SO_2)C_1-C_8alkyl and (4- to 7-membered heterocycle)(C_0-C_8alkyl); each of which is substituted with from 0 to 3 substituents independently chosen from hydroxy, halogen, amino, cyano, C_1-C_4alkyl, C_1-C_4alkoxy, hydroxyC_1-C_4alkyl, haloC_1-C_4alkyl, and mono- and di-(C_1-C_4alkyl)amino.

42. A compound or form thereof according to claim 41, wherein V and X are N.

43. A compound or form thereof according to claim 41, wherein V is N and X is CH.

44. A compound or form thereof according to claim 41, wherein X is N and V is CH

45. A compound or form thereof according to any one of claims 41-44, wherein Y is N and W and Z are each CH.

46. A compound or form thereof according to any one of claims 41-44, wherein Z is N and W and Y are each CH.

47. A compound or form thereof according to any one of claims 41-44, wherein W, Y and Z are each CH.

48. A compound or form thereof according to claim 41, wherein Ar_1 and Ar_2 are independently selected from phenyl and 6-membered aromatic heterocycles, each of which is substituted with 0, 1 or 2 substituents.

49. A compound or form thereof according to claim 48, wherein:

Ar_1 is phenyl or pyridyl, each of which is substituted with from 0 to 2 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkoxy and haloC_1-C_6alkoxy; and

Ar_2 is phenyl or pyridyl, each of which is substituted with from 0 to 2 substituents independently selected from halogen, hydroxy, cyano, amino, nitro, mono- and di-(C_1-C_6alkyl)amino, C_1-C_6alkyl, haloC_1-C_6alkyl, cyanoC_1-C_6alkyl, C_1-C_6alkoxy, haloC_1-C_6alkoxy, C_2-C_6alkyl ether, C_1-C_6alkanoyl, $-(SO_2)R_d$, - $N(R_x)S(O)_mR_d$, and $-N[S(O_m)R_x]S(O)_mR_d$; wherein m is 1 or 2, R_x is hydrogen or C_1-C_6alkyl, and R_d is C_1-C_6alkyl, haloC_1-C_6alkyl, amino, mono- or di-(C_1-C_6alkyl)amino or a 5- to 10-membered, N-linked heterocyclic group, each of which R_d is substituted with from 0 to 2 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, mono- and di-(C_1-C_6alkyl)amino, C_1-C_4alkyl, haloC_1-C_4alkyl, C_1-C_4alkoxy and haloC_1-C_4alkoxy.

50. A compound or form thereof according to claim 49, wherein:

Ar_1 is pyridyl, unsubstituted or substituted with halogen, cyano, C_1-C_4alkyl or haloC_1-C_4alkyl; and

Ar_2 is phenyl or pyridyl, substituted with from 0 to 2 substituents independently chosen from halogen, C_1-C_4alkyl, cyanoC_1-C_4alkyl haloC_1-C_4alkyl, C_2-C_6alkyl ether and groups of the formula $-(SO_2)R_d$, wherein R_d is C_1-C_4alkyl or haloC_1-C_4alkyl.

51. A compound or form thereof according to claim 49, wherein:

Ar_1 is phenyl, unsubstituted or substituted with halogen, cyano, C_1-C_4alkyl or haloC_1-C_4alkyl; and

Ar_2 is phenyl or pyridyl, substituted with from 0 to 2 substituents independently chosen from halogen, C_1-C_4alkyl, cyanoC_1-C_4alkyl haloC_1-C_4alkyl, C_2-C_6alkyl ether and groups of the formula $-(SO_2)R_d$, wherein R_d is C_1-C_4alkyl or haloC_1-C_4alkyl.

52. A compound or form thereof according to claim 49, wherein:

Ar_1 is pyridin-2-yl, 3-methyl-pyridin-2-yl, 3-trifluoromethyl-pyridin-2-yl or 3-halo-pyridin-2-yl; and

Ar_2 is phenyl, pyridin-2-yl or pyridin-3-yl, each of which is substituted at the *para*-position with halogen, cyano, methyl, ethyl, propyl, isopropyl, *t*-butyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2,2,2-trifluoro-1-methyl-ethyl, methanesulfonyl, ethanesulfonyl,

propanesulfonyl, propane-2-sulfonyl, trifluoromethanesulfonyl or 2,2,2-trifluoroethanesulfonyl.

53. A compound or form thereof according to claim 49, wherein:

Ar_1 is phenyl, 2-methyl-phenyl, 2-trifluoromethyl-phenyl or 2-halo-phenyl; and

Ar_2 is phenyl, pyridin-2-yl or pyridin-3-yl, each of which is substituted at the *para*-position with halogen, cyano, methyl, ethyl, propyl, isopropyl, *t*-butyl, trifluoromethyl, 2,2,2-trifluoroethyl, 2,2,2-trifluoro-1-methyl-ethyl, methanesulfonyl, ethanesulfonyl, propanesulfonyl, propane-2-sulfonyl, trifluoromethanesulfonyl or 2,2,2-trifluoroethanesulfonyl.

54. A compound or form thereof according to claim 30, having the formula:



wherein A, B, C, Y and Z are each independently CH or N, and wherein each "$(LR_a)_{1-3}$" represents from 1 to 3 substituents independently chosen from groups of the formula LR_a.

55. A compound or form thereof according to claim 41 or 54, wherein R_3 and R_4 are independently selected from (i) hydrogen and (ii) C_1-C_8alkyl, C_2-C_8alkenyl, C_2-C_8alkynyl, C_3-C_8alkanone, C_1-C_8alkanoyl, C_2-C_8alkyl ether, (C_6-C_{10}aryl)C_0-C_8alkyl, (5- to 10-membered heterocycle)C_0-C_8alkyl and -(SO_2)C_1-C_8alkyl, each of which is substituted with from 0 to 4 substituents independently chosen from R_b.

56. A compound or form thereof according to claim 55, wherein R_3 and R_4 are independently selected from (i) hydrogen and (ii) C_1-C_8alkyl, C_2-C_8alkenyl, phenylC_0-C_4alkyl, indanylC_0-C_4alkyl, (5- to 6-membered heteroaryl)C_0-C_4alkyl and (5- to 7-membered heterocycloalkyl)C_0-C_4alkyl, each of which is substituted with from 0 to 4 substituents independently selected from hydroxy, halogen, amino, C_1-C_6alkyl, haloC_1-C_6alkyl, C_1-C_6alkoxy and haloC_1-C_6alkoxy.

57. A compound or form thereof according to claim 56, wherein R_3 and R_4 are independently selected from hydrogen, C_1-C_6alkyl, C_2-C_6alkenyl, (5- to 7-membered

heterocycle)C_0-C_4alkyl, C_2-C_6alkyl ether, indanyl, benzyl, 1-phenyl-ethyl, 1-phenyl-propyl and 2-phenyl-ethyl, each of which substituted with from 0 to 3 substituents independently selected from hydroxy, halogen and C_1-C_4alkyl, with the proviso that at least one of R_3 and R_4 is not hydrogen.

58. A compound or form thereof according to claim 41 or claim 54, wherein one of R_3 or R_4 is taken together with an R_5 or R_6 to form a 4- to 10-membered heterocyclic group that is substituted with from 0 to 4 substituents independently selected from hydroxy, halogen, C_1-C_4alkyl, haloC_1-C_4alkyl, C_1-C_4alkoxy, haloC_1-C_4alkoxy, C_1-C_4alkanoyl, C_1-C_4alkoxycarbonyl, aminocarbonyl and (4- to 10-membered heterocycle)C_0-C_8alkyl.

59. A compound or form thereof according to claim 41 or claim 54, wherein R_3 and R_4 are taken together to form a 4- to 10-membered heterocycle that is substituted with from 0 to 4 substituents independently selected from hydroxy, halogen, aminocarbonyl, C_1-C_4alkyl, hydroxyC_1-C_4alkyl, haloC_1-C_4alkyl, C_1-C_4alkoxy, haloC_1-C_4alkoxy, C_1-C_4alkanoyl, C_2-C_4alkoxycarbonyl, aminocarbonyl and (4- to 7-membered heterocycle)C_0-C_8alkyl.

60. A compound or form thereof according to claim 59, wherein the 4- to 10-membered heterocycle is morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl or thiomorpholinyl.

61. A compound or form thereof according to claim 41 or claim 54, wherein each R_5 and R_6 is independently selected from hydrogen and C_1-C_4alkyl.

62. A compound or form thereof according to claim 61, wherein each R_5 and R_6 is hydrogen.

63. A compound or form thereof according to claim 41 or claim 54, wherein one R_5 and one R_6 attached to the same carbon atom are taken together to form a keto group.

64. A compound or form thereof according to claim 41 or claim 54, wherein n is 1.

65. A compound or form thereof according to claim 30, having the formula:



wherein:

Ar_1 is phenyl or pyridyl, unsubstituted or substituted with halogen, cyano, C_1-C_4alkyl or haloC_1-C_4alkyl;

Ar_2 is phenyl or pyridyl, unsubstituted or substituted with C_1-C_4alkyl, cyanoC_1-C_4alkyl, haloC_1-C_4alkyl, C_2-C_6alkyl ether or a group of the formula -$(SO_2)R_d$, wherein R_d is C_1-C_4alkyl or haloC_1-C_4alkyl;

R_3 and R_4 are:

(a) independently selected from:

(i) hydrogen; and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, (5- to 7-membered heterocycle)C_0-C_4alkyl, C_2-C_6alkyl ether, indanyl, benzyl, 1-phenyl-ethyl, 1-phenyl-propyl and 2-phenyl-ethyl, each of which is substituted with from 0 to 3 substituents independently selected from hydroxy, cyano, halogen, C_1-C_4alkyl and haloC_1-C_4alkyl; or

(b) taken together to form a 5- to 7-membered heterocycloalkyl that is substituted with from 0 to 3 substituents independently selected from hydroxy, cyano, halogen, C_1-C_4alkyl and haloC_1-C_4alkyl; and

R_5 and R_6 are independently selected from hydrogen and C_1-C_4alkyl.

66. A compound or form thereof according to claim 54, having the formula:



wherein:

A, B, C, Y and Z are each independently CH or N;

R_3 and R_4 are:

(a) independently selected from:

(i) hydrogen; and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, (5- to 7-membered heterocycle)C_0-C_4alkyl, C_2-C_6alkyl ether, indanyl, benzyl, 1-phenyl-ethyl, 1-phenyl-propyl and 2-phenyl-ethyl, each of which is substituted with from 0 to 3 substituents independently selected from hydroxy, cyano, halogen, C_1-C_4alkyl and haloC_1-C_4alkyl; or

(b) taken together to form a 5- to 7-membered heterocycloalkyl that is substituted with from 0 to 3 substituents independently selected from hydroxy, cyano, halogen, C_1-C_4alkyl and haloC_1-C_4alkyl; and

each R_6 is independently hydrogen or methyl.

67. A compound or form thereof according to claim 54, having the formula:



wherein:

A, B, C, Y and Z are each independently CH or N;

R_3 and R_4 are:

(a) independently selected from:

(i) hydrogen; and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, (5- to 7-membered heterocycle)C_0-C_4alkyl, C_2-C_6alkyl ether, indanyl, benzyl, 1-phenyl-ethyl, 1-phenyl-propyl and 2-phenyl-ethyl, each of which is substituted with from 0 to 3 substituents independently selected from hydroxy, cyano, halogen, C_1-C_4alkyl and haloC_1-C_4alkyl; or

(b) taken together to form a 5- to 7-membered heterocycloalkyl that is substituted with from 0 to 3 substituents independently selected from hydroxy, cyano, halogen, C_1-C_4alkyl and haloC_1-C_4alkyl; and

each R_6 is independently hydrogen or methyl.

68. A compound or form thereof according to claim 30, wherein the compound is selected from compounds listed in Table III.

69. A compound or form thereof according to any one of claims 1, 14 or 41, wherein the compound has an IC_{50} value of 100 nanomolar or less in a capsaicin receptor calcium mobilization assay.

70. A compound or form thereof according to any one of claims 1, 14 or 41, wherein the compound has an IC_{50} value of 10 nanomolar or less in a capsaicin receptor calcium mobilization assay.

71. A pharmaceutical composition, comprising at least one compound or form thereof according to any one of claims 1, 14 or 41, in combination with a physiologically acceptable carrier or excipient.

72. A pharmaceutical composition according to claim 71 wherein the composition is formulated as an injectible fluid, an aerosol, a cream, a gel, a pill, a capsule, a syrup or a transdermal patch.

73. A method for reducing calcium conductance of a cellular capsaicin receptor, comprising contacting a cell expressing a capsaicin receptor with at least one compound or form thereof according to any one of claims 1, 14 or 41, and thereby reducing calcium conductance of the capsaicin receptor.

74. A method according to claim 73, wherein the cell is a neuronal cell that is contacted *in vivo* in an animal.

75. A method according to claim 74, wherein during contact the compound is present within a body fluid of the animal.

76. A method according to claim 74, wherein the compound is present in the blood of the animal at a concentration of 1 micromolar or less.

77. A method according to claim 76, wherein the compound is present in the blood of the animal at a concentration of 500 micromolar or less.

78. A method according to claim 77, wherein the compound is present in the blood of the animal at a concentration of 100 micromolar or less.

79. A method according to claim 74, wherein the animal is a human.

80. A method according to claim 74, wherein the compound is administered orally.

81. A method for inhibiting binding of vanilloid ligand to a capsaicin receptor *in vitro*, the method comprising contacting capsaicin receptor with at least one compound or form thereof according to any one of claims 1, 14 or 41, under conditions and in an amount sufficient to detectably inhibit vanilloid ligand binding to capsaicin receptor.

82. A method for inhibiting binding of vanilloid ligand to capsaicin receptor in a patient, comprising contacting cells expressing capsaicin receptor with at least one compound or form thereof according to any one of claims 1, 14 or 41, in an amount sufficient to detectably inhibit vanilloid ligand binding to cells expressing a cloned capsaicin receptor *in vitro*, and thereby inhibiting binding of vanilloid ligand to the capsaicin receptor in the patient.

83. A method according to claim 82, wherein the patient is a human.

84. A method according to claim 82, wherein the compound is present in the blood of the patient at a concentration of 1 micromolar or less.

85. A method for treating a condition responsive to capsaicin receptor modulation in a patient, comprising administering to the patient a capsaicin receptor modulatory amount of at least one compound or form thereof according to any one of claims 1, 14 or 41, and thereby alleviating the condition in the patient.

86. A method according to claim 85, wherein the patient is suffering from (i) exposure to capsaicin, (ii) burn or irritation due to exposure to heat, (iii) burns or irritation due to exposure to light, (iv) burn, bronchoconstriction or irritation due to exposure to tear gas, air pollutants or pepper spray, or (v) burn or irritation due to exposure to acid.

87. A method according to claim 85, wherein the condition is asthma or chronic obstructive pulmonary disease.

88. A method for treating pain in a patient, comprising administering to a patient suffering from pain a capsaicin receptor modulatory amount of at least one compound or form thereof according to any one of claims 1, 14 or 41, and thereby alleviating pain in the patient.

89. A method according to claim 88, wherein the compound is present in the blood of the patient at a concentration of 1 micromolar or less.

90. A method according to claim 89, wherein the compound is present in the blood of the patient at a concentration of 500 nanomolar or less.

91. A method according to claim 89, wherein the compound is present in the blood of the patient at a concentration of 100 nanomolar or less.

92. A method according to claim 88, wherein the patient is suffering from neuropathic pain.

93. A method according to claim 88, wherein the pain is associated with a condition selected from: postmastectomy pain syndrome, stump pain, phantom limb pain, oral neuropathic pain, toothache, postherpetic neuralgia, diabetic neuropathy, reflex sympathetic dystrophy, trigeminal neuralgia, osteoarthritis, rheumatoid arthritis, fibromyalgia, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, bilateral peripheral neuropathy, causalgia, neuritis, neuronitis, neuralgia, AIDS-related neuropathy, MS-related neuropathy, spinal cord injury-related pain, surgery-related pain, musculoskeletal pain, back pain, headache, migraine, angina, labor, hemorrhoids, dyspepsia, Charcot's pains, intestinal gas, menstruation, cancer, venom exposure, irritable bowel syndrome, inflammatory bowel disease and trauma.

94. A method according to claim 88, wherein the patient is a human.

95. A method for treating itch in a patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound or form thereof according to any one of claims 1, 14 or 41, and thereby alleviating itch in the patient.

96. A method for treating cough or hiccup in a patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound or form thereof according to any one of claims 1, 14 or 41, and thereby alleviating cough or hiccup in the patient.

97. A method for treating urinary incontinence in a patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound or form thereof according to any one of claims 1, 14 or 41, and thereby alleviating urinary incontinence in the patient.

98. A method promoting weight loss in an obese patient, comprising administering to a patient a capsaicin receptor modulatory amount of a compound or form thereof according to any one of claims 1, 14 or 41, and thereby promoting weight loss in the patient.

99. A compound or form thereof according to any one of claims 1, 14 or 41, wherein the compound or form thereof is radiolabeled.

100. A method for determining the presence or absence of capsaicin receptor in a sample, comprising the steps of:

(a) contacting a sample with a compound or form thereof according to any one of claims 1, 14 or 41, under conditions that permit binding of the compound to capsaicin receptor; and

(b) detecting a level of the compound bound to capsaicin receptor, and therefrom determining the presence or absence of capsaicin receptor in the sample.

101. A method according to claim 100, wherein the compound is a radiolabeled compound according to claim 99, and wherein the step of detection comprises the steps of:

(i) separating unbound compound from bound compound; and

(ii) detecting the presence or absence of bound compound in the sample.

102. A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim 71 in a container; and

(b) instructions for using the composition to treat pain.

103. A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim 71 in a container; and

(b) instructions for using the composition to treat cough or hiccup.

104. A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim 71 in a container; and

(b) instructions for using the composition to treat obesity.

105. A packaged pharmaceutical preparation, comprising:

(a) a pharmaceutical composition according to claim 71 in a container; and

(b) instructions for using the composition to treat urinary incontinence.

106. Use of a compound according to claim 1 as a medicament for the treatment of a patient suffering from a condition responsive to capsaicin receptor modulation.

107. Use of a compound according to claim 1 as a medicament for the treatment of a patient suffering from a condition responsive to capsaicin receptor modulation selected from (i) exposure to capsaicin, (ii) burn or irritation due to exposure to heat, (iii) burns or irritation due to exposure to light, (iv) burn, bronchoconstriction or irritation due to exposure to tear gas, air pollutants or pepper spray, or (v) burn or irritation due to exposure to acid.

108. Use of a compound according to claim 1 as a medicament for the treatment of a patient suffering from to pain.

108. Use of a compound according to claim 1 as a medicament for the treatment of a patient suffering from neuropathic pain associated with a condition selected from: postmastectomy pain syndrome, stump pain, phantom limb pain, oral neuropathic pain, toothache, postherpetic neuralgia, diabetic neuropathy, reflex sympathetic dystrophy, trigeminal neuralgia, osteoarthritis, rheumatoid arthritis, fibromyalgia, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, bilateral peripheral neuropathy, causalgia, neuritis, neuronitis, neuralgia, AIDS-related neuropathy, MS-related neuropathy, spinal cord injury-related pain, surgery-related pain, musculoskeletal pain, back pain, headache, migraine, angina, labor, hemorrhoids, dyspepsia, Charcot's pains, intestinal gas, menstruation, cancer, venom exposure, irritable bowel syndrome, inflammatory bowel disease and trauma.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/39606

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D401/04 C07D471/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03/062209 A (BAKTHAVATCHATAM RAJAGOPAL ; BRIELMANN HARRY L (US); NEUROGEN CORP (US)) 31 July 2003 (2003-07-31) the whole document	1-108
P,A	WO 03/049702 A (DOHERTY ELIZABETH M ; NORMAN MARK HENRY (US); OGNYANOV VASSIL I (US);) 19 June 2003 (2003-06-19) claim 21; example 118	1-108
P,A	WO 03/099284 A (DOHERTY ELIZABETH M ; AMGEN INC (US); CHEN NING (US); NORMAN MARK H (U) 4 December 2003 (2003-12-04) claim 1; examples 10,11	1-108

-/--

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
3 May 2004	11/05/2004

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Von Daacke, A

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/39606

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02/08221 A (BAKTHAVATCHALAM RAJAGOPAL ; DESIMONE ROBERT W (US); NEUROGEN CORP (US)) 31 January 2002 (2002-01-31) cited in the application claim 1; examples 38-42,102-106	1-108
A	EP 0 652 218 A (TAKEDA CHEMICAL INDUSTRIES LTD) 10 May 1995 (1995-05-10) example 74	1-108

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/39606

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 73-98,100,101 AND 106-108 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 03/39606

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 03062209	A	31-07-2003	WO	03062209 A2	31-07-2003
WO 03049702	A	19-06-2003	WO	03049702 A2	19-06-2003
			US	2003195201 A1	16-10-2003
			WO	03099284 A1	04-12-2003
			US	2004038969 A1	26-02-2004
			WO	2004014871 A1	19-02-2004
WO 03099284	A	04-12-2003	WO	03049702 A2	19-06-2003
			WO	03099284 A1	04-12-2003
			US	2003195201 A1	16-10-2003
			US	2004038969 A1	26-02-2004
WO 0208221	A	31-01-2002	AU	8066701 A	05-02-2002
			BR	0112631 A	23-09-2003
			CA	2415606 A1	31-01-2002
			CN	1443170 T	17-09-2003
			EP	1301484 A2	16-04-2003
			WO	0208221 A2	31-01-2002
			US	2002132853 A1	19-09-2002
EP 0652218	A	10-05-1995	AT	203024 T	15-07-2001
			AU	678295 B2	22-05-1997
			AU	7773894 A	18-05-1995
			BR	9404403 A	18-07-1995
			CA	2135440 A1	11-05-1995
			CN	1107476 A ,B	30-08-1995
			DE	69427675 D1	16-08-2001
			DE	69427675 T2	16-05-2002
			EP	0652218 A1	10-05-1995
			FI	945281 A	11-05-1995
			HU	68810 A2	19-05-1995
			JP	8067678 A	12-03-1996
			NO	944252 A	11-05-1995
			NZ	264887 A	20-12-1996
			NZ	272711 A	29-06-1999
			RU	2135471 C1	27-08-1999
			US	5585385 A	17-12-1996
			BR	9501976 A	30-04-1996